var title_f26_2_26656="Shoulder strength PI";
var content_f26_2_26656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strengthening exercises for the rotator cuff tendons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Part A: The inward rotation isometric exercise is performed by holding the elbow at 90&deg;, close to the side. The rubber band is hooked onto a door handle and grasped with the hand. The forearm is slowly moved towards the body 2 to 3 inches, and held for 5 seconds. The hand should not rotate as the forearm moves.",
"    <br>",
"     Part B: The outward rotation isometric exercise is performed with the elbows at 90&deg;, close to the sides. The rubber band is grasped with the hands. The formearms are moved outward 2 to 3 inches and held for 5 seconds. Sets of 15 to 20 exercises, each held for 5 seconds, should be performed daily.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Bruce C Anderson, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26656=[""].join("\n");
var outline_f26_2_26656=null;
var title_f26_2_26657="Nordic lower starting position";
var content_f26_2_26657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nordic lower: Starting position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Nordic lower exercise strengthens the hamstring muscles and many other muscles of the posterior kinetic chain. Maintain the thighs and torso in a straight line throughout the exercise.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26657=[""].join("\n");
var outline_f26_2_26657=null;
var title_f26_2_26658="Signals T cell activation";
var content_f26_2_26658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    The three signals of T cell activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 369px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Signal I:",
"    </strong>",
"    Antigen presentation by APC to the T cell receptor.",
"    <br>",
"     <strong>",
"      Signal II:",
"     </strong>",
"     Costimulation - biding of additional APC ligands to specific T cell receptors.",
"     <br>",
"      <strong>",
"       Signal III:",
"      </strong>",
"      Newly synthesized IL-2 and growth factors feed back on T cell membrane receptors, causing clonal expansion of newly activated T cells.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Vierling, JM. Clinical Use of Immunosuppressive Drugs to Control the Immune Response. In: Liver Immunology: Principles and Practice, Gershwin, ME, Vierling, JM, Manns, MP (Eds), Humana Press, Totowa 2007. Copyright &copy;2007 Springer-Verlag.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26658=[""].join("\n");
var outline_f26_2_26658=null;
var title_f26_2_26659="Wrist sign in Marfan syndrome";
var content_f26_2_26659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wrist sign in a patient with Marfan syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist sign in a patient with Marfan syndrome. In a positive test, the first phalanges of the thumb and fifth digit substantially overlap when wrapped around the opposite wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koopman WJ, Moreland LW. Arthritis and Allied Conditions A Textbook of Rheumatology, 15th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26659=[""].join("\n");
var outline_f26_2_26659=null;
var title_f26_2_26660="Ethionamide: Patient drug information";
var content_f26_2_26660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethionamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     see \"Ethionamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/24/21891?source=see_link\">",
"     see \"Ethionamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trecator&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trecator&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethionamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime to stop upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11208 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26660=[""].join("\n");
var outline_f26_2_26660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168672\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168673\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027178\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027177\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027182\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027183\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027185\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027180\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027181\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027186\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027187\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=related_link\">",
"      Ethionamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/24/21891?source=related_link\">",
"      Ethionamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_2_26661="Mediastinal mass anatomic compartments";
var content_f26_2_26661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F88304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F88304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common diagnostic possibilities of mediastinal masses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 558px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIuAWADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuI1n4m6BpHxF03wZefav7UvlUpMqKYI2bdsR23ZDNt4AB6iu3rx3XfgjDrVzr+qXev3Q8RahqMV9aX6I6pZCIjyk8nzNsm1dyhm5+bjHOQD0Z/GHhpNQawfxFoy3yyNE1ub6ISB1GWUruzkdx2rF8KfFDwp4j8Oz61FqtrY2UExgm+3XMURjbcQpb5yAG2krk8iud/4VAWvlu5dbQzf8JUniYlbLH3RgwD94cAnnd+hqifgnKujWOnxeJGQaZqcuo6fIttJGyeYxLpKY51Z+owyNGRz1zQB6XL4t8NxJavL4g0hEu0EluzXsYEyFtu5Pm+YZIGR3OKkt/E+g3Oo3On2+uaXLf2wYz2yXcbSxBfvblByuO+elefaF8F9L0/WPD95eHTbq10i3niWx+wu0LPJJ5gkXzppWUgn1POSMdKqWfwTFuljavrUNzpmm/b/sVvNYtub7WGDi4dZQZlAYjA2E9zQB6JaeNPC16hez8S6JcIJkty0V/E48187E4b7zbWwOpwcdKdc+MPDNrC81z4i0aGFJntmeS+iVVlQZeMkt95QQSvUd685X4NX39hiwPiyXFvqFnf6fCbeWW1sjbggIkcs7vtbPI8wDgYA6VlXfwp8RaPqegSaHfW19N/wkl1rdzdyWoSK1E0argxGYM4BXs2efagD1278W+G7OxtL278QaRBZ3n/HtPLexrHP/ALjFsN+FRal4y8P2LXcJ1jTZb63haZrJb6BZmAjMuMO6gZQFssQMckgc15cP2f7aGz0tLfXXee3tZ7S6FxFMILpJpGkYbIJ4mUZYjbvIIwCDjNbOn/BjTrZvFEss1lLdavpkOm2k32DLaaEtDbM0bPIzkMCDjcDgYLN1oA7lPGHh9Y9M+26xptlcajDHPb21xewiSRXGRtw5D9cZQsD2Jq3aeItFvNUl0201jTp9RiZ1ktYrpGlQpjcCgOQRkZ44yK8tvvggZ7C5sYfEIjtNQ02w07UN9jvkcWiqFeFvMHlbtoyCHFdd4E+Hen+FNb1/Vibe91DU76W6S5e1CzW8bgfufMJLMMjOcjJPSgDdufFvhu11BrC58QaRDfK/ltbyXsayB8Z2lS2c45xSN4w8NLpKao3iLRhpjuY1vDexeSzjqofdtJ9s1wutfCEapqmtXh1oR/2jrNnq+z7Ju8v7OpHl5387s/e4x6Gs+7+B6y3Mt3F4gkS7/ti/1SP91KkapdKivCwinRzgJ95XXOSCCOKAOz+IHxD0Xwf4Wn1Z73Trm4+zm4s7M3qRteAY/wBWeSw56gGpdP8AH2iyQ3Mmq3VnpCW0ds8sl3f26oGnj8xV/wBZuU4z/rFTdjKgjmuDvfgcWs5bfS9btLCO50Y6NcRiwkmQR+aZA0W+4LocnkMzg+3GNGf4T6lHd6tc6R4uuNOl1BtO8wQ27oGS1gMRjZklR9r5B+VkIxjJ60Ad5c+MPDVrpttqFz4i0aHT7klYLmS+iWKUjqFcthsexrnR8WfC8mr+IdNt7uOa50aGOZyLq2RLlXXcTC7yqp2j7xYqASOa5G3+B1xZ6FZ2Nh4jitry1muZYdTjtbiO6g84jcI3S6XsMfPvz1PfOrqnwku7yTxXs8SZi8SadbWV21zZebKJII9iyhxIo55JUr1PBFAHcjxj4bW6itJ9e0mC/kMai0kvoRKGkUMi7QxySCCMZznjIqyviXQnlWJda0xpXumsVQXUZJuF+9CBn/WDIyvUelebap8Fxfp4iU66EOry6ZID9jz5P2NAn/PT5t+Pbb70+D4PTQ+JodQTxAn2GHxFL4iS2NifM8yQAPGZPMxt4GDsyPegDuV8d+EW37fFWgnYhkbGow/KoO0sfm4APGfWt62uIbu3iuLWWOa3lUPHLGwZXUjIII4II715FovwUXTItAQ66JTpUGpQ5+xY837WGGf9YcbN3vn2r0PwF4ePhPwdpOgm6+2fYIBD5/l+X5mO+3Jx9MmgDfooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8y8ReNtYin8R3OnzafY6ToVwLSZrnTLq9kmk8lZmYiBgYYgrgbyrjgnjgH02uP8AEPhjwlquvFNUIi1bUYCklvDqMtq97EowQ8cci+coBwdwYAHHSgCLT/iDZXeoQWosL9reS5SwOpRon2X7SYw/ljLCXvjcU254zXK6J8X2Md9faxp850K20mx1D7fFFFDhp/M++jXDEBmVUUDdghtzbcNXdQ+B/D0Osx6pFYMlzHKJ1QXEvkiUJ5Yk8nd5e/bxv27veqq/DjwskMUMenSpDHZpYeUl5OqPCm7YrqHw5XcxVmyyk5BBANAGXo/xZ0bWVhTSrHULy8luZLVbW2e2mPmJEJf9YkxiwVPBD4ByDjBr0IHIBIIJ7HtWHp/hTSrGeznQX089pI8sEl5qFxdNGzpsbBldjgrxjoOSBnmrNx4g0q21d9Lub6GC9WOGUxynYCJpGjiAY/KSzoyhQc57cjIBqUUUUAFFFFABRVJdW01/L26hZt5tw1omJl+edd26Ic8uNj5XqNp9DV2gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8h8TeEvFeoeMrzxbaJaCfTru3XTrF4w009vECJNs3mhI/M86cEMp4CZI7evV5NqfxH1Kz+I+o6GlxoskNrqVnZJpvlP8AbZopoY3knD+ZgLHvYnMeMLywPNAFC50TxwL7xH9gj1popyXiuLrUvLlZPtKM0MKrcyRKTEJFWTy4SuFzyWIq+JvD/ja6vbZvD0fifTNKFttjhl1AXd1BceYxaRydQRXUrswGaVeCNi9+psvjFoF1Bqji1vhLpxthLDDJbXTHz5hCu0wTOuQ5GVJDAdjkZt3fxO0+x8SWehX+l31tqd2yxxQNdWTyb2UsqmNLhnXOMbioXJHzDOaAMO58NeM476TUNOvtSXUJtUvx++1Fnto7RoJvs58kuUAEvlEALvHfgcZGj+FvFkWtpf22n65ZOy6PFcy32sLcSzeVdu90Q3nPiMxt9wYBBIC5JFWtH+J2u3cPgvUrvQ9Q8nUdKvLu7s7NbbE5jFsyzRl5crGBJJwzKxzyp4rtLP4jaReS28VvBfNNdS2aW8WxA0yXMZkSVRu+4FWQtnBHlPwcDIBxNx4e8baZoxvbXU9Qgv5NP1T7bLfar5kML7w1sQHcomFDfMo4/irV+Cep/wBqaj4llspdUk0hPssdv9u1b+0v3gRjLtlEsqdSuQremQOg1LH4nWuo2OlXOneHfEF02qW7XdpAkcAkkhQKXkw0wACl1XkgsWG0MOaIPiXp81wDZxXmordrZnT7W2t1SWYzxSSj5nlCn5I2Y7tgXHVs0AcRNovxNm1zVp7KK+0+K4tb1Nh1JpIvMLqYjEZLmXaxUPhlihCFsYxgja03w54putXsUYeItN8ONqLNLb3OtebdJB9jkVt0qyu21pimAHZlPzDbxjT0rxjq6fBbWfFNxC0+q2a6nKkMyoNvkzzqiuEYKQqooba2SFOCSedG1+I1oNP1KXU9L1OyutMtrW5uoHELNi4d1TaUkZT9wnrwCO+QADj9F8IeJ9Fd7TRYNWtJB4hurtry41Uz281rIl2YjsaZmOHkhLgoGZsMd+MjtfhhZX1lpTJq+n69a6l5cQuZtU1QXqTyAHc0IEzhFzk42x5yvHHFWf4mW66x/Z1t4c1+7ke+m02GSFbcJPPEpZ1XdMpACqx3MAODznimL8VdHlso72207V57NbSK9vJkijAsI5GZV80FwSco+RGHwFz0xkA4RND+Jk97rbrBqdhHdafPGkaaqzqtz50ZRone7kI+TzMEJCAOCvStTxP4Y8cW9ze22g3WrT6GuopLHE2oSS3EkRtlDbZDdQybRNuJUzL1yARxXpPhrxNF4huL9LPT7+K3s7meze5nWNY3lhlaN1UByx5XIO3GO+cgb9AHiv8AZfxCsdNu7VF1rU5r7T7CKG6a8hga0likk84uvnthmQpkoz7scmrmt2eueHPDOp+JLy+1M6tZ63NcWtpLqTmK5tWumEVuIwxT543AXILAlRwFAHr1FAHkF34d8X2mp+Gmjk1rVZIoojf51BobTzWmZ5W3LdI/AYgK0Uq7URQB81V4fA/iiUWL3d/4jEktrqTXoTXplCz+Yv2MKFlwo2luF44+avZ6KAM7w2l6nh3S01bcdSW1iFzuIJ83YN+SOD82enFaNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXIz33grTtf1awutV0e31jWHjW8s579BLOxjWNF8tmyMoFAAAz7k111eXrpXiKy+J2u3sMPiJNKv7u0kR9PbTjbyKkMaOZRMfOABUg7MHA45xQB0Fn8N/C9ojpHY3Lq0dvF+/v7iYqkEolhRS8h2qrgEAYHbpxVqXwL4el13+13tJ/tpulviFvJ1iNwqhRKYQ/ll9oA3bc4rza30HxvGbtWt/EM1j9qikmMurGG8uod7F44tt48SHlDuUwZAK45zVG/tvFS6lpmkXMfiWe5l0vU57WytdaEc0H+kQi3a4m85RIUVwCd0h+bo4yaAPSPDvhjwjDeXVjpMMzTaOJLJ4pLq4dbVbiOJ2jQOxAUoIiAvC9sHNWrLwTYWfirTdXhEaw6Xpg0yxtwhJiXP3i5YlvlAUZGRluTuriLLwf4qtdcutXaW8bU5NV0x5HgvzHBcQJbW8d07RB9rZKSD5lLcDaOmecay+IdhBrmo6ibzSNPayVpkm1j5EcXMbOsU013LsJh81RJiEA4yq8EAHrtz4C8O3GkaXpjWU0dppkRgtPIvJoZIoyoVk8xHDlSAAQSQcDOcUXPgHw3PCIzpzQhfs+xra5lgaLyFZIijIwKFVdhlSMgkHNePaXH4r8SaJdXXhafWpNEXW7gLC2qNdTtD9mgCFJxeR70WQTZC3BXJ6Ngiti70f4jHWvDrQpqbpaNYC4vDebBcRgr5/nRC8MSsBuBCxS7uofOKAPRNFtvCUXw9nt7NoU8JulykxupXCbGkfz97yncAWMmST344xUU/w08L3AjFxaXsuyNIT5mp3TGREcugkJk/ebWY7d+ducDArCu/CGq3fwK1bw01uU1aeC7WOEThcs00joN6nGCCuQTjnB4yKy9Q0/xnbpqsOh6X4iW11G1s1tFudYjkk0+SOaUzb3e4ZiXVlIKM2RgEjGAAekw+F9HhvLe6js9s9veTahG3muds8qMkj4zg5V2GDwM8AcVlv8OfCzrbIdNcRwRLCI0u5lSWNXLqsqh8SgMxIDhsZNcna+C/EF1rkE+p3/iGO2uNW1JrtYtcmRVtC7tahVSX5B9zAQBgDhuMisu00P4hG10r+0V1mXVVsrBIrmHVkjt7SVG/0g3MYkAmJHOdsm4cZU80Aew6TpVnpEM8Wnw+THPcS3Ug3M26WVy7tyT1ZicdBnjFXa5L4eaPqWn6bPca/cX8uqTXV1lbi9aZEhNzK0IVdxQfuyvP3sEKThQo62gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzLxH8TY9J+Ken+GhNpYsi0EF2JZgtyJpw/leWu4ZUFY93B/1q9MGvTa4K/vvh0f7Y0K91vQlm1K7L31q+qqsz3GVXn596sCiAAYxtGMUANf4p6RBc3QvtP1W0soJr6D7fKkRhke0DmYKFkL9I2IJUA4x14pF+I0U94to+l6npNylxYo6X8EL747pnCEeXOdv+rbJblePlPSty78FaFPbNF9giP727uFErSOnm3IcTMy7huDeY+VzjnjHGOc8K/Diw8N/wBoahr2oJekva3AkZ544rZbXeYzmaeV8LvYnL7cYGABQA9vixpSad9ul0nW47Wa1+22TtDF/p0Pmxx7ogJMjmWM4fYcMDirOm/Em1u9WSwuNB1ywb7f/Zcs1ytuY4bkx+aI2KSsTlMHcoK/MMkVasfh54SWF3tbAyQTxqif6ZNJGkXmLKFiBciNN6q21MA4HGK1JvCWiTvO01iHM98NSkzI+GuPKEW/Gf7gA2/d74zzQBwOr/GW2eyv49A02WfVbOa0V4GuLSdTHLdJC3zQ3DKG5ICswIZlJG3JrpR8RLMX5t59I1eGJLmKxnumWFore6kVWWBishJb51BZQyZYDdT4Phj4UgtZrdLC5aGSCO1xJqFzIY4o3EkaRlpCYwrKrLsxgjjFXIfAnh6LVIdQFpcPdRPHKDLezyK8qKESV0ZyryBQB5jAtwOaAMiX4qaLHollqf2PU2gu9LGrRoI49wiMscYVsvtVt0qkknaACSwAq5q3jJx8LtW8WaTZFpLexnuoIZJoZlJRWIZmhlZGTjJ2vnGcc8U6w+G3hnTnkewtb61doDaq8OqXSNFDvWTy4yJMxruUHamB1HQkHXs/DGkWfh+60SG0LabdCUXEcsrytN5ufMLuxLMW3HJJJ5oA53/hY9na6dfzatpep2dzp+mRancwMsLN5cjuihSsjKSfLJxnoRk5yAyf4mW66x/Z1t4c1+7ke+m02GSFbcJPPEpZ1XdMpACqx3MAODznird/8M/C2oW8cF7Z3s8aQfZT5mp3RaSIOXVJG8zMiqxJUOTt7YrZh8L6PDeW91HZ7Z7e8m1CNvNc7Z5UZJHxnByrsMHgZ4A4oA5hfiro8tlHe22navPZraRXt5MkUYFhHIzKvmguCTlHyIw+AuemM9HoHiWLXNQ1C3tNPv0hsZ5bWW6lVFiMsbbSq/PuOeoO3GOpB4rPf4c+FnW2Q6a4jgiWERpdzKksauXVZVD4lAZiQHDYya6HS9Ls9LW5Wxh8oXNxJdS/MW3SOcs3JOMnsOKALtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcJ4w0XXrvxW+o6DshlXw5f2VvdOy4iupJIGiyOv8DHOCBjnsD3dcHe6l4sT4i2uhQaloS2NzZz6grPpcrSJHHLEnlki5ALES/fwB8v3eeADj/DXhnxyYoYdSu9ehhfULVrhHuthWERzCYpJ9snchiY8rlMYBVQckU9U8K+OdR8Rahapa6lbaHNBf2ZD6vLLHNGYHW3cs927ZLBCcQxkbjksM10HhL4p+X4UtZ/Eun6s12LCW/a6EMOy5iilVJZECvkBN6khlUkAlQ3forz4iWUd6LTT9J1bVZnvZLGH7GsO2aSOMSSFWeRRtUEgk4+ZSBnFAHB3Ph3xgulW0Gl6d4ntimlpBZRnXlH2O+Dtvmn/wBIbzYiPL2rlwArLsXOa2F8G+IrvxDa3GoX+vrbTa1eNeCHWpooxYmNzAFRJRtHmCP7oDgEg4HS8nxXsb3TIbm10/U7AXMdpc2st5bRyLcQTXMcG5VSYEcyAfMVIzuAYDB6vwx4oXxHLK9lpWpR6apcRajN5Sw3BR9h2KJDJyQSCyKCB16ZAPJ9V0b4mPY6FFbW+o/bbO2t1e7TUyxkdZiXEy/akjzsAG4xTF92CVwDXvNcU3xF06LW3sJ9O1OG3S/fTDqDpF9n89YjLt4cvjaDzsx6kVi6T8a/DGrJL9hjvJp9sTW9vE9vLJc+ZIsSBVSU7GLMvyy7CAckDBwAen0VwM/xNtI5orWLQNdn1Im6EtlGlv5sBtxE0gcmUIflmjI2swIPHOAc20+JtvCdc1eeRrrQ99i1kvnWtsUSa2WTJaeSNeSehYnJ4GM4APUKK8/0v4q6Nqt/odrYWl9IdXgjuIHke3hAV2ZekkqtIVKtuEQcjj1GaafF6ykgWeLwz4keJ7KbUY2CWw328LBZJBmfICkjg4JyMA5oA9MoqGzuI7u0guYCWimRZEJGMqRkVNQAUUUHkUAFFYLSzRuyiV+Dj7xoF1OP+Wr/AJ1j7Zdjb2L7m9RWF9qn/wCerUn2mb/nq/50e2XYPYs3qK58zSnrI5/4EaaWY9ST9TS9v5B7HzOgLqvVgPqaY1xCvWVPzrAope3fYr2K7m219bj/AJaZ+gNRtqMI6Bz+FZFFT7aQ/ZRNNtTH8MX5tUTalKfuqgqjRU+0l3K9nHsWmvrhv48fQCr2mTNLE4dizA9TWPV3Sn23BXswqqc3zakziuXQ16KKK6jmCiiigAooooAKKKKACiiigAooooAKKKKACucl1DwsfG0KSappn/CUQ272iWxvVE6xyFJGXyt2ediNnbnA44PPR15NqXgPxBq/i7xXc/bLbT9Mn1Gz1GzzAJJZpoLaII3mB/3aCVMEGPcQDg4NAHbL4P0q1tIE0y2jt57SynsbR5S8yRRylSwZC3zgsiEgnPGARk1W8JeFtB0jTtH0uyeK5ufDamJXWX545ZI8uzqDwzhy2G/v5HY15r4e8NfENbRYr6812KZ7nT/tGbpdpVLhTPJHI15MeY9+VCRqwxhM/LW3qvh7xRbazeJCmv33hpdSjZLW11pkupYBZRqCsrzKwUTByymRSxOee4B2Y8BeGhZ2NoNN/wBHsreK1gXz5fkjilSVFzuycPGhyck4wcgkVa0nw3pHh24u77T0urZJBJJJD9sne3Xc29ikBcxoScnKqDyfU151JpnjeTx/pN3Y6fqljo0FzbiQS6o04e1EIVxKGu2UyAnBCwsSV3eaxJzAPC3i2Hwv4Yj1BPEeqTvYSJrFvBrhjm+1bEETFzMoMa/vAwRvmJDEOaAO+0ew8J69BBeaaIbpZbiPXVAlfcJJYiElZCcqGjJwrADrxkVUg8J+Eo7i48NIt8xa2jufsT6hdvHBGJPkaEFysRV048vaVwMYFcNB4e8c6d4Rs9OhsLyUR2Ok23lRakY2tzFbus5jEdzDkhwgI81Q2c/Niuh+FmheKLHUbK98VxzNcpo/2OWaadZHLrdysoJDuSfLKHJJ9yTmgDSvvhdolzqWlyxveQWVpHeCaGO8uFlunuDFueScSCRv9VghiwbIz0Fad18P/DVw6P8A2fJbyxtG8clpdzW7xFIvJXY0bqUAj+XCkAjrmuYn0TWZ77xOuryeILSadrlrLWoNW8uytIdmYv3AmGGXHJMRyQSWweMMweL/ABJ4IsvEEY1ptQ1Sf7Yun2N35UMcHlBI0J+027qrY8zKNnc/zKwGKAO8sfBXhTzLezsxNImjSRhbJdUuHhgkUiVPMh8woWyyuC6k8qfSr8XgvQIbeKCOwxFFYTaai+dIcW8rK0ife7lV56jHBFcv8PPDupaR401691TTtRjOoJbzJcDVGuLZWFtCkkZR5SzOJEfDlD8oxuHSvSqAIrW3jtLWG3t12QwoI0XJOFAwBk+1S0UUAFFFFAGDdjF1L/vGoamuzuuZT/tGoa4ZbnbHYKKKKQwooooAKKKKACiimyyJFG8krqkaAszMcAAdSTQA6isMeKdL8iKeRr2G1lxtuZ7C4igwehMrIEAPGCTg5HqK3KbTW4k09gqSB/LmR/Q1HRS2A6SiobKTzLaNu+MH8KmruTurnG1Z2CiiimIKKKKACiiigAooooAKKKKACiiigArj08WTwX3jb7VaNPa6A0TRx2iZmlQ26StwzAFsscAY4AHJrsK4270fwsfEGs6supNbaramK41Hy9YniiiKxjy2uIUlVNuxQcOAGUHORmgCG8+JOmRyRpp2n6nqvnXkNhC1msW2aaW3a4CqzyKOI1BYkjBZffGenxd0kabLf3eja5aWy2NzfxNNFD+/W3ZVmRAspIZWcD5toPOCRzWt4L8F6JpnhTw7aW5hvo7CQahb3cJ2JJM6ODMoViNpWVgFywCkAZwDTPE3w50fV/DFxpNmn2GQ2d3Z21xl5fIW5YNKdpYbssqnk8Y4IoAxPEXxEu11HR7TTtK1a2v01iG1vdNkS3M08MlrcSJtPmFAC0YOd6kbCDjkG83xW0k2H2yDS9ZuIYbRr2+8uKLNhEskkbNLmQZw0UvEe84QnpgnesPBGgWU0M8VpPJcxXa3wuLm8mnlMyxNErNJI7MwCOygEkDPSqlz8N/CtzHHHLpriNFdCiXc6LKjStKUkCuPMTe7NtfIG44AzQBQvPiZawaq1jb+H9dvP9POmRzwLbiOa5EZk2LvmU/cBO4gLx1qtffF/QLG10m5ura8ig1EDbvmtVkiYymIq0RmEjFWHJjVxjnJ5rprrQfD1jLBdXUcNu39qC+ieW4ZAbyRDCpGWwSwfaF6EkYGcVz994G8DJrFppc9pPFeX0LypbxXl0iXCQyiQmQK4V9rzgjfnG7jpwAeg0UUUAFFQR3dtJdzWkdxC91CqPLCrgvGrZ2ll6gHa2Ceu0+lT0AFFFFABTJpBFEznoBT6y9Un3OIlPC8n61E5cquVCPM7FAkkknqaSiiuM7AooooAKKKKACsafxNpaTvb280l9codrw2EL3LIfR/LB2fVsCp/E1jNqfh7UbK2dUnngeNC33dxHAb/ZPQ+2arXVxYa1pHhOxW3TT9C1KQpcWYUIu5I2P2RgOB86kMo4PlspyGIOtOCluZVJuOxkWnjFNYuvs2m3ugWDHKh9Q1KGSTP+zDE53Y7gyKR3puvLLBrFjpeva7aXeiXMRnukS2xLc4PEEKIzM6sc7xtPyjGTur1OS2gltvs8kET2+NvlsgK49MdMVW03R9M0x5X03TrOzeU5ka3gWMuffAGa3VOKMXOTIYtT0nVtCnuzPBLpbJIk7TDaiqMh1kDY24wQQ2Mc5rz3wd4l0yPwzpUc11MsPlrFFdTwyLE652x5lZdu5l28Ft2T60upyW1j4s1i78QLA/haLVkEu8lUt7k2luUklXO10zgDIG13DYOQV3L7VtZm0q71q60+BvDgB8zTJ7VjdS2mPmlOWwGxubyipJUAHDEgE4KSFCbiatFUU8KS20aSeFtaNtaOA0dtdRfa7dVI48v5ldR6DeVHYCoZZPEOnk/wBoaKt5CP8Alvpk4c49Wik2sPopc1zulJHQqsWdNpEn34if9of1rSrldG1S3voIr2wl82EkjOCpBBIZWU4KsCCCCAQRg811EbrIisvIIzW1KV1Yyqxs7jqKKK1MgooooAKKKKACiiigAooooAKKKKACvEfFHwz1zWfGfjDUbdo7bT9VeKKaNnBN9bpawkKuD8pE0RQ7sfJJJ6ivbq5jS/EFzda74vs50hWDR5IkhZEJZg1ukp3ZbBOWOMY4/OgDzzT/AA340s49Ft0h1RZre20uK2mg1NY7SyWNEF0k8IkxKTh8EI+crgrjNR6/ban4b8O6HqHijU9VWKS+nTUof+EhW0kkXMxt1jkeaNAACCVV1ZgBncEwOnsfipYnTrK4uNO1SeE2dhc3d/FBFHDALpR5bMhmLgZPKrv2+p6mWX4raRDp1xqM+m6vFp62c99a3DRxFb2KEgOYsSZB5BAkCZByKAPOobT4h6v4b8L3WkQaqXFnbSreHUpC0h84s4lV7qNfuY+ZopiwbGVwKct7rl34yutHstQ1O68Qg6t9pe31xZLfb5cgtlWBJiICpaMfOiEMOrcmvR4fiZbf2qbG88O6/ZOl5bWM0k6W5SGS42+Tu2zMSG3D7oO3+LbVrw38RdI1/wAW3Xhy3ili1GCF5+bi2mVkR1Q8wyuVOWU7XCnB6cGgDmYfDXi/T7qKKxutXls2fRp5WuNUaZvMS4Y3oBeQkKYwuUHyt0UHkVt/EPwtfa/4o0S6tvtqW9np2oxtNaXrWrrNJ5HlLuR1YglGPHHy8+/f0UAeJWOhfEZvFOjXOqXmpC3RdPaRreRXjj2xRi4jlX7XGh3OJMsIZThgVPAA1tJ8HeIJrTwqmsX+v+YzTHWSutSoQBG4iAKSDA3FfucngsT1r1eigDxGLSPiLHoEkd5b6he3MlnpsLL/AGmVdHQ3Hnuvl3EWX5g3fvEDjuduK9A+FNrr1j4Is7bxYZ21WOWcMZ5RK5j85zHlg75+Qr1dj6knmuuooAKKKR2CqWY4A6mgCG8nEEJP8R4UVhk5OSck96lupzPKWPA6AegqGuSpPmZ1U4cqCiiiszQKKKKACiiigArCsZdItLbxTpniP7ONKjnjvgsw+UJNyMDrvM8cpGOdxGOaludb8y8k0/Q7ZtU1JDtkjiYLFbn/AKbS9E/3eXI6Kav6F4Pji1NNa8QSxajrSgCJhHthtRz8sS9c8n52Jbk42g7a3oxd7mFWStYueCYL2HTZ2uzdpbSzl7K3vJDJNBBtUBXZssWLBmwxJUMFJ4qz4r8Q2PhjRJtS1JnKJhY4YlLyzyH7scajlmJ6D8TgAmn+JNdsfDumte6lIwXOyKKNd0kz4JCIv8THB49iTgAmvLLm6vtc1BNU1tVSdQRbWiNuS0U9QD/E5H3n/AYHX0MPh5VpeR5eNxsMLC71b2Rt/C2QavDMPEllH/bYum1fa4DrG0jMqhCTyY1VVzjgFe5ra8R+JNXme5svB2kPqMsD+Tc3bMgigbuqK7oJXHcBgoPBbI21y+i38WkeIbPULlwlsI5beZiM7VcBhgDksXjjUAAklsCugm+IFsEh1WxZNT0CcJCBbxOl1BO4zEro5Hyykqq5C4LL1DZV4ul7KpyrYWXYh4iipy3u7mJ4cu9Q0dLTRbDV54Li2hSJNM120UFkRQP3Tx7dw4GWUyAdK6N9X8VsGkWy0SPbjEH2iV/M9f3mxdmf91se9LrlzeXOnE+JvCdvdaRnfJHDOLuaED+MxeWAcdf3bM3oCay2kbw7aw3sV1JqfhKdBLHe7zNJZqcEF25MkODnfyV/iyuWXhkpLVM9KLi90WdBiuWv9Yv7iybT0vrhJltXkV2DCJEZyVJUbivQHtk8sQOq0qfBMLHjqtZkUiSxJJE6vG4DKynIYHoQe4qRGKMGU4IORWCm1LmN3BOPKdFRUcEgmiVx3FSV2J3OTYKKKKACiiigAooooAKKKKACiiigArnLrwXo1zrdzqzLqEd5cujz+RqdzDHMUUKu+JJAjfKoGCuCOua6OigDhLP4YaHBrLXUizy2McNnBaWH2iZYYhbAiPevmbZsfKRvU42981cPw48KmO9jbTXeK7gltXie7mZI4pDukSJS+IgxAJ8sL0FdfRQBi3fhfR7u6uLi4s981xdW97I3muN00BUxNgHjaUXgcHHINUvD/gTw94f1KO/0q0niuIopLeLfezypDG7KzIiO5VFLKpwoHTiunooAR2CIzEEhRnCjJP0FZ+gazY69pcV/pkpkgclSGUo8bg4ZHU8qwOQVPINaNch4g0G9sNUk8ReFAP7RYD7bpzOFh1FQMc9kmAGFk9grZGCoB19FZXhrXrHxFpgvNPaQBWMU0MyFJYJB96ORDyrD0+hGQQa1aACiiigArL1O43N5KHgfe+tW7648iLj77cD2965nWdQj0vS7q+mDOsKF9i/ekbsq+rE4AHckVjVn9lG1KP2mVrnUrmTUm07RbIX99GqvNulEUNurZ2+Y+CQTg4VVY98AYNR6jc+INI0651HVdJ0/7Fao0s5s9QaWRY1BJYK8KA4AyRuz6ZNLZW+o6JpumaNaSRL4i1iSS7vrsrvWHAUyyAH723dFEgPQFM5CkG5rfhPU9S02WxbxVqEkE20Src21u25QwJX92kZw2MHk8E9OtNUo21E6rvoW6Khj8Hs7F9Q17WLlj0VZEgRfoI1U/wDfRNO/4Q23ywGra2I26x/az/6FjcPwNZ+xZftkSVjXPijRoJzbrfx3F0OtvaBrmYf9s4wzfpWwvgbw6SDdaeb/AB0GozyXgH0ErMBW/aWtvZwLBaQRQQr92OJAqj6AVSo92J1uyOMS51u+IGl6BLGh/wCW+pTC2THsoDyZ9mRfrVlPCN3qH/Ix6xLPCRzZ6eptIT7MwYyN+DqD3XnFdhWH4k8V6J4bj3azqEMEhXesAy8zjplY1yxHuBVqnGJm6kmaenWFppllFZ6bawWlpEMRwwIERR7AcCsDxj4007w00Fox+16xdcWthG4DyHBOWPRE4J3H0OATxXF658QNY1YCDQbf+yLaQgG6uNslyQSoyiDKJw4ILFvdQa87urI3Hw902dds2pXj2M0txclpGmmd41LyNnc33j3yOMYxXfSwkpay0R5WIzKnT92m7vbyX+Z1Wpagovhq3ivU7T7eylIy7iOG3UnlIgx47Zb7zYGeAAIf+EhtX/49YL+6PbyrSTa30cgKfzqlY+HrqyctbTaRbOfvS2+mFZT/AMCaVs/iDV3+wVmH/Ew1HUrz/ZafyV+mIggI9jmvXhFwXLFWR81VnGpJzqSu/wCun/BMbW9dv2lghhtIYbmOaG5jsXlEt1OY5FcLtQlYgSAPMLEDOeOtes6V8PrRp/Dl5q8iXMmj2NvBBFEpRGkjAxJIc/vNrDKAgBSScEnI46w0+z06IxWFrBbRk7isUYUE+px1PvXovw7uzN4aWCRiZLKaS2bPZQd0Yz7RslcGPptJTfoezk1eLcqSVupta3qtroumy3187LDHgBUUs7sThUVRyzEkAAdSa5b4cazYHTl06aUWeqSz3F1/Z1wjQyRCSV5NiK4G8KGALJlcg4OMVb8ZabYavNo0t7rbafHHK32QwyKrPcsNqMpbKsQvmrtKsDv9uccWxvLm78P+KYLe7uLcLcQziPas8RJCyqP4JFIIO08HawxuAHkzk469D6GMVLQs6ppcPhfWbK40wGHStRnNvcWi/wCqhmYMyyoP4NxGxlHBLqeDuJ16w20nUZIYLG51mS60qKeKdUuIt9xmNw6L52eVDKvJUsQOW6k7lc9Rpu6N6aaVmX9Km2uYmPDcj61q1zisVYMvBHIrfgkEsSuO4rWjK6sZ1Y2dySiiitjEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDlPEvh67XUv+Eg8LyJb62ihZ4HOINRjXpHL6MMnbIOVzzkcVpeF/EVn4ispJbZZYLm3fybqzuF2zW0o6o6/qCMgjBBIOa2a5jxR4cuLq8j1rw7cpY+IYE2CR1zFdxg58mcDquc4YfMhJI6kEA6emyyLFGXc4ArD8KeJbbxBFcR+VJZ6rZMIr7T5v8AW2zkZAPZlPVXHDDp3Am1C586TYh/dr+pqJy5UXCPMyvPK00pdu/QelY00P8Aa3izS9OwGtrMf2ldDGRlTtgU/V9zg+sFajsqIXchVUZJJwAKj8AwNNaXetzAh9VkEsIIwVtlG2EfiMyYPQysKwpLmldm1R8sbIkhZB8R7wTtiQ6TB9mDcbh503nbfXH7jPplfWulrx34q38et+JbfS0H+jaOwmklUlX+0unyqGHI2o244PJdf7tc6PtYz/xONe9f+Qxdf/HK5cRm1HD1HTkm2u3/AA55NbH06U3B3Z9CUjusaM7sFRRksTgAV89SRSyf67UdWm9PN1K4fH0y5xWTqGm6X9t0yOS1gmvJr2AQiVRIzYlXdndk7dud3tmud57SekYv8CIZjTnNQSep7xf+OfDNiZFk1m1mljGXhtCbmVRjOSkYZh+VY0HxAk1e8ltfDWjT3BjiSZrm+lFtBsfOwjAdySATgoOMHgEGtOCGKCJY4I0ijXoqKFA/AVleF9AtvDtlPbWjs6SzGX5gBtXAVEHsqKij2WvnK3F1WcJezgovp1/yPcWGSepm6zL4gvNZ0ayv9caKK6eR57bTYzbKYUQk/vMtJne0QyrLwTx0xn+PtOstF8G3CaVaxW8txdWod1XLSkTISXY8sdqnkkmu1a2he7iumjBuIo3iR+4VipYfiUX8q5n4kWban4faxhkEc7ussTkcK6EMufbIGfbNcmW4zFZpmOHp1Jt6ptdNHfbbZGWMlDD4ec/L89Dk59kBEgG2JWOB1wFeJf8A2Ws542i+GdsXGHttPhmPsY1V8/8AjtNbUlutKu2mie3ubQOLq3floS0gYf7wIBII4IrXgsPtnhKPT5iYxPYiByOSu6Paf51+2fFt2PgPgtzdzWorh9N8W3l9ZxZl0uC4HySLH5t3IHBIYGJFUg5HTJ6irAvNVuvuT6vKev8Aoemx2o/8mSf51Sqp7EvDyTtLQ7Cs7ULi0uYNV0ktHI0Gl3usTQO2Y2eOOOOHzFzgjLMcHglAcfKCMBtL1O6GZLa4fOMm+1V0/OOEbD9M1ueB/C1jF4rsP7XMJilDww2dhbi3t2cjzCZhktJnyh1OCQMrya5sXedJ6HdlvLSxEfe30Oq1nw7b6Vb2mleDtHkngurcQ3OnSRvHYTQlSokkcjakikBiU+dhwVOVKp4l8I6/Z+HbfU4PFFzf65o1u8sbXVrF5cwCAvH8oV8PtAO525wfvAEen15/4m8dRT2mradoem6peXSIbd50tiI4HcEK7KT5jpnJzGj52nGa8N26n1qv0E03xHFIba31aBtMvpwvlJKcxTkjI8mXG2TI5A4bHVR0rdpuj3Xh3X9JbQo9l1DBAkUtleQPHJ5YAALRSANjjg4696ybW3uNB10aLNcSXVjPC9xYSzMWlRUZVeJ2PLbfMQqx5IJByV3HnnTsro3hUu7M2K0dJlwzRE9eRWdT4nMciuOoOazhLldzSUeZWOhopFIZQw5BGRS12nGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHPKsMTO3QfrQ3YNzlPHOitfS29/o90NP8Q2ylYLsLuVoz1hlXjfG3p1B5BBrN8M+IU1Zp7O8h+xa1aAC7smbJTPR0P8cbY4YfQ4IIHQSOZHZ2OWJrmPG+mW82nNq32v+zdQ0yN5oNQVdxiAGWVl/jjIHzJ34xggEckpc7OqMeVD9Ze21jxLpvhaa5hSK6iku7uEsN80MZUCHHo5Y59UjkHuOs8Xa7D4b8P3Woyr5jRrtggBwZpTwiD6nH0GT0Brivh3HYavYXmleMdKgTxRPJ9vvrK8jV9wPEUkWc5RV2oCOVYEHDEk8VrI03UPFU1zpERXS7AG1ti0ryLJICRJKgYkKo+4pXGQGPIYVOJxEcHRc3v+pwYvEqlFzfyI7OOWOEm5l866lZpZ5cY8yRiWdsdsknjsOKmorO1m9kt0it7MK9/ckpCrchcfedv9lRyfU4HUivim5VZXe7PltZyu92N1HUpFufsOmxrPfkBm3E7IFOcM5H04Ucn2GSJ9E01LG7W5kka5v3K+ZcyfeIBztUdFUdlH15OSV0vT4tOtvKiLO7HfLK/LyuerMfU/oMAYAArRtUMl1Ci9WcAfnSqTUYtR2/MtPVKJ6rRRRXyJ+ghXL+JJd98EHRF/U11FcTfy+feTSZyGY4+navueAcJ7XHyrvaEfxen5XPneI63Lh40/5n+X9I4/x3p8zabcalp0Ze7igZJYl63EOCSvuyn5l98jjca6DTmR9PtWidJIzEpV0OVYYGCD6VYrF0L/AEG+vdIIxFERcWvp5Tk/KP8AdYMMDopSv121pX7nx/M5Qt2HeEhs0GGDtbSS2w+kcrRj9FrYrG8PyJEuqQuwQwXspYE4ChyJAfxD5+pNTT+INGgfZNq2no/91rhA35ZzRFpRVxTi5TdkadMkuo7GW1vJ5VhhtrmGaSQnG1FkUuf++dwx3zjvWV/wkent/qPtlx7wWc0in/gQUj9axfFOvzQ2lpPJp09vZx3ttIzXLKrzbZVYJGilmJyASGC8A1FWUXBo1w8Jxqxdtmj33SfE2manfGyhlmhv/L80Wt3byW8rR5xvVJFUsucZIyAeDg8VzWvXSTWGn+NNPilVIojFqEDL8/2bcd2QOrwvubvx5gGSwqG6sbq+03U/FMdq8eoi5iu9PjmHlS/Z4RgRndjYZVM/DYwJgDgg4PBHihJtLuE0rSNT1NJL26uMWyxbIlknd8NK7rGzZYkqrMVzggHivnGrqzPuU7aov6npdprEMErMyTR/vLa8t32ywk/xI49e45BHBBHFUQNcvNZ0pdWggcaeJWOoROFFwGXaFMfVW7t1X5QQedq0PD+o2+l6xJoixz2ti74s4LlNklq5Bb7Ow6FcBmjZSVKq6A/u+eurlblC8TpVp2kFFFFZmht6cxa0TPbIqzVLST/ozf7x/kKu12w1ijjn8TCiiiqJCiiigAooooAKKKKACiiigAooooAKKKKACiiigArH1KfzZdin5E/U1oX03kwEj7zcCsOsK0vsm9KP2grHtrVvE2vvDIMaLpUyGYf8/VyArqn+4mVY+rYH8LA39UvodM026vrpiILaJpXIGThRk4Hc+1aXgrTZdK8MWNvdAC8ZTPdYOf38jGSTB9N7Nj2xU0Y3dx1ZWVji/js0EukabZWzvb+ILmY/Yb2ElZbRFA86QEEHbtIQjOCZFz7eY+H9QKFdI1CGK01C3jAWOLiKWMcB4s/w9AR1U8HsTvapqZ8R+J9R1vdutSfslhjp9nQn5x/vtufPddnpTdo3BsDcBgHHI/zgV8zmmMVaq4dFt6ny+OxCqTceiEdlRCzkKqjJJOABWRoKNdyS6vOpD3QCwKwwY4B93jsWzuPfkA/dpdeJu3tdKU8XZLT/APXBcb/++iVT6OfStcDivN+GPr+X9fkcXwx9Qre8I6e11qK3DD9zAdxPq3Yf1rJjtwLZ7u7lW1sYyA88mcZJwFUdWYngAck8V0+m2+s3trHFZj+wtMxw0iLJeSf7WDlI8/7Qc+oU8V52Kq2g4xdvP+uvoerleAlVmqs17q19f+AaHinxLp/hu1SS+kXzpciGHeqFyOpLMQqqMjLMQBkc5IBpaauq67ai8PiG3t4H+4mjrFMq+xlkVw59wq/Svn34ra3Lo/iGzfw/ate+ItSkaOzubxPtkscCStGhjEm4b5JBIwwBhdgUDJr1X4fR+I9G1HTB4ue2fWb79zePAABIrJJJC0mAFMiGGVCR1Ei9cA0quWrD4aNVNXd97X03stdOl97+TPp1PmlY6y71HUPDoP8AbNyt5p0pEUV95YSSKRuFWUL8pDEgB1C8kAjnNZdWvi6kdz4OexmQPHd3MMbKe4VxIf0jNc74XunmsZbW4dpLmwma0ldur7fuufdkKk+5NffcAwX1WpVas5St62X/AAWfK8Sa1IJPZfmbFY2ugW19pWojjypvsshx1jmIXH/fwRH6A1s1neI7Z7zQdQghH754H8r2cDKn8Gwa+7lsfOU3aSuc7Por6j4t1e5WPRw0YhRften/AGhz8md4beuM5K4x/APetiDSdQRNn9qpbJ/dsbNIgP8Avvf7f56N0W5S61y7nhOYrixtLhe/3jN/RRW7UQgnqaVKkk1F9EvyMg6GZRi81XVbgf8AXcQfrEEqey0XTrO4FxDaoboAgXEpMkvPX52Jb9a0KKvlRm6knpc9A8LR2+t+CtJXVIYb3EEayidBIGlj+Utg99yk+tdEiLGipGoVFACqowAPQV5Xoutarpvg469bPE2m29+9ummRwl3uFNwYmKvnPmtIxKj7uCoOMlh0HxBup9S8I6fNoM8UsF9dW2JPMdI5o3I2KXT5lV2KLkZ+9yCMg/OVFaTR9zQlzU4t9Uh3iTTrHWfGlvps7kNPpNw0/lPiSMpPAYJP9llYylT67uuDUWiXN2s95perFW1GwZVaZV2rcRsMpMB23YII7MrAZGCcGxtbJLSPXPCemRWer2MrfaLRYlillPHnW8vTLEYIJONwRsleu7p0s2p69qOsvazWltPBBa28c42yOsZkYuy9VyZSADzhcnGcVyTkpR8zshFxl5GtRRRWBua2kf6h/wDe/pV6qOkj/R2P+1/QVersp/CjkqfEwoooqyAooooAKKKKACiiigAooooAKKKKACiiigAoopk8giidz2FD0AydSl8y4Kj7qcfj3qpSkknJ6mo55o7eCSadwkUal3ZjwqgZJNcMnd3O1KysZLwnxB4mg0xCTYacyXl+R0eTOYYfzHmMPRUB4ep/i3rD6d4WaxtJTHf6s/2KFlPKKwJkcem1A2D/AHivrWj8PLNrbwtbXM8ZS81EnULkMPmDy/NtP+6pVB7IK828b6l/bXjm8dWzaaUn2CDngyHDTMPx2J9Y29aWMrfVcO5Lf9Ty8bX9nTc/uMqCJIIY4oUCRRqEVR0AAwBTqKrm3u9Y1BNG0pzHcyrvnuAMi1hzgv8A7x5CjueeitXxLa3k7I+apUpVpqEFdsp6DG+p6vf3kCtIGYWkAUZysZO4j6uWHuEFei6P4WVNsupEM3URKeB9T3rX0HRLHQrCG00+EJHGgjB6kgDAGa068bF5jKq2qei/E+owmUQg+etq+3T/AIJhWOhs2qHUdWeOeeF2WyhRcRWkfQbR3cjqx9SBgZzu0VFdXENpbyT3UscMEY3PJIwVVHqSeAK8+U5VGrnspJHjXw08M/bfiFa69fxBl0/w5p8dmG5w0kbBnHuCki/8CNdvrDibxxp8URDfv4EcjnYY4bqQ5/77i/7+CuTu/EKaJcz3Okw6veaOgkmS806EDZEzNIyN5yhJI1beyOh+UEjoDu3/AAHcWl9q3266kni1CaFzbW1zFNG5jYqXk3SInmO22PO0bUVUUccn28V7STdea05bJdvXt3f9XxjbZFj4nPul8NQjr/aQlI9likH83WuV05/I8Uqna/05Zm9PMRzk/U+b/wCO+1dD8Q5V/wCEm0RGPyx208pHoRJBz/3yJPyrnrlDFq2hyNhXSYWj5Pb7PIx/8e2D8K/S+DKfJlVOXdt/jb9D4/O5c2KkvL/gnSUUUV9gfPnA6LeXWl3MCQwW0kX2EWpae48kKbaaRDg7SD98Z9PetOTxPIjbJbrw1A3X5tWLHH08sfzqvpltbzeJIYLiCOUQHUmUSIG2lp4Hzz3+f9a7GKKOJSIkRAecKAKwgpWsmddWUL3auzlP+EoLYCan4ccn/nneGQ/XAHNNfXNTkU/Zp43YjC+Xo11ID77iyr+BP4119FXyS7mXtILaP9fcO8CSz3vgXRtGj07UzqCajb3N1JLbvHHGVuEnldnICnO1+FLcsB710Oo6Lq+m6nb2tnZS6h4YF5/aK29q8YmilB3iIiV0XyhLiQEEkEbcBQDVz4YysYNZhdmJS8DqCcgKYYxx6cq1dm7rGheRgqqMlicAV4OIVqkkfZYOXNQg/I8x8V395pWpL4o/4RzUrCyRBHq7SPA26AdJisUjkmLueuwtwcLjq43SWNZI2V0cBlZTkEHoQab4o8Q+HxoOqQXeqWEga3kieBZ1Z3JUrsCg5LHoAOSeK5vQbW58KnTdHv8AIsryFTZuT/qZwm6S2PtwzJjjaGXjYM8VWF/eR30p291nT0UUVznQbWmDFop9STVqorRdltEP9kVLXbFWSOOTu2FFFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUtWfbAF/vGrtZWrtmZF9FzWdV2iXTV5FCsLxbH9vtrPRB97V7hbRwP+eOC82frEjrn1ZfWt2qHh2P8AtPxjeX+AbbS4TYxN/emkKvLj/dVYhn1Zx2Nc9ON5HRUdom74r1mPw/4c1DVJF3/ZoiyR5/1kh4RB7sxVR7mvC9Nt3trKOOeTzbg5eaX/AJ6SsSzufcsSfxrufjBqJuNQ0nQoz8in+0boA9lJWFSPQvuYe8NcTeXMVnbSTzkiNBk4GST0AA6kk4AA6k14meV+epGjHp+b/r8T5nM6jlNUl0G3Us3mwWljF5+o3TbLeHOAT3Zj2RRyT+AySAfSfCnh+Hw/pxhWTz7uZvNurlhgzSY645woHAXsB9SczwF4el06F9U1VANXvFG5M5+zRdVhB9e7EdW9guOtr4fH4rnfsoPRb+b/AMv+H7HuZZgFhoc0vif4eQUUUV5p6ojEKpYnAHJNchAkWpGLxB4meOCxVg2n2dx8qwgn5ZZAeszcEA/czgc7iewryX49prNzBpNh4eupLbUL2ZbaKRGK7A7qrvuHK4yg3Dna7AfeIPbgKftaqpXtfr2XX+uxE3ZXJdRlttPnOnJLFPpN5eQXdlLG4dGjN3b+dDkcEJhjjpsbH8Jrzz4Y+H9Zs/Blx4zvL+8utQl1Jphbu5ILRuybhnne8m6In+47fUdzong6/utA1fwvrOqG71S2RHh1AZBM+w5ckkt/q5EjPqqnoah0DxkkelSabqKwWt/Ddi4ntGbbL5yzCSVIk58ze6uVCkkF8Y2gM3uQqShSlTo+9qr+ce69evmvNIya1uzU8XXMd94qeaFw8K6ZC8TDuJBcE/oi1n+IG23FkwOGTVIW+gKqh/8AQwPqRUOn2stpfSWl0B51nDaWEgByPkgtyfwzIw/E1Jr3/Hta/wDX7F/6Ww1+pZDRVHLKMF/Lf79f1PiMxnz42T87HS0UUV7x45yOmnb48ukz8o+07R9Y7Fj+pNddXCavaNeaxNDAkb3B1kFfMdlAX7Am4krzjpwOpx9avf8ACO3I4kstMnx0Mk85/Q7sfnWMZNN2XU6qkIyUW30Otorkv+EamfP+haLF6DZJJ+PVfy/Wj/hE7jGDNpTR/wDPNrKYp/3ybjH6VXNLsZ8kOsvwO8+HlnH4nfU7pr26j0yCc28UdjcvbmeRQA8jvGyswByirnHDHnK4u+Gz/wAJF4f1LRPErtcaReWYvbWaWX96trI8gQO/HzqERw55+YckqWOR8P8AQNXj0vWdK0/WdOt7e5YNIVsSJYFdNn7sCQKOFO0kcEchuldX4s8FzaoLMaRqCWNvHbizubSSHzIbu3BBEbYIZQMEHB5VmU9cjwsTf2srn2GAt9Xhy7Hn3he6uNLXw1fahaRPrcFhHck28IWS/sZEG/CYz5sTFWK9Tt+XHmYHo3ja9s9S8C/2lYzxz2oltrqGeM5X5Z0YMD+Bz+INNu/BNncaHqi6jFb3+sXitI175AjdJAuI/K5JjCYXbhsgjOckk8v4Ji0LxLo9nq8mk2S6mRHLdBrdQyz7VcORjnOQ6ueSCpFccnyLyO+K52drT413yKo7nFMq3pib7oHsozXPFXdjok7K5sgYGBRRRXacYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYupnN4/sAP0rarDvjm7k+tY1vhNaO5la5qCaTo19qEql1tYXm2Dq+0E7R7noPrW14S0ptF8OWNjMwe5SPfcSD/lpMxLSP/wACdmP41zPiBftl/oOlgZF5fxvJ7RwgznPsTGiH/fq58V9UbT/B89vBIUvNTcWEJBwRvB3sD6rGJGHuoqYNQg5y2QsRNR1eyPLptROuavqWt5LR302bf2t0+WLHsyjfj1kNaHgnSv7c1g6ncoG0zT5CtsD0muBw0n0TlR/tbj/CDWM9vLczWWjaYfJuLs+UjKP9REo+eT/gK9O24qO9euabZW+m6fbWVlGIra3jWKNB2UDAr86zXGvWX2p/gv60+883KsN7eo8VU76f15Fmiiivmz6QKKKKACsnxDoy6vBEBIIp4X3I5BI9wQCp9CMEEMqsDkCtaiqhNwfNHcTVzkzB/wAInpWparcTR3N3II0y7MiZ3ELvZix+85y393AC4UCuP+H3xA0/XfFAnsJYntdUzDOY1ZALmNRtco3K7kwpJJB2x4Od4X0XxXpzaroF3aIgkdgrCMnaJCrBthPYNjbntmvKIdMt/wCwNG0rRrYQ6rptvsxgAyXMC7oZGXJOciRiDypbBwSufXwnsq1Kbq/E9L9Erbv5oyldNWNW3b7RrurTHpPqMgPr+6eRB/6JX/PSprB/4l0Dd2uNPc/VrtSab4eu/tNj/aAGfOaa+X3DkyD8/OJpdejKw2MO4kDUrSLPqqFXA/MfrX7fgafssJTp9opfgfn2Ilz4mUvP9Tp6KKK9E885K2y3jKdOgW+kkz64s4Fx/wCPfpXW1xIvILHxbLeXr+XbyXNxCDgna/k2wBOB0xG/J4+YCugPiPR/+ghB+dZQkle76nRVhJ8tl0Naisn/AISbQx9/V7CM+klwqH8iRUkWv6PNnytW098ddtyhx+tXzR7mXs59jrfBupWWjXGu3+q3MNpZpBahppmCrnfMAMnqckce9d1pGsafrEUkmmXkNysbbJAjfNG391l6qfYgGvOPh0bLWvFd7OZYbqDSbeKSHawdEmlMgZvQOqRgA9QJG9TV+xvp7rxdpfimZorXTL+3uLeGMJteS2VfNSaViMnOwsq8bVf1ZhXg4r+NKx9jl11hoXF8SeL9TudOludGiis9C83yptWkYtKsOdr3EUWMbF6h2boC21gButeKtHsvDtpo2paWBbS2ctnpZUHAnt3kSFY39ShcMp6gggcM2cDwNHcW/hzT/DmvfvPP0qKa2dgB5kDRqHjPGN0ZYKfVWQ8knGlYxavqg0W21y1MNvpEamRmkVxe3Sjasq7SSEA3MA2DuZeBsyeFz3Uj0lDZxOlrV0hMRu/qcf5/OsqtvTl22ie+TWdFe8aVXaJZooorqOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEZgqlj0Aya56Ri7sx6sc1sak+y1Yd2OKw5pEhieWVgkaKWZieAB1Nc9Z62OiitLlLRIxfeO57jBMel2XkBu3mTsGYfVVijP0k965D4lah/aXjZbVCTBpEGwjnBnlAY591jEeD/00au28E7NP8ISaxqWbd73zNVuTJwY1YZUN7pEsan/crxqS+lj0y+1i+Ui4n82/mRjypbL7P+AjCj2UV5+bVXSw6preWn+Z5WZ1bQ5VvI674Z2Anm1HXZVyZHNlak9oo2w59i0gbPqEQ13tZfhbTm0jw1penyYMttbRxyEfxOFG4/icn8a1K/LsXV9rWlLp09Fse5hqKo0o010Ciiiuc3CiiigAooooAKbtXfv2jdjG7HOPSnUUAeL+GUH9gwxrgIsCW8YH8KkiLn6CMGpdXPmanokZyfOv5GI7ZjVsH8An50nhVf8AiT2qsQQ8w+Yf3QDIP1/nRJ++1zQ16ld1yT6HypA36zL+lf0fR1pRv2R+a1P4svn+p01FFFdRxHEWFtJqGtoYrue02SX8u+DYWJE6xjO5SMYRu3celdCNKvP+hg1T/v3bf/GaxvBhM2oPNjhrQXGf+u880nH4AH8RXX1lTSaudFaTjLl7GU2n6juO3WpwueAYIj/7LUUuj3spBl1Z3I6brWI4/wDHa2qKvlRkqjX/AAyIfBOgalcXevaUup2qWuowxfaZBbFZvIG5CibSFDHc3z9RkfL0Ndx8QPDGoa9HpkelzwQ2tt5iT2rMYvOjdNm0SBWKrtLAgLk54ZcZrI8Dypaa7e3V06Q2q2iq00jBVB39CTXW6p4o0yx0u31COU31tPOlvG1liUM7fdGQcDJ45PJIA5IFeFjFasz6/LJOWGi3/Wpy/irStcuH0f7fqdkssl55cBtbQp9jfy3KujFiW6bXU4DKzDCmrei6o91JNY6jEtrrFpgXNsCSMdpIycbo26hvqDhgQKPiDxha3sljLFY6nFaabqKPe3c0GxLYKpDb1J39HHIXAB3E4FbPxLtLeTwtdaqmI9T06F57C5Q4dZcfKme6udqsp4IP0I4pwUz04ScC1XQwLthjX0UCsBBucL6nFdFWdBbsut0CiiiugwCiiigAooooAKKKKACiiigAooooAKKKKACiiigDM1d/mjT0GTXJ+Kojf2tpoyk51a4W0fH/ADxwXm/OJHGfVhXSag++7f0HFY+lRi58fM0pA+wacDED/EZpCGP/AAEQKP8Atp71zfFUOj4YEfxfuxB4NexXh9TnjsQB0KElpR+MSSCvK7+MXAtLVhuW5vLeB19UaZA//jpauu+KuoC+8YWGnRtmPTbZriYA5Hmynag9iEST8JBXKzOIr7SZX+4moW24+mZVXP5kV85nVbnxCgvsr8d/8j5/EzU8XCHRNfmew0UUV+dH1wVFdXENpbTXN1KkNvChkkkkYKqKBkkk9ABUtcf4g/4qTxFF4dj+bTrPZd6qez85itz/ALxG9h/dUA8PWtGn7SWuiWr9P60XmS3Y66N1kjV0YMjAEEHginUUVkUFFFFABVHXL9dK0W/1BxuW1geYqOS21ScD3OMVergPiPrMcl5aaBAwaX5b+6X0jjO5EPuzqD9EIPUV3Zbgp47Eww8Fu/w6mOIrRo05VJbI5/SLVrHQrK0DbmgtSikHqxwqH6nn86LT994xYooC21o+QO3mSKg/9JifbNXDtgXDZZIyqEr1KxrvyP8AgXH6VU8NIX1PWp3O5kliswexEcYY4/4HJJ+Oa/oVR5bR/rQ/N3K/NL+tToKq6vdiw0q9vD0t4XlP/AVJ/pVqsfxac6FNCelzJFan6SyLGf0Y1rJ2TZhBXkkzF8NzpoTXlpdW163leREksNs8y7Vtoht+QEgg7jyB96tz/hItOH+sa5i9fOtJo8e53KMD3rO0XTf7RhuNRnvb5Xu7iSQLDO0aBAxSPAH+wqZPc1o/2Ky/6nVdUiP/AF2D8/8AA1b/AArKPMlpsb1ORy97cP8AhJNH/wCghD+Zqa11zSbvi01OxnI7R3CNj8jUH9l3y8rr+oE+kkVuR+kYP61Dc6PfzgCW+srkDp9q09ZPzwy/piqvLt/X3kctPv8A19x0XgaOw1zxpeGQQX8OkWayCIbZAk0rNhsdN4WNgO4Dn1pjWem6N4QsfEeptMdM163B13yg7rmePdHKiqDtMbbY1KgfKwJyVFN8AaX4gtL3WTpEuhtLPbQQFtr24tQGmKyCIb/M5duCyA7cZHJr1fS9Nt9O0W00uFS9rbW6WyiT5iUVQoz68CvExbbqu59blqSw0eXY88vDLodlpGv64Y1g1Ozt7bW95XYlxsAWY84wSTG2M8bDwqE1V0i/n1jw1pXhy1jgvbTT7i3jm1S2u4pYHit2V04DlxI3lxhlK4GWO4jGfQbPwr4esbtbqy0LSre6U5WaGzjRwfUMBmuY8d3Vponi3SNSMUiNNbTrezQpuAt0MeHkA52o7r8/O0O2cAkjilFq7R6MWnZM6K1G65iH+0K3qwtLZZbiF42DIw3BlOQRjgit2po7FVtwooorYyCiiigAooooAKKKKACiiigAooooAKKKKACgnAyaKiu22W0h9sUm7K40ruxhO292Y9zmufsfD9l4m8Tareai14P7MMdjbG1vprVoyY1lkO6J1PzCWMEE4+Qe9b1cne6y2hfDjxFq0UywXd5qFzBFKxA2Seb9mVznsqxhvotc1NpNyfQ3rNRicNDDbRaprR06SaWwe+k8iWeUyySBQqMzO2WfLq+GYk7dvOMU+8t47u1lt5gTHIpVsHB57g9j70/w9o+ralZ28PhvRppLFEVI7q6b7NBtA4IZgXcY/iRGHvXRP4D1OCES6z4l0fTAeqLbmTH0keRQev8Acr5mWBxWJqOtGNru+uh8s8NXrTdRRtcb4f8AHUVtFHZeLJFtLlPkXUGG23uB2Yt0jc91bAz90nt3UUiSxrJE6vG4yrKcgj1Brz9fD/hJSVvPiWm/JBWO7sUH0wyMf1qvbeEfA1rK0mneO9WtCxJLWF3BCrn1PlxAN9TnNcdXhOpUfNGSi+26/wCB+J9FhsTXSSrJPzR2vinWV0LRprzymuJ8iK2t1OGnmY7UjH1YgZ7DJ6CovCOjPoukCO6lWfUrlzc31wBjzZ2+8R/sjAVR2VVHavPbJNL1rxBcXLfEuW3sNGl8rTpNQlsi8s20iaXa0a5QBvLUnnIkwcHnttMtNevLdho3jnw1q79VL6duJ7ctFcADof4fX8OepwtjYU+SDi776/ctV/T9EdixEb3Z09FcnPb/ABJs1ZpLHw7qC5O0WTyK5HusrKv/AI9WXeeMtf0vP9teHUsgPvSXMsscSfWVYnj/APHq4nwvmV7Rgn81+rCWLpRV2/wZ6BRXBR+J9cv4Flsl0WCNxlZFkku1/DHl5/z+NW5/ta/yNR1u68s/ehsgLZD/AMCXMg/77rvw3BGaVmueKgvN/wCVzz6ue4OntK78kdL4j8TwabOLCxVbzWHGVt1PEIPR5T/Av6t0APOPMtPtW/4SfVJJZ3upyYYriV+DJLjezY6AGOTaB0CoB2FdTYWFrp8JisoI4ULF2CDlmPViepJ9TzXMaB/pVvc3R5+23EkgYd0Ztkbf98N/477V+h5Hw3QyeN0+ao95fol0PnMbmtTG3W0V0/zNgsCkRc7QUDsO2HYuw+gCEfjUXgtWOgRXEnMl3LLdE+okkZlP/fJX8qreJLt7bStSuIhudY5GVPVsbAB7kI/51u6baJYabaWcX+rt4khX6KAB/Kvo4/EeVLSHq/6/MsVi+I5UW60hJWAjFy08vOMJHE7Z/Btn51tVyPjGRGm1LzGIS10ecNt6lpyFQD/aJiYD3NOo7RFRV52NrwrG8XhnSklUrKLWMyA/3ioLfrmtSuRs/Fcv7uC4t9PS54Hki8MTt9I5URh9P1rXGq3vfQNRJ9UltyPwzKD+lKM42sh1Kc+Zt9fNGvRWSNYmH39G1RW7jbGf1DkUDXY/+fDVP/AR/wDCq5kR7OR2vgK5t7LUNeuryaK3t47a1LyyuERRun5JPArtLjWrCPw/PrUVxFc6dFbvdedbuJFeNVLEqQcHgV5r4KWPXZ7zUZ7NxYaKWKxXKBfNutiurFTz+7RvlJ7ykjkA1b0dY/CnhKyXW5kn8J6pbKbya4OPsk8y5kZuwhkdj6bGf+63yeDimnVk0fZZfFxw0E+w+21TxPNew2XiHUJdD1C6UvDHaQQvC4AyVikcPl1HUMATgkLgcR+GtU0XwidQ/wCEpuWHiAEIby5kaabUYi37vyVJJJ6BokAAYZxgqTv2umz+I/hrpMNxOY9YSzt5lncfNDdoisCw6j5uGXuCw70zQdRTWNKt7wwmGXLJLC/LQSqSkiE+qsGU/SuKcnB36Howipq3Uf8ADuxlsrIiW3WzWSSSeKyU5W0jZsrED04B5A+UEkLwBXZVlaQP3zn/AGcVq06WquKpo7BRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9VbFtj+82KuVnaweIh9TUVHaLLpq8kZlcLcaPrN7d2Wnvp1gtlpmpXWpQ3d6PPileVnaMiFWBLJ50oO7ABVWBOcDuqK5YycdjplFS3MiTR57w7tY1nVL0/wDPNJzbRD22w7dw9nLU608OaJaOZLbSNPikY5Z1t0DMfUnGSfc1q0UOTe7BRS2ERQihUAVVGAAMACub8a6hciK10XSJTHq+qsYo5F620Ix5s/8AwEEAersg9a6C7uYbO0mubqVIreFGkkkc4CKBkkn0AFc14Kt5r+S58T6hG0d1qaqLaJxg29oMmNMdmbJdvdsfwiku432Og0rT7bStMtbCwiEVrbRrFGg7KBgf/rqLUNG0vUs/2jptld5/57wLJ/MVfopXAxo/DlpakHS577TGAwos7p0jX/tkSY/zU1Ol14o08jybqx1iEHlLtPs02PXzIwUP08sfUVpUVaqSXUlwi+hyV9D4Q1K7/wCJvYXPhXWJmAFyCLfzXOMfvUJhlJ6BXJP+zVbWPDmvaCplVG1ywXrJbR7bqMerRDiT6pgnsldpLHHNE8cyLJG4KsjDIYHsR3rFt9KvNC+fwpcrbwg5Om3JLWreydWh/wCAfKOpQ110MbOm9H/kcOKy2liF7y/zOB1zV4x4YvL3T7hGZkMULqc4lY7FB9CHIBHUVFpduthZ28USYW3jwiZ/ujaE/FmfH0rrda0DSvG9zI0EbaF4sgK3E1rL/q7oLgBnC8TJ0AkX5lOAcYKVysck1tdzWOqWz2mo2qq89uxB3Io3CRW/jVnY4YdcEHBBFe3QxUaz7M+YxmXzwsdNY/1uUdZjMkmmWSnd5t5Egbp8sXzkH2Ijl+tdVXNwIZvFdtGxDCztndyOhdiFVvqf34rpK64dWebVeiQVyF3/AKVrc2TnzNUtrVPQrDH5/wCjb/yrr647Q2Fxe6ISeJ/tmqrzyQzgJ9fknx+FKp0Q6Ol3/Xf9Drpoo542jnjSSNuquoIP4GsseGdEX/V6TZRZ6+VCqZ+u3Ga16KtxT3M1KUdmZA8OaWD8tu6D0SeRR+Qaj/hHrDpm92f3Pt0+z/vnfj9K16DS5I9h+0n3ZqeD/BtveeGC1je3mlxXj3NvfQ2zZS5jEjRg4bOx9qgeYuDgn0Ur2ev+GrbXltLXUJJG0mAq7WKfKkzoQU3nqVUgHaCATjORxXH6L4tl0PQdHEWizXenXSSTxNBNuupoxmSS5EO3Aj+YNy+751G3cQp6/W9Yl+xaQdDltWfVZ1it7mZTJEqmJ5d5VSpbKoQBkZLDmvnJvmk2fdUY8lOMX0SMfxP4f0jRdPhv9D02007U47q2igls4VhZi8yII22gbkIYgg8YOeCAQmqxNovjFHUY0/W8g/7F2ifyeND+MXq1Y/iceKR4i0y3vtS01kj3XenGGyaGK4uUBzDMWkkIGwsRt5+83WPBv6vrR8SR6TaW+mahb3Ud3Fc3X2q3aNLYJliBIRtkJI2jyyw+bOcVhNpppm8E000ddo4/1p+g/nWlVDSB+6kPq1X6dP4UFT4mFFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZesH54x7GtSsvWP8AWx/Ss6vwmlL4jPooorkOoKKKyvFGspoWiz3piaeYYjt7dT808zHaka+7MQPbr0FAjD8Sf8VL4hh8NR/Np1sEvNWYdGXOYrf/AIGRuYf3Vx/HXY1ieENGk0XSNl5KtxqdzI11fXAHEs7feI9FAAVR2VVFbdNggooopDCiiigAooooAo6tpdvqkUYn3xzQt5kFxC2yWB8Y3I3Y4JHoQSCCCRWJqln/AMJCLbRvErrb65Dl9K1qGPCysOdrL0DYUF4s4cDcuCvydTVbU7C31OxltLxC8MmM4YqVIIKsrDlWBAII5BAI6VrTqum7oyq0o1FZnlOgQXlrr2twa1Attq0TxxNEG3B4gpYSoe6M7ykH8Dgggb9aGp6feeILV7R3T/hMNEXzLS4b5F1C3bs3GMNjaw/hdVYDBUHG029j1CyjuYg6hshkcYaNgcMjDsykEEdiDX02DxCrQ8z4jM8G8NUuvhZB4iunsdA1G6i/1sVvI8YHdgp2j88VzceiPqMrxRJpb2WmqljBHe2ZnzsQbmU7xsJLbeh+4PoNzxKfMi0+0Bw11ewqPcIfNYfisTCjwn+80VLjqLuWa6U+qSSM6f8AjpWt5LmlZnJCThT5lv8A1/wTI/sa9tzlNPAUf8+OrTxZ9/LICfmTSgaigA/4qiBfrZzZ/wDQjXVQTxT+Z5MiSeW5jfac7WHUH3qSn7NdGT7Z9UciNQ1KHG271Ar3Nzo7ykfXyiufwH6VG93e6veafpE2oFE1G7itHVdIuLRnjZh5gWSRiAfL3ngZ44rsqsaVYw6rrlhp91BHcWsxkaeNx/AsbYYEcghzHgjkHGKyrpwpyd/6+86MI1UrRjbr5f5Hb6FBFL4s1y5VAoslg0yEAYCKI1mYKO2fNTPrsX0rjrDW9Otrnw/oEl5DG9jrN2HDMALeFJJo7dCeilt8KqDjcA2ORXo+maPZaXaTW9lG8aTOZJXMrvJI5ABZpGJYtgAZJzwPSsLXtH0DQvA2vRfYYYbCS0mN1hdzzkqcl2OWkck9SSxJ7k14B9mbHiPRoNd0xrSd3ikV1lgnj+/BKpyrr7g9jwQSDkEiua0+8vYdSl0jWool1CKITJPb/wCpuY87d6gnKEHqhzjIwzdao6T4daz0uy+yXuoabfJEm77NcsYg+0bv3LZiIJ/2fpitLStKSxmuLma4nvdQucefd3BG9wM7VAUAKoycKoA5J6kk805xkvM6IQlF+R1OlDFr9WNXKracMWcfvk/rVmt4fCjGfxMKKKKokKKKKACiiigAooooAKKKKACiiigAooooAKy9Y/1sf0rUrL1j/Wx/Ss6vwmlL4jPooorkOoK5DTv+Kn8WSak3zaPo7vb2Q/hmuuVlm9wgzGvuZParfjXUblIbXRtJkMer6szQxSKObeIDMs//AABTx6uyDvW1pOnW2k6Za6fYRiK1to1ijUdgBjn1Pqe9PZC3ZaooopDCiiigAooooAKKKKACiiigDK1+0uWSDUNLC/2tYMZbcE4EoI+eFj/dcDHsQrdVFcp4iW1g1Wx8QaZu/sbxEBvBXb5N2FyCw/hLqpUjs8eOrV6BXNvpi339v+FXkEKajEdS06Q/8sZgw3kD/Zl8qX3MjV2YOu6U0zgx+FWIpOLOC16Qf2xbln2x2dncXTN/cbCop/JpPypvh7W9Lg0jTrOe6is7mKCOM210fJkUqoBG18E4x1HFYsM8uva08bCS2a4Mdtdxg4dEhjMkig9iJZ0Qkeh9q6J9HvY0aO01VnhIx5N/CLlB+OVc/ixr6SMnJ80T4qcFBKE9H/XkyPwowM+vBGDRjUnK4OescbH9Sa36850bR5k1fxEBpNk7pfJuksbp7OTBt4ThAo6ZyeX6lvqdcG+tx8p8SWi/wpIsF2v4kb3/ADYU4TaWqFUpJy0fb8v66HX1c8KT3/8Aa+oXmkWEN0bOI20s91cmCGIsFkZRtR2dseUcbQAO5JwOAu9b1W2tZpBcOzRozBG8P3TMxAyBuV9v8vwr1PTVTw/8J95uEutR1SBpEa3x/pN1cLlEi9RlgFPZVyTwTXJjq3ucq6npZRhn7b2j6G/4J8UP4isx9u06TS9REUdw1o8okzFIMpIrDGQcEHgEMpBHQnG0fw3b+KNLnm8Tz3t5qKXE1u5+0ukcDxyMoeGNcKh+UMrYLjIyxOa0/EGlT2Ok2Op6SYk1PRbdgiOdsdxFsG+Bj2VtikN/CyqcEAg4XhPVPEGmaYk11plpqcF7JJfM1lP5cyGVjJsCS4Vgu7aCXXgDjrXjuSW59Mot7Fm5n1Lw0VTX8Xel5CrqsQwU9PtEYGE7DzF+XPJCDFbdZ+oeO9EfSrmIxtLqbjyV0W4TZcTOwICeW3VDzlxlMBjnANP8NafJp+jaZp00vnS28EcDSc/MQoBPPOPrzXPUilsdFOTa1Ott12QRr6KKkoorpWhzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVmax9+L6GtOs3WOsX4/wBKzq/CzSl8Rm1FdXENpazXN1IsVvChkkkY4CKBkkn0AFS1x/icf8JJr8HhmPDafAEvNWPZkzmK3/4GylmH9xMH74rlSudLJPBNvLqM914p1CN0udSUJaROMG3swcxrjsz58xvdgP4RXWUUUN3BKwUUUUhhRRRQAUUUUAFFFFABRRRQAVieLJDYWltrcYPmaRMLtsd4cFZh7/umcgf3lX0FbdNmiSeGSKVQ8cilWU9CDwRTTs7iaurHlUulJZfE7xQ0Cr9jjkEkLBs/vLhUmmB/4EEP0YVr1geA0kXwxZtc3H2m8cbrmQnLeZ0Kt7rgLj/Zrfr6/DR5aUUfneOnz4ibXcwdD+XxL4kU9TLBIPoYVH/sprerB0r5fF+vL2aG1k/EiQf+yit6tIbff+ZjV+L5L8kSWrAahYxmMy+dcxRFAeSGcAn8Bk/QGu5tvBthpuJtF/0e+jBS3nuS9yLdCeUjV2wikcYXHvmuU8KpbN4r0+S6vLSHyVkeGGSYLLLKV2Dap5YBWkzjuVr0u/uGtLG5uEgluGhjaQQwjLyEAnao7k9BXkY+pzVOXsfTZNR5KHO/tM5fWfB1zrOl3FnqXirXCkyFW+zmGAAEcj5IwSPUMTVTwjqB1XwvpN8xhLXFtHITDwhyo5Udh7dulSDUtT8baGE0m0GnaVfxlJL2a5RpliPDCNIywD4yMsw2nkgkbadeeGrrRbiS78KxxvayEvPpTtsQt3eFuiMe6n5WPOUJZm82rByWh7dOXK9S+VUuGKgsMgHHIz1/lVvTl3Xae2TWRpOox6lbvIkU0EsUjQzQTqFkideqsASPQ5BIIIIJBzW9pCfNI/oAK54L3kjeb91s06KKK7DkCiiigAooooAKKKKACiiigAooooAKKKKACiiigArP1j7kX1NaFUNXH7lD/tVFT4WXT+JHLeJtYj0LRp72SNppBiOCBPvzysQqRr7sxA/WoPCGjyaPpRF7Is+qXchur6dekkzYzj/ZUAKo7KorK08/8JR4tk1E/NpGiyPb2g/hmu8FZZfcICYx/tGT0FdhXI9NDqWuoUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGJqPhTQtQuGuLnTLf7U/3riJfKlPGOXTDfrWfL4HsQP9C1DV7M+q3Zm/8ARweurorSNapD4ZNGM8PSqfHFP5Hldt4W1CPx9rNvY65kjTrKUvfWiylt0l0MYjaMcbBz71qvovieE7fs2k3a5wJEupISfcoY2wP+BH6Vsw/L8S7vI/1mkQ7ffbNLn/0Jfzrpq6Y4+vDaRx1MqwlXVw+7Q5Cz8KpbeFdShvra31DVL1Hln3DcrybTsRS2MKowq9PXqSa2NL8Q+II9KtRFoPnxwwojve3whuZioAZhGEZcnkjc6++2teiub2srtvdnaqMUlFKyRzUWuw23ii1u/DVnJMNYtriS9sWdYfLuIHhTzHB+648wq2AS2EPIUE7p8YNYyj+39MmsLVv+XuJ/tEKH0kIAZB/tFdo7sO8VvpVhb6nc6jBaxJfXICzTKuGcAADP4AD8B6CrtV7Zi9ijE8K3EV/DqWpW8sc0V7qFw6SxsGWRUcxKwI4IKxLg+mK7PS022uf7xJrHroLdNkEa+gFOl70mwqaRSJKKKK6DnCiiigAooooAKKKKACiiigAooooAKKKKACiiigAri/ibqdzFYWejaPL5etatIYYHAybeMD97OR6IpGPVmQd66+6uIbS2luLmVIoIUMkkjnCooGSSewArh/C9tNqovfF2pRNHcakFjsoZAQ1vZAkxjB6M+fMYdfmVT9wVM/hZUPiRe0fTbbR9LtdPsI/LtbaMRxrnJwPU9yepPc1booriOwKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmZPk+JcHcS6RJ+GyZP57/0rpq5m9+X4l6Lg/wCs0i+3f8BmtMf+hmumpsSCiiikMKKKKAJIE3zIvqQK6CsfTE3XQP8AdBNbFdNFaXOas9bBRRRWxkFFFFABRRRQAUUVxniz4jaH4V8XaH4e1j7THc6vnyLgKvkRnO0B2LAjJwBgHqOlAHZ0V554Y+LWgeJrdrjSYbtrcasmkCSeS3hDyMMq6b5QXUjkBcueyHmrN38SdKX4iaN4V06Wx1B71Lk3M8F6jGyaFd210APJ56lcYPWgDuqK8k8T/GzTdMv/ABBDo1vZ63baTpK6kbm11BWSRjMsRh+VWCkbgc5PpjvXoQ8T6Iuo2um3Gr6bBq1wivHYvdIJ23DIwhO4/lQBs0Vlaz4j0TQ3jTWtZ03TnkUui3d0kJZR1IDEZAyOaZa+KfD92boWuu6VObWMTXAjvI28lCMhnwflBHOTxQBsUVhp4u8NPpD6qviHR20tH8trwXsRhV/7pfdtB9s1y/gf4o2Pia3s5ZbSOzW7ury3if7dAybbcZMnzMjsCOfkRwvViBzQBueMdMvNfu9N0fySNDlcz6lMWH71EIK24Gc4diCxxjYrL/Fx0N5GZLVkjAJ4wPxrIs/Gfhe9tLq6s/Emi3FtaKHuJor6J0hX1dg2FHuaw7/4reD7TW9C01dZsrr+2GlSK6trqF4ITGAf3j7/AJdxO1cA5bik1dWGnZ3N/wCw3H/PP/x4UfYbj/nn/wCPCqNr488PNYrc6jqunaWryzRIt5qFtlzEcOQUkZTjIyM5GeQK0W8U+H0Qs+u6Uqi1F8SbuMAW5OBN1/1eeN3TPesvYxNPbSGfYbj/AJ5/+PCj7Dcf88//AB4Uy48ZeGLa5S3uPEejRXD+Xtie+iVm8wZTALZ+Ycj1HStDSNX03Wbd59H1Czv4EcxtJazLKquOqkqSARnpR7GIe2kVPsFx/dH5ij7Bcf3R+YrZop+xiHtpGN9guP7o/MUfYLj+6PzFbNFHsYh7aRj/ANnz+i/nR/Z8/ov51sUUexiHtZGP/Z8/ov50f2fP6L+dcjrnxc0bRtW1y0vNM1j7Lok9vBqF+iQmCBpgPLJHmeYQcgZCHFdjF4j0ObWn0eHWdNk1dM7rFbpDOuBk5jzu4HPSj2MQ9rIb/Z03+x+dH9nT+qfnXN+K/ix4N8OaTc30mt2OoG3lSGS20+7hlnDM237m8dOSfQA+lb8ni/w1E9kkniHR0e+UPaq17EDcKTgGP5vmBPcZo9jEPayJf7On9U/Oj+zp/VPzrN1jx54e061v5I9V069uLI4ntYNQtlljxIsbbvMkRV2s6g7mHJA6kA6j+I9Dj1oaO+s6aurnGLE3SCc5GR+7zu6c9KPYxD2shBps396P8z/hR/Zs396P8z/hTtH8Q6LrUkkejaxp2oSRjc62l0kpUZIyQpOBkEfUGqTeNvCqSyxN4m0NZYt5kQ38QKbPv5G7jbjn070eyiL2sjB1nT5E+IfhnJQF7S+QNz/0wO3OP9nOP9n2rqf7Nm/vR/mf8Kz9S1zwks2j6vqGuaRHkOdPuJL9ESXeArFDuw/HHesv4kfEnSvBdvbqJbG+1Sa4giGnfbUjm2SNt8zbgsVHXpg+tP2UQ9rI6UabL3dP1o/s2T++n61mL478PRR3cmq6pp+kpb3stjm91C2USSR43YKyNj7w+VtrjuoyKu3/AIt8OaebQX/iDSLU3aCS28+9jTz1PQplvmHuKPZRD2sib+zZP76frR/Zsn99P1rlNM+LPhrVE1Q2Ewkk07Uv7Nkje6tomc7gomTfKA0RJwDnJwQFJ4rpoPFnh241P+zYNf0mXUfMeL7Kl5G0u9PvrsDZyuORjI70eyiHtZF+xtWt95YglsYxVusWHxX4dmigkh17SZI54pJ4WW8jIkjjz5jqc8quDkjgYOelVl8d+EWRnXxVoJRNgZhqMOBv+7n5u/b1q4pRVkQ227s6OigHIyOlFMQUUUUAFFFFABXB+Nfhrp3jHxZY6prciz6dBYzWU2ntGR5wdgwbzAwK4Kg8D8RXeUUAeTQfBuC2nH2TVlhtk8S2/iCKFbXiNIU2i3B3+n8fbH3azdN+BjW0OmWU/iMSaZp1pqNnAkVj5c7JeKwYvJ5hDOu7qFGcdK9rooA8Tk+B91c6de2t54ltyZtAh0CJoNMMYjjilV1kIMx3MduCMjk546Vfm+DEB8XTaumqJNbT30GovaXaXLbJ4+N8ZiuY0B9C6OVz3HFdxDr903jbXNINusttYabbXsQiH72R5HnVlyWC/wDLJcdOScn0xpfilo/2CG7s7HVL1JYrJwtvEm4PdSeXFCdzgCTP3lzwO/IoAl8a+AB4n8T2OrnURbfZdOvLDyTb7932hNm/O4Y2+mOfUVxtx8B7e709bO51+Xyh4eh0ImG28slo7gTiY/OeMqAU9P4q6ux+KFjcXYgudD1yxzNdWvmXCQFfPt43kki+SVjnajENjaem7NY3iD4oyTaZYNpWm6vYXstxplzHBcRQM95Zz3KIfLw7KCwJXDFWBYdOtAFeP4MyR/Z7uLWbSPV7fVINVW5+y3MyTSRKyjzlmupGbhuquhGO/GJNH+Ds+mTaNPH4lZbnTp9UuFlhsghL3kewFcu20xn5hndn2roF+JllJ+5t9D1ufUozc/aLCNIPOtlgZVkZyZdhGXXGxmJzwDziCb4rab9pZLHRdc1C3E1tbrc2yQCN5biFJoUG+VW+ZZFGSoAJ5IHNAHKQfA26e5v7rWPElvrNze2MdnM2oWdzIHKSiQSk/aw4b5QAEZVHYDpW3Z/C3Vba78L6hL4vnv8AVNCu7q4Sa/t3uEeO4QI0QDTbwFA+Ul2IzzmrusfF7RNI0GLVb6xvoojLcwTQyT2kc0EkDlJEKPOpkOVOBFvzj3APodtMlzbxTwndFKgdD6gjIoA8o0n4Niw1HRbptcEo06bVJihs8eb9tTbjO842fju9qyT8B5otJgsrTxMiH+wX0G4eXTi/mRmczB0AlGxgxA5LAgdq9xooA8b1b4IjUbTXITrwT+07bTLfcbLd5X2MKM/6znft6cYz3ruvBvhH/hG9a8Uah9t+0jW777b5flbPJ+ULtzuO7p1wPpXVUUAFFFFABRRRQAUUUUAedRfCnSJ/GfiDXtblk1KPVLm3uY7JmkjhhaFNo3oH2TcgEb147VlW/wAHvJ1aCQ62sml22rT61BbPZ/vfPlXG2SbzPnjB7bQSOC1etV5N48+Juo+FPGWqWk1pZtoFpYQu10ytvhuZvO8oyHdjyi0QQ8AguOcUAZz/AAPuJfD2q6M3imS3066jiW2sbW3m+yWjpMJd6xTXEhySCCFZRz0q34q+DT+I/EF7q99rFtLNqNvBFf20tvdC3keLG1kSK6jKjgHa7Pg8g5q/pvxj0Jr7RtK1EkapeJZpOYpIVjinuI0ZVCNJ5rL86/MqMBnk8HGnL8UtEi0Ww1RrXUjb3unzalGoiQuIopI0YEb/AL2ZVwBkYB56ZAOfvfgnYXPhrxlp/wBttV1PxFqUl7/af9nqZreJ5o5fIzuyygx/3gMnOOKs3XwjE/iCe5GtldKn11PEL232X/SPtCjG0T7+I/bZkdjW7dfES1tLueG50PW40tfK+2zFISlmJXKxmTEu45ADYQMVUjcFOQKsvxV0eAPPdafqtvpZiupodRkji8mdbc4kKKJDJ16bkGaALfwr+H1h8P8AQfscH2W6v3eRp9QS0WGWYM7MqsQSSF3YGSenaud0r4PrYajpF0daEv2DWb3Vtv2PHmfaFA8vO/jbj73OfQVf034waJqkEZ0yw1C9vJL2OxW0tZbSZy8kUkqHek5iAKxOPv5BHIFSJ8UdOcx3CwXzRTW0bRWQtl+0PO101uIg3m7d29SMY2jG7fjoAcfbfs/x22laTbLr/wBoktNPl0y4FxBOsNzE87zcpDcxsMF8EF2U4BxmtDUfgpJPLfpZ6/DbWV9NYXM0LWDSur2qhVCSGbIQgHhtxH94857Xxp4p1HRfhrrPiKDR57bULO2kmSyvTE5BU4Bfy5SpXHzHD5x78UyT4g2VvHrP9oaXqllcaTDbT3NvKIWcCd3RACkjKT8hJ+boR3yAAcrffCLUZU1SKy8X3Fraalq17qd1apBIkcq3CqojYxzI52bSQd2055Ujg1rb4LXllbaJHp3icafc6daxWbajZWs0N1NGjlyhIuPLKk9mjbFdMfidbvqZsrTw14hu3a8urGB4ltgtxLbsVlC7pgQBtYgsFBA9eKWD4p6PdW1vd2Wn6tc6e1vbXNxdxxRiOzW4/wBWJAzhie52K+ByaAMW8+EU88Gu2kevxpYanry6+EaxLSRS71Zk3+aAynbgfKCPenW/wgEN/BcnWtxi8UT+JMfZMEiUAeRnfxjH3+/92u48NeJovENxfpZ6ffxW9ncz2b3M6xrG8sMrRuqgOWPK5B24x3zkDfoA8T0b4GzadDp9s/iWOW10/Tr/AE22UaeVfZdb/mdvNIYqXJ4C5GBx1qaX4HrJp1xa/wBvAeb4bh8P7/sPTy5A/nY8zvjG39a9mooAraXamx0y0tDJ5ht4Ui34xu2qBnH4VZoooAKKKKACiiigAooooAKKKKAOY1Hw3oGreJpruSe7j1pLeJZlstVuLZ/JDOY96RSKCu4yYLDn5h2qv4f8BaXpumXFteJHdy3GrHWZZEQwg3AmEkZChuAm1AASQdvPUis/UbfVbD4iaxfxaBqmo6bqOl2lms9hcW8bRuklwXz5kyMMCVSCufzFcjolh4s8S+HGl/tXUZVg1G00mOa0v2h+0Wltc7bm73Bl+eRd4JGSQnGc8gHpN/4M0e5t5FjtvKn865uo5d7t5c88bxySY3YOVkb5TxzxjisG18F+FPCejaYurefcTedp9qt3cT3EzvPHKotwuXYonmkEICEGeeK50+GvE2iO1/Hfa40EN5qXm/aNXknVbH7PMbc7XkOSJPLw2DIO5wOMPSfDXijxJoOlyCLXo9MuF0eeUahqwmmllS4WSe5hbzXMS+XyACpJxhQRQB6vqPgHw5qDyPcWMyySSzSvJBeTQu5l2+apZHBKNtXKH5TgcVai8H6DEzGLT1j3XMF5hJHCiWBEjiIAOAFWNBgcccg1meHdL1rT/DPiCwmlvHm+03Q017i7M0vksP3X71mLdScFjkVxT+F/Glja28drca7dWslhpz6jCdYJnlnWVvtKQyPJmJiu3lWRSBgEHmgDstb+H3hGa2vbjULKeOFkunuWgvbiLzI5nMsyv5bgurMSdpyB2ArqdGltLjR7GbTG3WEkEb25wRmMqCvXnpjrzXj+oeHvGNxpcMF3Z+ILrTHS/SLT4taWO5gZ2X7Obibzl81QvmZAd8ZGQ+Kj0vwz4+tfEmh+bcahDplsmnoi2sivFDHHFGs8UqG7jU5YSZbyZTggqcgAAHsZ1SzGsrpRm/09rc3Qi2nmMMFLZxjqQMZzV2vNviJ4U1bWfEF1qGlm/ikh0C5htJbO+NsxvC4aJSVdSRkZw3yetZkA8Qv4zvdLk1S7NhZWya1dMty2+Kd4DGLUkH7hdHm2g46DGMUAeuUV89eHtN8eav4Fs73QptcgW70axeZtR1Pz5L6YujySQf6RmIGPcPvxE7h9wjdXV+FfDXiuS+0JNdvNdXTIvt7XMb3hgddxtzAjFLqZ3AKzEMZCQMqcA4YA9N1nVLPRdMuNR1KbybOBd0km0ttGcdACT17CrtfOuiaP4t8T+DjLZxa3LBdaXNHcPqWqCdL6czoYjCjSt5QVVkySEzkDBPNdBd6T4+n8d3t1Hb6tY6S/2+Jja6h5oZGicQSRrLdlA+8IQvkxBScEkZNAHsk13bw3EEE1xFHPcFhDGzgNIQMkKOpwOTjtU1eM6LpPjq1sYMWGoMYHuyY7vV5A90DaYi8zNzPs/e8DZIcEb8JW58HtO8V6fda7/wAJTHfRWc32drOO7uTMUba4lA3XNwwGQnV8HqAORQB6VRRRQAVzHiHQ/C11dXkOupafaPEECafJFPcFGu0j3MqIu4fMN7HKYbvngY6evJviL4O8TeJvE93qmmyWdqNJtYhpK3MXmtPOJFnZkZZV8rLRxRksrZAbjB5AO1tfBOh2d9b3dlDeWksKxIBbahcRJIIlCp5iK4WXCqq/OGyAAcish/AHgi0vGhmtwk91bTxpby6jMR5BdJJRFG0mEQNsJ2ABcjpnnn4NL8azeJftUlvq9vNJeTTSTtqitZrZtC3l26wCQ/vVYoNwQcqW3kHFUF8D65BN4F1S8h8Q6lqlvpb2+psmtuHgumS32tgzqhjDRvvCZ34BYOeaAPQ7zwr4b8SXkGtyQi7M6QyLLBdyCC6RDviZ0RhHKATlSwb2rnrD4WWkfie61DULi3n0t47uKLTIo51iVbhsvuEk8iDjOfLSMEnJHQCj4O0jxPa6lo7eK7XxBfMlhYIk1tq4WG2lSECf7RGJ185jJuYttlyCPTmP4xad431DVIh4PtLxVitlaK6tb9owZvMJKPH9qiQDaB8xjlzuIwMUAdxZeDtHtPseFv5zZ3Iu7c3epXNyYpRG8YK+ZI2BtkcY6c5xkDFd/h/4Ye2ktzpn7t08s4nlDKPPafKtuyrCVmYMCCD0IAFcr/wjfi6LWhqNne6ktzLrF9uE+otJbR2TQy+QfJLlMCTyjwu8Z9OBznh7QfiNYxQ3N5Jrs8tvcWctzZm6TF0EkPneXI97L1VjlSIUIA+UHigD2A+HdNk8O3Gh3Mdxd6bcRvFKl3dS3Duj53AySMXPX+9x2xWPefDjwzemM3lrezssaRM0mp3TGVUdnQSkyZl2szFS+7GcDArmdE0LxXqWt6dLr51iy0xrjVZriBNV2lVkmha1RmikzgKHwFPy4IOAxBytMsvE2r6P4jhi1XWLiPSmbR7CWwusy3ZW4DySsXljBYII4ixdWG2ba2WoA9QtPC+j2l1b3FvZ7Jre6uL2NvNc7ZpyxlbBPO4u3B4GeAKyo/hv4VjFksemukVpFDCkS3cwjdITmISoH2y7T0MgbFed3PhXxzfaHev/AMTqxvYNIkXT4oddlG6889yjSbrh/mKbflaSRADjccDHpHgzR9Q0XVvEEE89/PpLzQvYNe3rXT48pRJhnZnA3gnBwOTgYoA3tJ0qz0iGeLT4fJjnuJbqQbmbdLK5d25J6sxOOgzxirtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHkfxC+Ieu6D4p1iw0uO0a306xtrwI+lXNyZfMeQOHnjcJbqFjzudSOvXFdJN8SNPBuTa6Xqt5FFeDT0lt1hK3Fw2zYkZaQZ3B9244UBTkjjNfxfp/gCbxJIPEmrWtnq97BHby2za5JaNcxZYIjwrKokUlnGCpzkiugm8G6DLpl1p5sNlrcXK3jrFNJGyzLt2ujKwaMjYuNhGMfWgDCufibZxC2jj0LXJ76UXZks40gElv9mMfmhy0oTpKpG1mBHTtlzfECLVbG+bw5p2p3UcNosz6gqwrDbNJbiZAweQMx2uhIVWxuAPetmx8FaBZC3+z2LBoI7mNXe4ld2FwVMxZmYl2YouWYk8cEVTk8E+GdMie7W3urSCC0WGVYL65jjkhii2L5kavtkIQbcsGOAOeBQBgeH/ihF/YenR6xpmsf21LZ2UqQ+VDuv2nyqvFtk2qCyucOUwBnArRl+JliqLHBoutXGoqLh7iwjSETWqwFRI0haUR4yy42u27cMZq/F4R8La5pdjdRWbS2sljbQ2syTzRusEZ8yEowYMjAtkMMNzyayPFHwvstR0u1stDmi0sxi4WS5kN1NO4mIMmZFuI2bcRk+YZASBkcUAR2Pxj8MXuv2GkxGcT3bQRKzyQLskmRXRDH5vmnhlBZUKgnG7g1GnxYsr3QZb+307VNO36aNUtZL23ikE0G9ULBEmzkF14Zk65GRXSaP4G0bSZ7W4sxfxTwRxIxiv54o5jGgRWkiRxG7bVAJZTnA9KhvPBvhKx0WOK9tYrfTbOw/s4NNdSIkdtvRthYt/eRPmJzx15oAu6H4oTW9SuoLDStRaxt5pbZtSbyVt2liYo6qPM8w4YFc7MZB5rm7H4izRazrdrrGjXkdpba7Fo1rdwCIozSiAIHBlLZzKWJCgbMfxZWuq07wvpem6xc6lYJdQT3DvLLGl7N5DO/3n8jf5e4nkttznJ6mqmoeBfD9/cajNc2lwX1B0muBHezxo0qFCkqqrhUkHlp+8UBvl60AZupfEaytbr7LbaRrGoXX2m6tvKtkhzm3VWkbLyKNuHGOcnpjOM07T4r6XcwQuNH1uOW7htriwgeOHffJOxWMx4lIXkEnzCmBzXQaZ4I8P6YYjZ2UgeJp3V5LmWRi0wUSkszEsWCryc9OO9VT4M8JXka6cltG76da29gqRXcgltY4iHhAZX3Iw4IbIY+poAgt/iFaXN5YWMGj6w+p3bXSGz2RB4Wt2jEgkYybBxKrAhiCOhyQD2tYOk+ENE0meynsLNkntBOIpXnkkf9+ytKWZmJdmKKSzZPHWt6gAooooAKKKKACvNvFHjDWLPx9c6HYzw21pBY291vHh+81R3aSSVSCYHURgCMY3DnJ9K9Jrk9Z0Dw1qGv3d/d3lxb6rBaxi6NprFxaMsCl2QyLFKo25MmCw/velAGTd/E633X0Fpo2q+bG9/bW08qw+TcXFoHLouJdw/1bEFgoI7g8VkP8bNJ0nStKfxPZXVlqFzYRX00Xm2qhY34EiKZ8upIYhF3SYHKjIz2On6D4VvXVrBLW6NvPNe4iuTIFku1ZpHIDHh1lYgHjDZUDiqVt4G8Kw3UNjaSX0N7aWyBUg1u7SdLfc2xWKyhzEGVwqn5QQ2AOaAI7jx/BJcrHaWd9Fbpqy6XLeSwRtC0nmBCi/vVbnOQ+CAOoJ+Wtnwl4nHie1W8tNK1K20yWMS215c+SqXKHoyKshcAjn51Xg1BqWmeG9NbT7a9i8o3+r/abZd0jeZe4ebdkHjiN2wcLxj0FHhzS/D/AIe1qbSdHa6gujbi5+xNdXEkMURcgGON2McY3AjCAfTFAFFviHaDT9Q1QaNq7aJZSPG+pAQCF9koidlUy+ZtU7iWKAYRiM8A19Z+KGk6ZIimyv5xJez2MUokt4YpXh2hysk0qJ99tgBIYsj4BAzWpN4J02K31j+yfNs59SinR0e4mltQ8udz/ZjII8knJwATk88mo4/AGiHwtpugXAvn0+ytzbeXDfT26zqQA/mrG6iTdySGyPmPqaAE8A+KNQ8Ry60t/pM1nHZahPaxTkxbJFRyoGFkZt4HU4C88V11YHh3RtC0vUtVbQ22XDyj7Zbx3jvHFIVDf6ksUjYqVPCgkEHmt+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPFviX4T8Rap4r8SSafY6tPYanpdtbR/Y5bIQSyxtK224ExEgQF1/1eCQW68Vo3nh3xdLpmp3dzNqs1++qoxtbPVGhEtj+6MiQfvAqElWwWKsAGAZdxz6xRQB4/F4X8WX66dFeS69a6fHFqjLCNadZ4yzQ/ZEmljlzIwxKQdzAA4LHuthoviuXzl8S2Ou393Np8EdvNa6qkdrbv9kVZUmhEyB2M3mEtskBDLjAGB6/RQB4pF4R8X6Rptnaaa+syad/Z2m/bbVNW/evKkjfaIoHaT90dmz7jIhAwCDWT4tuNb8O6RZyeI7zVrbTXXUPsdj/wkKW96jlkNv5svnq04Vd/yo8hG5Rh+K+gaKAPD/DOi/EBvE2jXuo3erGxxZyF1ffGIhAgljlRrtBuLb8t5EjZIIbsH6f4V8dWPhqGOK61qTUrjQAl2Z9YaUrqAliI2FpCEOzzOUwp7knFe20UAcH4SsNXtvFWpS69Z63NO91cPBfjUg1h9nL5iRbfzvlYJtUkxdQTuOc1nT6Jq934h8QprP8AwkUKXLTCx1ez1fybOzgMOFzAsynepzyY2+bB3Y5HptFAHiEEHi/xP4Ftde87WJL/AFCeOaO00262Q/Z0hKKT/pFuwWRiZcpICdyZBC4rovh/4d1PSvGWoX+raXqcTX1rav566u9xbRusCpJG6vLudgynDlG4/iGa9NooAKKKKACiiigAooooAK8u8UeDtd1Txb4uvrG/v9PtbzRYLWD7KbYi7lXz8xv5qOVA3ryNn3jzxx6jXm3ijxhrFn4+udDsZ4ba0gsbe63jw/eao7tJJKpBMDqIwBGMbhzk+lAHOT6D44tdBSxgsb2aICwjVYdRZHt1jswsnlrHdQZHmjBBlUHO7DYFVdF8LeMrG4j1TUtM1TUtbk8OrZeYNaMKLcxtccTFZwSGR49pUNhyWypy9duPilpHnawn2HUM6bL5DrvtzLLKZlhSNYRL5ql3YbS6IpHOcEEyH4kW5u47GLw9r0urmaaB9OVbcSxNHHHIdxMwjwUlRgQ5zn14oA43wr4a8atqemvrdvetZWmvQ3sS3d0HaGH7FPHIRuuZ2x5jpx5jfeyABkDd+I/hPW9V17V9U0Vr+K6j0Aw6fJaX5tt14JHZFYB13DkcP8nPPtDpnxSil1q+vTBqN34amg02S3nhiiC2n2glcyZYOcsVBCh8YPQVqX3xa8Padr2o6VqCzwTWUU8zOk1tOGWEAt8kUrSISCCA6qT9QRQBzTaF8QW8aX9zNd6mLZ5bhoHgkBt2haFhHGQbwBCGI+ZbfduAO4gk1an8GeI5oNNR7/xBuHh+c3LJrcqE6mRAIwdsg4G2Tp8mck/eOdjUPizpWkwXJ1vS9U0q5hlghFtevaxtI0yO6YfzvLUbY3J3uuMY6kCoJfjP4ajsdJvSk5tNR4Rxc2m5G84wsDH5/mPhhy0auuOQSKAMPV9J8fzW11G1tf3H2i6tnEkWosjwqtjErlEjuoMqZxJlfMAz8wVuDXo3w7h1m38DaHB4nMh1uO1RLsySCRjIBg5YEhj75OawtM8UamngHxZrMo+23mmXuqpboUVRsgnlWNSAVBAVQCc5IHUmltviRbw6PdXOs6TqVndWWijWriLELbovmHybZWGSUJAJHBGSDkUAd9RXA3vxNtbfVJrKHw/r155d+mmCaBLfy3uWiEqxjdMp5Vh8xAUdyOtRf8LX0lrFruDStamit7Z7u/EcUWbCJJZImaXMgzhoZeI95whPTGQD0OisDQ/E0OtarqFnZWF95VjM9vNdusaw+YoQ7R8+45D5BC44OccZ36ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuF8UweBx4qWXXNdi0zXp4YofLj1+WwlljDMYwY45U3Dc74yD1Nd1Xi3xL8J+ItU8V+JJNPsdWnsNT0u2to/sctkIJZY2lbbcCYiQIC6/6vBILdeKAPQLrwD4evJ7ya+tbu8luo2iZrrULiby1LrIRFvkPlfMiMNm3BVcdBWXe/C/RZ73Tnhkvre1t3uZZ0jvrkTXUkyopZ7gSiQ4CAYJORgdqxLzw74ul0zU7u5m1Wa/fVUY2tnqjQiWx/dGRIP3gVCSrYLFWADAMu45rxeF/Fl+unRXkuvWunxxaoywjWnWeMs0P2RJpY5cyMMSkHcwAOCx7gHc3PhHwzZaTeJJp6Q2Hk2/nIjyBRHa/NFgKeNuM8de+ayrbwB4S1LTzqGm2hkivrad7cXFxcSW6rcqS5Fu0gVQ+7JChSfUHkc5YaL4rl85fEtjrt/dzafBHbzWuqpHa27/AGRVlSaETIHYzeYS2yQEMuMAYFOLwj4v0jTbO0019Zk07+ztN+22qat+9eVJG+0RQO0n7o7Nn3GRCBgEGgDp/DfwvsrGHUP7cvJdSubueGZZYprmFoDEjIhjkaeSZWw7jPmdDgADitS7+G/hm8fdd21/M5RI5Gk1W7Yzqjl0EpMv73azEjfux2wAK8u8W3Gt+HdIs5PEd5q1tprrqH2Ox/4SFLe9RyyG382Xz1acKu/5UeQjcow/FaPhnRfiA3ibRr3UbvVjY4s5C6vvjEQgQSxyo12g3Ft+W8iRskEN2AB6s+l6JpGh6lBOsFtpVzJPPd+fKQjNMxaUszHgMznjIAzgYrFvfhj4VvrKO0u7S+mgS3a0w+qXZLwk58t283LoDyFYkL2xXDaf4V8dWPhqGOK61qTUrjQAl2Z9YaUrqAliI2FpCEOzzOUwp7knFdj4SsNXtvFWpS69Z63NO91cPBfjUg1h9nL5iRbfzvlYJtUkxdQTuOc0AbVpoHh2e5uWtIoZZoNTW9nEdwzGO8WFEBYBvlPl7PlPGCDjnNUrr4b+FbpFSXTX2DzAypdzIsqvM0zJIFcCRPMd22vlRuOABXFXXhfxFpuveJLzR7HWmmn1221WOSHVQsN3ag23mwCNpgBIdkgyyBdoC7sYWrC+H/Fut3cT6r/benWb3eoztBDq5idEdI/syloZegYNhQSAc54PIB6fpml2emNeGxh8o3c7XU3zE7pCAC3J44UcDA4q7XicXhfxxZ6Zp4W4125E2nae+rQf2yTNLcLITcxwO0n7pipHKMikDAbPNbOg+HfE9xqehrq0utWuixnUWkt31YtMiNJAbaOaRJC0jALKchmwPlLEE7gD1OiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvJvHfxF1TQfGl/pVnPo2La2s5rfT54na71F5pXRo4WEgwQFB+43XnA5r1muW1HVfB/hzxNc3eqazpGm63e28Ucgu79InkiRn8vCMw4yz8gc++KAMBvjB4fjv8AV7OW3uxcabbPdSLFNa3G9FkVDjypn2nLqdr7Tjtwat678T9M0DUdOs9Z0+9s5b10RBJcWm9N8vlqTEJ/NIPytlUbCsM4IYCST4c+DNMtLq4ubR4bKO1likNxqM5hgtyyySBQ0m2JMoGO3AGOwzWjq/gfw5r2ovqV9azSzT+S0hivZ445vKbfEXRHCPtOCCQaAMT/AIWvpTG8EWl6nK1vdx2XlpJamV5XmEKr5XneYmWYHMipxz3GYr/4qafZ7ri4tb+3jtLe/kvbJ7eN50e18ksu9ZtgOJgQBuDBh8y4+a54i+GWkauRLHPqEN41zbzPcy39zPII451mMUbNLmEMUHKEYOCOgrQk+HfheWxNpNprSQtFcwuZLqZnkW4KGYu5fczMY0+YktxwRQBSufiRY2mn6ncX+lahYzadNFFPbXk9pAwEi7kcO84iwR237vaofBfjYeLfE8M2mSyDRLnRlu44ZETcsv2iSNiWXOfuY4Yrxketbms+CtB1i6lur20m+1STR3Bngu5oJFkjRkRleN1KkK7D5SM55zUHgXRvDNvp9nqfhWFhbSW7QwzNJKxaIyvIQRIc/fdzk88+mKAMbX/ibptlr934bRZYdXaGf7PKJ7WVd8cLScxrK0icKcb4wCRiqOk/Fa2tPDFpN4h03VYtQXT7S7cyLboLlZfk85WEgRE3A58wx7QRkCrdvovgLUPFWIVnk1Wa5vpRD9puhF5yARXLCMt5atiYAkAZ3ZGcZG1YfD7w9p9tLBZRalD5sccJmXVrvzljjzsjWXzd6oMn5FYL7UAQad8QLbUrlIrHR9TnRIo5rueOS1aKyRycF3E2H+VSx8rfx78VgWHxv8L31le3NrFeSC2hS4CJJbOXiaRYw52zERAFlJ84x7QcnHOOnsPh/wCHNOuLabT7S5tJIFVP3F/cRiYKzOPOAcCb5mYnzN2dxznNVtK8M+GY59S0PTLjWIWtki862h1e+jW3RiWjEeJAEHyniPHAweOKAK8fxN019R0WyGn3n2jVY1mhzdWWwKZGQYfz9sh+UttiMhAxkAkCu8rlF+H3h0Q2kH2a9NrbOJUtzqNyYXcSmXfJGZNsreYdxZwxJxk8CuroAKKhvLu3sbWS5vZ4re3jGXlmcIij1JPAqagAooqCe7tree2gnuIYprlikEbuFaVgpYhQfvEKrHA7AntQBPRRUEd3bSXc1pHcQvdQqjywq4Lxq2dpZeoB2tgnrtPpQBPRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXl/ibSvEUPxKvtV0yHxELC5061txLo7ad8zxyTswkF2cgASLgoO5z0FeoUUAeM654V8W6uPFllMmqtpGoWN9DpcEurA/Z5nXAM2Gy8btyi7nCKSGADYWzbeHvEYju5rWx16G3g0OKOy02815xvvhLcb98kc7NyrR4O/GCo4KDb67RQB4f4e8MeOrlorXWJNbt9LbWYZ3A1R4pVtRazLIu8Xc0gUy+Udvmk85AGMCVfCfj2y0iH+ytR1UanPp2oQ3L3uqNcKsglj+y7VZyFYxBxvXBycsQea9rooA8Q0zQfG0VpbjUU8S3em/bjJcafDfrbXOzySqmOc30rlN+CVMy8ngEcVVt/D3j/RfCR07TbDU3luNChs4Ut9SiQWN0s0rOxLSjko6fOm4krg4617zRQB4xfeFfFNrqt1f6dpXnyBtcaJftohLfaJbcxYdHVlLLG5BBUgjkrkGofCnhrx1Lf21trc2tW+j/ANqvLJ/xMmSUWpsmUqT9pmkA87bx5rEE7ht42+20UAea+Do9XuPiBrFnLqdzcaHoVxL5T/aWczS3CpIIZCT8whVmABJwHTuuBX8UeFNen8UeINa0c38N0z6Z9iNvfmGOVUk/f74w4VwEJ4kB6/LzXqVFAHgsvhz4llfEebzVjfS2t6kEkNwFgndzmEozXh8orxgrBFjkE966KXwd4isdfubnS7/X5baHVtOe0WfWpZUNrmP7XuV5CGBG84YEj+ACvWKKAPnnUPCfxB1v+34L6x1CGxvNOmH2Q6q7RtcieN4xGz3chwVDjO2FcHDLjFdNc6L4sbWY5NOs/EdvEZbM2D3GtBo7KJWH2hLpPPfzmYbyDiXhlG5cV7BRQB4B4fsvG2taNLeaBNrkMr2+oRzXV9qvmRXb+ftiW3QyP5TKqsA5VMe/Wt630Txv9rjbSRq+mWH2qZoYNU1QXUsINhKitK3mSb0+0GMhNz4I3YHb2GigDwfTPDfj1dAvo76fxP8AaGNsRBHMp3uu/wAxhI2pF9hyNwV4eilV+8K0bjQ/G0umXYmj1u3LWunCK3stSMxEiNcGZSz3Ub4IaHcRMGJ2gMwU17PRQBjeDYr6DwvpserQNb36wgTRNcvcFW9DI7MzH6s31PWtmiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The differential diagnosis of a mediastinal mass depends upon the anatomic compartment in which it arises.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Baue AE, Geha AS, Hammond GL, et al. Glenn's Thoracic and Cardiovascular Surgery, 5th ed, Appleton &amp; Lange, Norwalk, CT 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26661=[""].join("\n");
var outline_f26_2_26661=null;
var title_f26_2_26662="Classification of iatrogenic bile duct injury";
var content_f26_2_26662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Classification of iatrogenic bile duct injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 698px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Strasberg classification:",
"    <br>",
"     Type A - Injury&nbsp;to the &nbsp;cystic duct or from minor hepatic ducts draining the liver bed.",
"     <br>",
"      Type B - Occlusion of biliary tree, commonly aberrant right hepatic duct(s)",
"      <br>",
"       Type C -&nbsp;Transection&nbsp;without ligation&nbsp;of aberrant right hepatic duct(s)",
"       <br>",
"        Type D - Lateral injury to a major bile duct.",
"        <br>",
"         Type E (1-5)&nbsp;- Injury to the main hepatic duct; classified according to level of injury (ie, below).&nbsp;",
"         <br>",
"          - E1 (Bismuth type 1) - Injury more than 2 cm from confluence",
"          <br>",
"           - E2 (Bismuth type 2) - Injury less than 2 cm from confluence",
"           <br>",
"            - E3 (Bismuth type 3) - Injury&nbsp;at the confluence; confluence intact",
"            <br>",
"             - E4 (Bismuth type 4) - Destruction of the biliary confluence",
"             <br>",
"              - E5&nbsp;(Bismuth type 5) - Injury to aberrant right hepatic duct",
"              <div class=\"footnotes\">",
"              </div>",
"              <div class=\"reference\">",
"               Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 1995; 180:101.",
"               <br>",
"                Bismuth H, Lazorthes F. Les traumatismes operatoires de la voie biliare principale. Paris, France: Masson, 1981.",
"                <br>",
"                 Chartrand-Lefebvre C, Dufresne M-P, Lafortune M, et al. Iatrogenic injury to the bile duct: A working classification for radiologists. Radiology 1994; 193:523.",
"                </br>",
"               </br>",
"              </div>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26662=[""].join("\n");
var outline_f26_2_26662=null;
var title_f26_2_26663="Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects";
var content_f26_2_26663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26663/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26663/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26663/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26663/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26663/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/2/26663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactam antibiotics are among the most commonly prescribed drugs, grouped together based upon a shared structural feature, the beta-lactam ring. Beta-lactam antibiotics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Penicillins",
"     </li>",
"     <li>",
"      Cephalosporins",
"     </li>",
"     <li>",
"      Cephamycins",
"     </li>",
"     <li>",
"      Carbapenems",
"     </li>",
"     <li>",
"      Monobactams",
"     </li>",
"     <li>",
"      Beta-lactamase inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since this category of antibiotics is so broad, it is important to subdivide these drugs into functional drug groups to facilitate understanding and prescribing practices. It is not necessary for clinicians to know every drug within each of these groups. The grouping of these agents can be based upon spectrum of activity, for choice of agents for an antibiotic formulary, for therapeutic use or for routine susceptibility testing. Within each functional group, differences between antibiotics in pharmacokinetics, safety, duration of the clinical experience with their use, and cost allow reasonable choices to be made in selecting an individual drug as representative of that group.",
"   </p>",
"   <p>",
"    The mechanisms of action and resistance and major adverse reactions to these antibiotics will be reviewed here. The penicillins, cephalosporins, and novel beta-lactam drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1110?source=see_link\">",
"     \"Penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38519?source=see_link\">",
"     \"Cephalosporins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44789?source=see_link\">",
"     \"Combination beta-lactamase inhibitors, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactam antibiotics inhibit the growth of sensitive bacteria by inactivating enzymes located in the bacterial cell membrane, which are involved in the third stage of cell wall synthesis. It is during this stage that linear strands of peptidoglycan are cross-linked into a fishnet-like polymer that surrounds the bacterial cell and confers osmotic stability in the hypertonic milieu of the infected patient. Beta-lactams inhibit not just a single enzyme involved in cell wall synthesis, but a family of related enzymes (four to eight in different bacteria), each involved in different aspects of cell wall synthesis. These enzymes can be detected by their covalent binding of radioactively-labeled penicillin (or other beta-lactams) and hence have been called penicillin binding proteins (PBPs).",
"   </p>",
"   <p>",
"    Different PBPs appear to serve different functions for the bacterial cell. As an example, PBP2 in Escherichia coli is important in maintaining the rod-like shape of the bacillus, while PBP3 is involved in septation during cell division [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/1\">",
"     1",
"    </a>",
"    ]. Different beta-lactam antibiotics may preferentially bind to and inhibit certain PBPs more than others. Thus, different agents may produce characteristic effects on bacterial morphology and have different efficacies in inhibiting bacterial growth or killing the organism.",
"   </p>",
"   <p>",
"    Beta-lactam antibiotics are generally bactericidal against organisms that they inhibit. The mechanism of bacterial cell killing is an indirect consequence of the inhibition of bacterial cell wall synthesis. Enzymes that mediate autolysis of peptidoglycan are normally present in the bacterial cell wall but are strictly regulated to allow breakdown of the peptidoglycan only at growing points. Beta-lactam inhibition of cell wall synthesis leads to activation of the autolytic system through a two component system,",
"    <span class=\"nowrap\">",
"     VncR/S,",
"    </span>",
"    which initiates a cell death program [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain bacteria are deficient in these autolytic enzymes or have mutations in the regulatory genes; these strains show the phenomenon of \"tolerance\" to beta-lactam antibiotics, that is, their growth is inhibited by the antibiotic but the bacteria are not killed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF BACTERIAL RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three general mechanisms of bacterial resistance to antibiotics, including the beta-lactams, have been well characterized: decreased penetration to the target site; alteration of the target site; and inactivation of the antibiotic by a bacterial enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Decreased penetration to the target site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outer membrane of Gram negative bacilli provides an efficient barrier to the penetration of beta-lactam antibiotics to their target PBPs in the bacterial plasma membrane. Beta-lactams usually must pass through the hydrophilic porin protein channels in the outer membrane of Gram negative bacilli to reach the periplasmic space and plasma membrane. The permeability barrier of the outer membrane is a major factor in the resistance of Pseudomonas aeruginosa to many beta-lactam antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alteration of the target site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The target sites for the beta-lactams are the PBPs in the cytoplasmic membrane. Alterations in PBPs may influence their binding affinity for beta-lactam antibiotics and therefore the sensitivity of the altered bacterial cell to inhibition by these antibiotics. Such a mechanism is responsible for penicillin resistance in pneumococci [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/5\">",
"     5",
"    </a>",
"    ], methicillin (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    ) resistance in staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/6\">",
"     6",
"    </a>",
"    ], and for bacteria with increasing intrinsic resistance to beta-lactams, such as gonococci, enterococci, and Haemophilus influenzae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inactivation by a bacterial enzyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;Production of beta-lactamase is the major mechanism of resistance to the beta-lactam antibiotics in clinical isolates. Such bacterial enzymes may cleave predominantly penicillins (penicillinases), cephalosporins (cephalosporinases), or both (beta-lactamases). Their production may be encoded within the bacterial chromosome (and hence be characteristic of an entire species) or the genes may be acquired on a plasmid or transposon (and hence be characteristic of an individual strain rather than the species). Bacteria may synthesize the beta-lactamase constitutively (as for many plasmid-mediated enzymes) or synthesis may be inducible in the presence of antibiotic (as for many chromosomal enzymes). Inducible beta-lactamases may not be reliably detected by initial susceptibility testing, particularly with the newer rapid methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chromosomal beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although virtually all Gram negative bacilli possess a chromosomal beta-lactamase gene, certain species express insignificant amounts of this enzyme and their susceptibility to beta-lactams is largely determined by plasmid-mediated beta-lactamases and antibiotic permeability. These include E. coli, Proteus mirabilis, Salmonella, Shigella, and H. influenzae. Klebsiella pneumoniae produces a chromosomal beta-lactamase that is primarily a penicillinase; thus, these strains are frequently more susceptible to the cephalosporins. The last group of species within the Enterobacteriaceae, including Enterobacter, indole-positive Proteus, Serratia and Citrobacter, produce an inducible chromosomal beta-lactamase that may be difficult to detect on initial susceptibility testing but that can mediate resistance to all currently available beta-lactams with the exception of the carbapenems [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition to inducible production of this chromosomal enzyme, these species may give rise to regulatory mutants that are \"derepressed\" and produce high levels of this broad-spectrum chromosomal enzyme constitutively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Plasmid-mediated beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common plasmid-mediated beta-lactamases of Gram negative bacteria (such as TEM-1, TEM-2, and SHV-1) mediate resistance to the penicillins and first- and second-generation cephalosporins, but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    , cephamycins, third- and fourth-generation cephalosporins, or the novel beta-lactam compounds such as the carbapenems or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    More recently, extended-spectrum plasmid-mediated beta-lactamases (derived from the common TEM and SHV enzymes) have arisen, which are capable of cleaving later-generation cephalosporins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/8\">",
"     8",
"    </a>",
"    ]. Originally described in strains of Klebsiella from Europe, these beta-lactamases have now been found in a variety of Gram negative bacilli in several areas of the United States, and spread between patients in intensive care units has been documented. In addition, a study from Chicago documented that nursing home patients may be an important reservoir for strains of Enterobacteriaceae producing extended-spectrum plasmid-mediated beta-lactamases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/9\">",
"     9",
"    </a>",
"    ]. In one nursing home, for example, 18 of 39 patients were colonized with such resistant strains, and of the 55 patients in an acute care hospital colonized with resistant E. coli or K. pneumoniae, 35 had been admitted from nursing homes and 31 of them were colonized on admission. Although the strains of resistant E. coli and K. pneumoniae differed, most harbored a common plasmid encoding the extended-spectrum beta-lactamase, suggesting intragenic and intraspecies transfer of the plasmid between strains, rather than transfer of a single strain between patients. All of these strains were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , and 96 and 41 percent were also resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , respectively.",
"   </p>",
"   <p>",
"    These enzymes mediate high-level resistance to the third- and fourth-generation cephalosporins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    , but not to the cephamycins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    ) or the carbapenems. However, use of the cephamycins against strains containing these new enzymes is limited by the development of permeability mutants in the porin protein, OmpF. The beta-lactamase inhibitors, clavulanate, sulbactam, and tazobactam have generally retained the ability to inhibit these newer plasmid-mediated beta-lactamases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another plasmid-mediated beta-lactamase has been described in Klebsiella, which is homologous to the chromosomal beta-lactamase of Enterobacter cloacae [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/10\">",
"     10",
"    </a>",
"    ]. This plasmid-mediated beta-lactamase is capable of cleaving all of the currently available beta-lactams (with the exception of the carbapenems) and its activity is",
"    <strong>",
"     not",
"    </strong>",
"    inhibited by clavulanate, sulbactam, or tazobactam. This plasmid-mediated beta-lactamase confers a broad resistance pattern similar to stably derepressed mutants of Enterobacter.",
"   </p>",
"   <p>",
"    Over the past several years, carbapenem-hydrolyzing enzymes have been described in Klebsiella pneumoniae and other members of the Enterobacteriaceae. These are encoded on transmissible plasmids, which facilitate their spread. In one report from New York City in 2005, 45 percent of 602 isolates of K. pneumoniae had a plasmid-encoded, extended spectrum beta-lactamase, and of those, 3.3 percent also carried a carbapenem-hydrolyzing beta-lactamase termed KPC-2 (Klebsiella pneumoniae carbapenemase-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/11\">",
"     11",
"    </a>",
"    ]. In a subsequent report from New York City in 2007, seven strains of Escherichia coli out of 1417 tested had a similar enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/12\">",
"     12",
"    </a>",
"    ]. Resistance to the carbapenems in these strains was not always detected by currently available automated susceptibility methods. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=see_link&amp;anchor=H19876835#H19876835\">",
"     \"Carbapenemases\", section on 'Klebsiella pneumoniae carbapenemase (KPC)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The New Delhi metallo-&beta;-lactamase 1 (NDM-1) is another plasmid-mediated enzyme that mediates broad resistance to all currently available antibiotics (including the carbapenems) with the exceptions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/13\">",
"     13",
"    </a>",
"    ]. This enzyme has been found in a number of Enterobacteriaceae in India and Pakistan, as well as in individuals returning to the UK, US, and other countries who have travelled there, particularly for medical care. These organisms have been referred to in the lay media as &ldquo;superbugs&rdquo; because of their extensive resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=see_link&amp;anchor=H19877222#H19877222\">",
"     \"Carbapenemases\", section on 'New Delhi metallo-beta-lactamase (NDM-1)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of adverse reactions have been described for beta-lactam antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     IgE-mediated allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I, IgE-mediated reactions present with various combinations of pruritus, flushing, urticaria, angioedema, wheezing, laryngeal edema, hypotension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anaphylaxis. Symptoms usually appear within four hours of drug administration and may begin within minutes. When the allergy first develops, the initial symptoms may appear during the later days of treatment and then escalate rapidly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum sickness is a late allergic reaction characterized by fever, rash (usually urticarial), adenopathy, arthritis and occasionally glomerulonephritis. It is associated with circulating immune complexes and has been reported with all of the beta-lactam antibiotics. Each of the beta-lactam antibiotics is also capable of causing drug fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link\">",
"     \"Drug fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dermatologic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of rashes occur with the beta-lactam antibiotics, of which morbilliform rash is the most common. Erythema multiforme is an acute eruption characterized by distinctive target skin lesions and diagnostic histology; when the mucosal surfaces are involved as well, the reaction is termed the Stevens-Johnson syndrome. Exfoliative dermatitis is a severe skin disorder with generalized erythema and scaling. Toxic epidermal necrolysis is an acute severe reaction with widespread erythema and detachment of the epidermis; there may be a positive Nikolsky's sign. Hypersensitivity angiitis is a small vessel vasculitis involving mainly the venules of the skin and characterized by palpable purpura. The beta-lactam antibiotics may also cause photosensitivity reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neurologic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the antibiotics, the penicillins are the most common to cause encephalopathy. Penicillin neurotoxicity is characterized by a change in the level of consciousness (somnolence, stupor, or coma) with generalized hyperreflexia, myoclonus and seizures. This syndrome occurs with high-dose penicillin therapy (&gt;20 million units per day), particularly if excretion is delayed by underlying renal disease, or if preexisting neurologic disease is present. Penicillin neurotoxicity can potentially confuse the management of patients with bacterial meningitis.",
"   </p>",
"   <p>",
"    High doses of the beta-lactam antibiotics (particularly penicillins) may cause seizures. Imipenem may cause CNS toxicity and seizures, especially with high doses, renal dysfunction, or underlying CNS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/14\">",
"     14",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     Cefepime",
"    </a>",
"    has also been associated with seizures, particularly in the setting of renal impairment. Between 1996 and 2012, 59 cases of nonconvulsive status epilepticus during cefepime use in patients with renal dysfunction were reported to the United States Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/15\">",
"     15",
"    </a>",
"    ]. The majority of cases occurred in patients whose dose was not appropriately adjusted for renal function and resolved following discontinuation of cefepime or hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactam antibiotics occasionally cause the pulmonary infiltrate with eosinophilia (PIE) syndrome, which has an abrupt onset with fever, chills, dyspnea, pulmonary infiltrates and peripheral eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    .) Beta-lactam antibiotics may also cause drug-induced lupus, with manifestations including serositis (pleural effusions or pericarditis), fever and pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastrointestinal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is a frequent nonspecific complication of antibiotic therapy, especially with certain oral antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    . All antibiotics can predispose to Clostridium difficile colitis, and ampicillin is a commonly implicated beta-lactam [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hepatobiliary reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The semisynthetic penicillins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    , may cause hypersensitivity hepatitis accompanied by fever, rash, and eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/17\">",
"     17",
"    </a>",
"    ]. This syndrome is more commonly seen at higher doses.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    may cause biliary sludge and pseudocholelithiasis, particularly in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Renal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of reactions can occur in the kidneys.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerulonephritis may be seen in association with hypersensitivity angiitis or serum sickness following administration of beta-lactam antibiotics.",
"     </li>",
"     <li>",
"      The cephalosporin antibiotics may potentiate the renal toxicity of aminoglycosides.",
"     </li>",
"     <li>",
"      The beta-lactam antibiotics, particularly methicillin, may cause allergic interstitial nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/19\">",
"       19",
"      </a>",
"      ], characterized by acute, often severe, renal failure, with an active urinary sediment with hematuria, proteinuria, and pyuria, but generally no red cell casts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"      </a>",
"      .) Signs of hypersensitivity are generally present, including fever, peripheral eosinophilia and rash; eosinophiluria is characteristic but not always found.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several case reports of cross-sensitivity between beta-lactam antibiotics eliciting acute allergic interstitial nephritis, so the occurrence of this syndrome with one beta-lactam antibiotic generally cautions against the use of other agents in this class.",
"   </p>",
"   <p>",
"    The antipseudomonal penicillins, particularly ticarcillin (which is a disodium salt), may cause sodium overload and hypokalemic alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link\">",
"     \"Causes of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hematologic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactam antibiotics may be associated with immune-mediated destruction of polymorphonuclear leukocytes, which is characterized by an abrupt onset of neutropenia with fever, rash, and eosinophilia. Similarly, beta-lactam antibiotics may cause immune-mediated hemolytic anemia, characterized by a positive non-gamma Coombs' test or by subacute extravascular hemolysis with a positive gamma Coombs' test. This latter reaction generally requires prolonged, high-dose therapy and signs of hypersensitivity are usually absent.",
"   </p>",
"   <p>",
"    Acute immune thrombocytopenia has been associated with beta-lactam antibiotic administration. The platelet count generally normalizes within two weeks after the drug is stopped. Platelet dysfunction may be caused by high doses of ticarcillin; the newer anti-pseudomonal penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"     piperacillin",
"    </a>",
"    , has less of an effect on platelet function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Broad spectrum antibiotic therapy suppresses gut flora and may contribute to vitamin K deficiency. Hypoprothrombinemia has been a particular problem with antibiotics containing the N-methylthiotetrazole side chain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26663/abstract/22\">",
"     22",
"    </a>",
"    ]. This same side chain is associated with intolerance to ethanol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"       \"Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29594957\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta-lactam antibiotics inhibit the growth of sensitive bacteria by inactivating enzymes located in the bacterial cell membrane, known as penicillin binding proteins, which are involved in cell wall synthesis. These antibiotics are generally bactericidal against susceptible organisms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major mechanism of resistance to the beta-lactam antibiotics in clinical isolates is production of enzymes that cleave penicillins (penicillinases), cephalosporins (cephalosporinases), or both (beta-lactamases). Decreased penetration to the plasma membrane target site and alterations in the penicillin binding proteins are other mechanisms of resistance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of bacterial resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enterobacter, indole-positive Proteus, Serratia and Citrobacter produce an inducible chromosomal beta-lactamase that may be difficult to detect on initial susceptibility testing but can mediate resistance to all currently available beta-lactams other than carbapenems. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chromosomal beta-lactamases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common plasmid-mediated beta-lactamases in Gram negative bacteria mediate resistance to penicillins and first- and second-generation cephalosporins. Extended spectrum plasmid-mediated beta-lactamases can additionally cleave later-generation cephalosporins and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      . These plasmids can transfer to other species and genera. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Plasmid-mediated beta-lactamases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=see_link\">",
"       \"Extended-spectrum beta-lactamases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of beta-lactams is associated with various adverse effects, including IgE-mediated allergic reactions, rash, diarrhea, renal toxicity, and other hypersensitivity and immune-mediated reactions. The penicillins are the most common antibiotics to cause encephalopathy and high doses of beta-lactams can cause seizures. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/1\">",
"      Spratt BG, Cromie KD. Penicillin-binding proteins of gram-negative bacteria. Rev Infect Dis 1988; 10:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/2\">",
"      Novak R, Charpentier E, Braun JS, Tuomanen E. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol Cell 2000; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/3\">",
"      Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996; 335:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/4\">",
"      Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/5\">",
"      Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/6\">",
"      Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/7\">",
"      Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995; 21:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/8\">",
"      Katsanis GP, Spargo J, Ferraro MJ, et al. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol 1994; 32:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/9\">",
"      Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/10\">",
"      Papanicolaou GA, Medeiros AA, Jacoby GA. Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1990; 34:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/11\">",
"      Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/12\">",
"      Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007; 44:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/13\">",
"      Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/14\">",
"      Asbel LE, Levison ME. Cephalosporins, carbapenems, and monobactams. Infect Dis Clin North Am 2000; 14:435.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment, June 26, 2012. file://www.fda.gov/Drugs/DrugSafety/ucm309661.htm (Accessed on June 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/16\">",
"      Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/17\">",
"      Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. Ann Intern Med 1978; 89:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/18\">",
"      Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/19\">",
"      Ditlove J, Weidmann P, Bernstein M, Massry SG. Methicillin nephritis. Medicine (Baltimore) 1977; 56:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/20\">",
"      Tan JS, File TM Jr. Antipseudomonal penicillins. Med Clin North Am 1995; 79:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/21\">",
"      Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26663/abstract/22\">",
"      Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986; 105:924.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 479 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-87592D432B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26663=[""].join("\n");
var outline_f26_2_26663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29594957\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF BACTERIAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Decreased penetration to the target site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alteration of the target site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inactivation by a bacterial enzyme",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chromosomal beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Plasmid-mediated beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IgE-mediated allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dermatologic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neurologic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastrointestinal reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hepatobiliary reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Renal reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hematologic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29594957\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9754?source=related_link\">",
"      Carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38519?source=related_link\">",
"      Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/47/44789?source=related_link\">",
"      Combination beta-lactamase inhibitors, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1110?source=related_link\">",
"      Penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_2_26664="Evaluation and treatment of regional lymph nodes in melanoma";
var content_f26_2_26664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and treatment of regional lymph nodes in melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Michael Stone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26664/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/2/26664/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is the appropriate treatment for melanoma. Although resection usually controls the primary lesion, melanoma often metastasizes through lymphatic channels to regional lymph nodes. Accurate staging at diagnosis is important to assess the prognosis and determine whether the patient is eligible for clinical trials of adjuvant therapies (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination of regional lymph nodes is often inaccurate, since approximately 20 percent of clinically node-negative patients have metastatic involvement, and 20 percent of those with clinically positive nodes are pathologically negative. More definitive information about the status of the regional nodes can be obtained from sentinel lymph node biopsy (SLNB), elective lymph node dissection (ELND), or fine needle aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the management of clinically apparent regional lymph nodes and the staging of subclinical disease with either lymphatic mapping with SLNB or ELND will be reviewed here. The surgical management of the primary lesion and adjuvant therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261295543\">",
"    <span class=\"h1\">",
"     CLINICALLY NEGATIVE REGIONAL LYMPH NODES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sentinel lymph node biopsy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic mapping is based upon the concept that sites of cutaneous melanoma have specific patterns of lymphatic spread and that one or more nodes are the first to be involved with metastatic disease within a given lymph node basin (",
"    <a class=\"graphic graphic_figure graphicRef52249 \" href=\"UTD.htm?29/18/29999\">",
"     figure 1",
"    </a>",
"    ). If the sentinel lymph nodes are not involved, the entire basin should be free of tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Knowledge of the regional lymph node status is important for several purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To determine prognosis",
"     </li>",
"     <li>",
"      To facilitate regional disease control in patients with regional lymph node involvement",
"     </li>",
"     <li>",
"      To select patients who may benefit from adjuvant therapy",
"     </li>",
"     <li>",
"      To select candidates for clinical trials",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, lymphatic mapping with SLNB permits the identification of patients with positive nodes and avoids ELND in those without nodal involvement. Completion lymph node dissection is used for patients with tumor involvement of the sentinel lymph node, and lymph node dissection can be restricted to those who are most likely to benefit.",
"   </p>",
"   <p>",
"    Tc-99 can be used for both preoperative mapping and for sentinel node identification in the operating room using a hand-held gamma probe [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. The technique for SLNB is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=see_link&amp;anchor=H10#H10\">",
"     \"Imaging studies in melanoma\", section on 'Lymph node imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphatic mapping is particularly useful to identify the appropriate lymph node basins draining from primary sites located in areas of ambiguous and possibly multiple nodal basin drainage. These areas include the trunk, head and neck, and distal extremities. Dynamic lymphatic flow studies have shown that ambiguous and multidirectional flows are more common than previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While a learning curve exists for the technical aspects of SLNB, the importance of a coordinated and consistent approach, including surgeon, nuclear medicine physician, and pathologist cannot be overstated.",
"   </p>",
"   <p>",
"    In contrast to the widespread acceptance of lymphatic mapping and sentinel lymph node biopsy for extremity and truncal melanomas, the role of this technique for melanomas of the head and neck is evolving. The use of this approach has been limited by the complexity of lymphatic drainage patterns and the frequent need to remove sentinel nodes from the parotid gland, thereby risking damage to the facial nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Skin of head and neck'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sensitivity and specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial feasibility studies, SLNB was followed by completion lymph node dissection in all patients. The sentinel node was successfully identified in 75 to 90 percent of cases, and a negative SLNB with a positive nonsentinel node occurred in 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In subsequent studies, SLNB was followed by completion lymph node dissection only if the sentinel node contained tumor. In a review of the literature and meta-analysis involving a much larger recent experience, sentinel nodes were successfully identified in 97 to 98 percent of patients, with metastases in the sentinel node being detected at the frequency expected, based upon the incidence of regional disease observed in earlier studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The false negative rate following SLNB is defined as the number of patients with a negative SLNB who then develop a regional recurrence divided by the number of patients with positive SLNBs plus the number with subsequent regional recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/11\">",
"     11",
"    </a>",
"    ]. The false negative rate needs to be distinguished from the negative predictive value (the number of patients with a negative SLNB who do not recur divided by the total number of patients with a negative SLNB), which depends upon the patient population studied. The reported rate of false negatives in a meta-analysis that included data from about 25,000 patients in 71 studies was 12.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/10\">",
"     10",
"    </a>",
"    ]. The test characteristics for SLNB are illustrated by results from the Sunbelt Melanoma Trial, in which 486 of 2451 patients had a positive SLNB and 59 subsequently had a regional lymphatic recurrence, for a false negative rate of 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/12\">",
"     12",
"    </a>",
"    ], and a negative predictive value of 97 percent in that patient population.",
"   </p>",
"   <p>",
"    The likelihood of detecting metastatic deposits in a SLNB increases with the thickness of the primary lesion, providing a rationale for deciding which patients may benefit from this procedure. For lesions &lt;1.0, 1.01 to 2.0, 2.01 to 4.0, and &gt;4 mm, the risk is approximately 4, 12, 28, and 44 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/13\">",
"     13",
"    </a>",
"    ]. The impact of lymphatic mapping with SLNB (with completion lymphadenectomy when indicated) on survival remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/14-19\">",
"     14-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Multicenter selective lymphadenectomy trial-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Multicenter Selective Lymphadenectomy Trial-I (MSLT-I) is the largest trial to address the role of lymphatic mapping with SLNB in determining prognosis and its impact on survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the MSLT-I, 2001 patients were randomly assigned to observation (40 percent) or to lymphatic mapping with SLNB (60 percent) between 1994 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/14\">",
"     14",
"    </a>",
"    ]. The primary study group was defined as the 1347 patients with melanomas 1.2 to 3.5 mm thick, which was the group thought to be most likely to benefit from SLNB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients randomly assigned to lymphatic mapping with SLNB underwent immediate completion lymphadenectomy if a histologically positive node was identified, while those with a negative SLNB were observed and underwent therapeutic lymphadenectomy if there was evidence of subsequent nodal recurrence.",
"     </li>",
"     <li>",
"      Individuals assigned to observation had a therapeutic lymphadenectomy only if there was clinical evidence of nodal recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The third of five planned interim analyses was published in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/14\">",
"     14",
"    </a>",
"    ]. At a median follow-up of 60 months, the findings in the primary study group confirmed the role of SLNB as a prognostic tool, although a survival benefit was not demonstrated for the overall study population randomly assigned to lymphatic mapping and SLNB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Incidence of nodal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cumulative incidence of regional lymph node involvement was similar in the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 769 patients randomly assigned to lymphatic mapping with SLNB, 16 percent had a positive lymph node biopsy. An additional 3.4 percent subsequently relapsed in the regional lymph nodes, for an estimated overall incidence of nodal involvement of 19.4 percent.",
"     </li>",
"     <li>",
"      Among the 500 patients randomly assigned to observation, 15.6 percent had a clinical relapse in regional lymph nodes, and the actuarial rate of regional lymph node relapse was 18.5 percent at eight years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Prognostic implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients randomly assigned to lymphatic mapping and SLNB, the disease-free survival at five years was significantly higher in those with a negative SLNB (83.2 versus 53.4 percent in those with a positive SLNB). Patients with a negative SLNB also had a lower melanoma-specific five-year mortality rate (9.7 versus 26.2 percent).",
"   </p>",
"   <p>",
"    Multivariate analyses incorporating the other known prognostic factors demonstrated that the presence of a positive SLNB was the single most important factor predicting melanoma recurrence (hazard ratio [HR] 3.04, 95% CI 2.11-4.39) and death (HR 2.48, 95% CI 1.56-3.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Survival effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma-specific survival was not significantly improved in patients assigned to lymphatic mapping with SLNB (87.1 versus 86.6 percent; HR 0.92, 95% CI 0.67-1.25, compared to those assigned to observation). However, distant disease-free survival was significantly higher at five years (78.3 versus 73.1 percent; HR 0.74, 95% CI 0.59-0.93).",
"   </p>",
"   <p>",
"    Despite the lack of an overall survival benefit, one would only expect benefit from lymphatic mapping and SLNB in those patients in whom microscopic disease was present at the time of diagnosis. This expectation was supported by prespecified subset analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphatic mapping and SLNB, followed by completion lymphadenectomy, improved five-year survival in the 16 percent of patients who underwent immediate completion lymphadenectomy for a positive SLNB (72.3 versus 52.4 percent in patients managed with observation who underwent a therapeutic lymphadenectomy only when clinically positive lymph nodes were subsequently detected; HR 0.51, 95% CI 0.32-0.81). However, this conclusion must be qualified because the two groups do not represent a randomized comparison.",
"     </li>",
"     <li>",
"      In those patients managed with lymphatic mapping who had a negative SLNB, the five-year survival rate was much higher and was not appreciably different from those managed with observation who did not have a regional lymph node relapse (92.9 and 92.4 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLNB is associated with significantly fewer complications than regional lymphadenectomy. This was illustrated in 2120 patients enrolled on the Sunbelt Melanoma Trial, of whom 444 underwent completion lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/21\">",
"     21",
"    </a>",
"    ]. At a median follow-up of 16 months, the overall complication rate was significantly lower for SLNB alone (5 versus 23 percent with SLNB plus completion lymphadenectomy).",
"   </p>",
"   <p>",
"    The decrease in the rate of complications included wound infection (1 versus 7 percent with completion lymphadenectomy), lymphedema (0.7 versus 11.7 percent),",
"    <span class=\"nowrap\">",
"     hematoma/seroma",
"    </span>",
"    (2 versus 6 percent) and sensory nerve injury (0.2 versus 1.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/21\">",
"     21",
"    </a>",
"    ]. Differences in complication rates were particularly striking in patients who underwent groin procedures (total complications 8 versus 51 percent, and lymphedema 2 versus 32 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Minimal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because fewer nodes are resected with SLNB compared to ELND, more careful pathologic evaluation is possible. Serial sectioning increases the likelihood of detecting melanoma metastases, although eight to ten sections may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though studies have shown that low volume involvement of the SLN is only rarely associated with tumor involvement of other lymph nodes, follow-up suggests that minimal metastasis in the SLN confers an increased risk of relapse and death relative to patients with no SLN involvement.",
"   </p>",
"   <p>",
"    The impact of extent of SLN involvement is illustrated by a study of 1009 patients with a positive SLN who underwent completion lymph node dissection over a fifteen-year period at nine EORTC melanoma centers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/23\">",
"     23",
"    </a>",
"    ]. Among the 113 patients with SLN tumor size &lt;0.1 mm, 10 (9 percent) were found to have tumor involvement of non-sentinel lymph nodes. The frequency of involvement of nonsentinel lymph nodes increased progressively with tumor size in the SLN (16 percent for those with 0.1 to 1.0 mm tumor and 25 percent for those with tumor &gt;1.0 mm). On multivariate analysis, lesser tumor involvement was significantly associated with improved melanoma-specific survival.",
"   </p>",
"   <p>",
"    However, the data are inadequate to distinguish subsets of patients based upon the extent of tumor involvement in the sentinel lymph node, and completion lymph node dissection is indicated for patients with a positive SLNB regardless of the extent of tumor involvement. These issues are being addressed in the Multicenter Selective Lymphadenectomy Trial II (NCT002978950).",
"   </p>",
"   <p>",
"    However, a small number of SLNBs will be falsely reported as negative even with optimal technique. In the MSLT-I trial, for example, 3.4 percent of patients with a negative SLNB subsequently relapsed in the regional lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar rate of relapse was observed in a report from M D Anderson [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/24\">",
"     24",
"    </a>",
"    ]. Ten of 243 patients (4.1 percent) with histologically negative SLNB subsequently developed a nodal recurrence in the previously mapped basin. Reexamination of the original pathologic material using serial sections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunohistochemical staining identified melanoma in the sentinel nodes in eight of these ten patients.",
"   </p>",
"   <p>",
"    Immunohistochemical staining for the melanoma markers S100, HMB45, or",
"    <span class=\"nowrap\">",
"     Melan-A/Mart-1",
"    </span>",
"    further enhances sensitivity, detecting 1 melanoma cell in 100,000 cells compared to 1 in 10,000 cells with routine hematoxylin and eosin stains (H&amp;E).",
"   </p>",
"   <p>",
"    Further efforts to improve the detection of occult disease have included the use of the reverse transcriptase polymerase chain reaction (RT-PCR) assay to detect tyrosinase messenger RNA and other tumor markers in lymph node tissue. Although the RT-PCR assay frequently detects tumor markers in histologically negative SLNBs, the presence of such markers has not been consistently correlated with subsequent clinical relapse and the biologic significance of these findings remains uncertain. The use of RT-PCR is investigational, and it should",
"    <strong>",
"     not",
"    </strong>",
"    be used in patient management decisions outside of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H10#H10\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'RT-PCR analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLNB has become the standard approach for the management of patients with melanoma in whom there is a substantial risk of regional node metastasis. Proper application of SLNB requires sufficient experience to ensure a low false negative rate.",
"   </p>",
"   <p>",
"    The indications for SLNB have varied, but the generally accepted approach focuses on tumor thickness and related risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SLNB is indicated for tumors &ge;1 mm thick.",
"     </li>",
"     <li>",
"      Tumors less than 1 mm in thickness have less than a 10 percent likelihood of nodal metastases, and routine SLNB is not indicated in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]. However, certain high-risk features (eg, ulceration, a mitotic rate &ge;1 per mm",
"      <sup>",
"       2",
"      </sup>",
"      , lymphovascular invasion) are associated with a higher rate of lymph node metastasis, thereby potentially justifying the use of SLNB [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/28-32\">",
"       28-32",
"      </a>",
"      ]. In one series, for example, the five and ten year risks of metastasis in such high-risk patients were 11 and 22 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/29\">",
"       29",
"      </a>",
"      ]. In contrast, women with extremity lesions &lt;1 mm thick and none of the above risk factors had less than a 3 percent actuarial risk of metastasis at ten years.",
"     </li>",
"     <li>",
"      Tumors &gt;4 mm thick have a 65 to 70 percent risk of distant metastasis. However, SLNB may still provide important prognostic information. In one series of patients with primary lesions &gt;4 mm thick, five-year survival was higher in biopsy-proven node-negative patients compared to those with positive nodes (82 versus 42 percent for extremity lesions and 52 versus 8 percent for truncal lesions) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/33\">",
"       33",
"      </a>",
"      ]. This information may be important to the patient and could influence the choice of adjuvant therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management of a positive SLNB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no randomized trial has demonstrated the therapeutic value of completion lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/34\">",
"     34",
"    </a>",
"    ], standard therapy for patients with a positive SLNB is completion dissection of all involved nodal basins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/35\">",
"     35",
"    </a>",
"    ]. Not doing a completion lymph node dissection is only acceptable in a clinical trial setting for selected patients who will be monitored with regular ultrasound or imaging.",
"   </p>",
"   <p>",
"    An increasing tumor burden in the sentinel lymph node (manifested by the size of the metastatic focus, number of metastatic foci, extracapsular extension) suggests an increased likelihood of involvement in nonsentinel lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. For patients in whom completion lymph node dissection is not feasible, careful follow-up is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An ongoing phase III trial (the Multicenter Selective Lymphadenectomy Trial II [NCT00297895]) is comparing immediate completion lymph node dissection with a strategy of observation and completion lymph node dissection if there is evidence of regional lymph node recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/39\">",
"     39",
"    </a>",
"    ]. This trial is limited to patients with a primary melanoma that has a Breslow thickness of 1.20 mm or greater and Clark Level III or is a Clark Level IV or V regardless of Breslow thickness. Results for the primary endpoint, melanoma-specific survival, are not anticipated until 2022.",
"   </p>",
"   <p>",
"    The staging evaluation of a patient with a positive regional lymph node is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=see_link&amp;anchor=H4#H4\">",
"     \"Staging work-up and surveillance after treatment of melanoma\", section on 'Positive sentinel lymph node'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjuvant treatment with interferon alfa should be considered for all patients with resected node-positive melanoma in the absence of serious comorbidity and with an adequate life expectancy. Participation in a clinical trial is also an option, especially for patients not considered to be candidates for adjuvant interferon therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261295706\">",
"    <span class=\"h2\">",
"     Elective lymph node dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective lymph node dissection was advocated as an approach to the regional lymph nodes prior to the development of SLNB. However, the availability of lymphatic mapping with SLNB and its success in predicting regional lymph node involvement have obviated a possible role for elective lymph node dissection.",
"   </p>",
"   <p>",
"    Multiple prospective randomized trials were conducted to evaluate the role of elective lymph node dissection, but these have not confirmed a substantial survival benefit from elective lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. The largest of the trials was the Intergroup Melanoma Trial, in which 740 patients with melanomas 1 to 4 mm thick were randomly assigned to immediate ELND or wide excision followed by nodal observation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Patients were stratified for thickness, site, and ulceration, but not for age. At 10 years, the difference in survival between the two treatment groups (77 versus 73 percent) was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261296095\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint guidelines from the American Society of Clinical Oncology (ASCO) and the Society for Surgical Oncology are consistent with the above approach, recommending SLNB for patients with intermediate thickness (1 to 4 mm) melanomas as well as suggesting SLNB for patients with thin melanomas (&lt;1 mm) that have other high risk features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/6\">",
"     6",
"    </a>",
"    ]. Those guidelines also suggest considering SLNB for patients with thick melanoma (&gt;4 mm) for prognostic purposes, to aid in achieving regional disease control, and possibly to help identify patients for standard or investigational adjuvant therapies. Completion lymph node dissection is recommended for all patients with a positive SLNB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261294206\">",
"    <span class=\"h1\">",
"     CLINICALLY APPARENT REGIONAL LYMPH NODES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261294261\">",
"    <span class=\"h2\">",
"     Therapeutic lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical (therapeutic) lymphadenectomy is the preferred treatment for clinically detectable and cytologically (fine needle aspirate) or pathologically proven regional lymph node involvement in patients with melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/2\">",
"     2",
"    </a>",
"    ]. This approach may be curative. Even if patients subsequently develop distant metastases, aggressive regional therapy at presentation can prevent morbidity caused by mass effect from involved nodes or skin breakdown.",
"   </p>",
"   <p>",
"    Approximately 20 to 40 percent of patients with clinically apparent (macroscopic-N2) metastatic involvement of regional nodes are alive at 10 years following therapeutic lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/46\">",
"     46",
"    </a>",
"    ]. The number of metastatic lymph nodes is a significant prognostic factor; patients with only one positive node have a better prognosis (40 to 50 percent) than those with more than one positive node [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261294268\">",
"    <span class=\"h2\">",
"     Extent of dissection and morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete regional lymphadenectomy, rather than partial dissection or sampling, is necessary for melanoma because of the high risk of involvement of other lymph nodes within the basin or extranodal spread.",
"   </p>",
"   <p>",
"    The morbidity of completion axillary dissection (ie, level I, II, and III nodes) for upper extremity melanomas or truncal melanomas with lymphatic drainage to the axilla includes short- and long-term complications. Common short-term complications include wound infection and breakdown, seroma formation, and shoulder dysfunction after axillary dissection (",
"    <a class=\"graphic graphic_table graphicRef79661 \" href=\"UTD.htm?22/55/23419\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/21,48\">",
"     21,48",
"    </a>",
"    ]. Long-term complications include lymphedema and paresthesias.",
"   </p>",
"   <p>",
"    Complications are more common after inguinal lymph node dissection (for lower extremity lesions or truncal melanoma with inguinal drainage) than after axillary nodal dissection, with lymphedema being a frequent problem [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/21,48\">",
"     21,48",
"    </a>",
"    ]. Some surgeons electively add a deep ilioinguinal dissection to the superficial inguinal node dissection when the highest superficial node (Cloquet's node [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/49\">",
"     49",
"    </a>",
"    ]) contains metastatic melanoma, when multiple superficial inguinal nodes contain melanoma, and when imaging suggests deep ilioinguinal metastatic disease.",
"   </p>",
"   <p>",
"    The role of a deep ilioinguinal dissection is controversial, since it is not clear whether the addition of a more extensive dissection improves survival [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The addition of the deep ilioinguinal lymphadenectomy significantly increases the risk of subsequent lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26664/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients undergoing inguinal node dissection usually benefit from compression support stockings for at least six months postoperatively. Prevention of lymphedema is critical since established lymphedema requires lifelong treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphatic mapping with sentinel lymph node biopsy (SLNB) is the standard clinicopathologic approach to evaluate regional lymph nodes in patients without clinical evidence of lymph node involvement. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sentinel lymph node biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with clinically negative regional lymph nodes, the decision whether or not to perform an SLNB is based upon the likelihood of regional lymph node involvement: (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H261296095\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a thin melanoma (&lt;1 mm) and no other factors placing the patient at increased risk for nodal involvement, we recommend not performing an SLNB.",
"     </li>",
"     <li>",
"      For patients with a thin melanoma (&lt;1 mm) and one or more factors placing the patient at increased risk for nodal involvement, we suggest performing an SLNB (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Factors suggesting an increased risk include ulceration of the primary tumor, a mitotic rate",
"      <span class=\"nowrap\">",
"       &ge;1/mm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      lymphovascular invasion, or &ge;0.75 mm thick.",
"     </li>",
"     <li>",
"      For patients with an intermediate thickness melanoma (1 to 4 mm), we recommend performing an SLNB (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with a thick melanoma (&gt;4 mm), we suggest performing a SLNB (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a positive SLNB, we recommend completion lymph node dissection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).(See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of a positive SLNB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a positive SLNB, adjuvant therapy with interferon alfa should be considered in patients with a life expectancy of ten years in the absence of serious comorbidity. Participation in a clinical trial is also an option, especially for patients not considered candidates for or uninterested in receiving interferon alfa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"       \"Adjuvant immunotherapy for melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who present with clinically apparent regional lymph node involvement that is confirmed cytologically (fine needle aspirate) or histologically, we recommend therapeutic regional lymphadenectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Partial dissection or lymph node sampling is",
"      <strong>",
"       not",
"      </strong>",
"      an acceptable alternative because of the propensity of melanoma to spread microscopically to other nodes in the basin. (See",
"      <a class=\"local\" href=\"#H261294206\">",
"       'Clinically apparent regional lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/1\">",
"      Rodrigues LK, Leong SP, Ljung BM, et al. Fine needle aspiration in the diagnosis of metastatic melanoma. J Am Acad Dermatol 2000; 42:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/2\">",
"      Voit CA, van Akkooi AC, Sch&auml;fer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? J Clin Oncol 2009; 27:4994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/3\">",
"      Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995; 130:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/4\">",
"      Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/5\">",
"      Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/6\">",
"      Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/7\">",
"      Mudun A, Murray DR, Herda SC, et al. Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology 1996; 199:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/8\">",
"      Norman J, Cruse CW, Espinosa C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg 1991; 162:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/9\">",
"      Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg 1999; 189:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/10\">",
"      Valsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol 2011; 29:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/11\">",
"      Sondak VK, Zager JS. Who is to blame for false-negative sentinel node biopsies in melanoma? Ann Surg Oncol 2010; 17:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/12\">",
"      Scoggins CR, Martin RC, Ross MI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 2010; 17:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/13\">",
"      Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003; 10:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/14\">",
"      Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/15\">",
"      Kretschmer L, Hilgers R, M&ouml;hrle M, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004; 40:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/16\">",
"      Roka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 2005; 92:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/17\">",
"      Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/18\">",
"      Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience. Melanoma Res 2003; 13:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/19\">",
"      Leiter U, Buettner PG, Bohnenberger K, et al. Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph node metastasis as well as distant metastasis after nodal involvement. Ann Surg Oncol 2010; 17:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/20\">",
"      Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/21\">",
"      Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003; 10:676.",
"     </a>",
"    </li>",
"    <li>",
"     Reintgen DS, Rapaport DP, Tanabe KK, Ross MI. Lymphatic mapping and sentinel lymphadenectomy. In: Cutaneous Melanoma, 3rd, Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Quality Medical Publishing, St. Louis 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/23\">",
"      van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 2011; 29:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/24\">",
"      Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/25\">",
"      Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/26\">",
"      Zapas JL, Coley HC, Beam SL, et al. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J Am Coll Surg 2003; 197:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/27\">",
"      Warycha MA, Zakrzewski J, Ni Q, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (&lt;or=1 mm). Cancer 2009; 115:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/28\">",
"      Murali R, Haydu LE, Quinn MJ, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg 2012; 255:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/29\">",
"      Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal \"thin\" malignant melanoma. Identifying patients at risk. Ann Surg 1988; 208:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/30\">",
"      McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003; 98:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/31\">",
"      Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006; 13:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/32\">",
"      Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 2006; 107:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/33\">",
"      Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 1990; 125:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/34\">",
"      Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 2006; 13:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/35\">",
"      Sondak VK. Nonsentinel node metastases in melanoma: do they reflect the biology of the tumor, the lymph node or the surgeon? : Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1. Ann Surg Oncol 2009; 16:2965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/36\">",
"      Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008; 26:4296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/37\">",
"      van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/38\">",
"      Kingham TP, Panageas KS, Ariyan CE, et al. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. Ann Surg Oncol 2010; 17:514.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health clinical trials database. file://www.clinicaltrials.gov/ (Accessed on November 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/40\">",
"      Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/41\">",
"      Balch CM. Randomized surgical trials involving elective node dissection for melanoma. Adv Surg 1999; 32:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/42\">",
"      Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/43\">",
"      Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986; 61:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/44\">",
"      Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/45\">",
"      Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224:255.",
"     </a>",
"    </li>",
"    <li>",
"     Stadelmann WK, Rapaport DP, Soong SJ, et al. Prognostic clinical and pathologic features. In: Cutaneous Melanoma, 3rd, Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Quality Medical Publishing, St. Louis 1997. p.12.",
"    </li>",
"    <li>",
"     Stadelmann WK, Rapaport DP, Soong SJ, et al. Stadelmann, WK, Rapaport, DP, Soong, SJ, et al. In: Cutaneous Melanoma, 3rd, Balch CM, Houghton AN, Sober AJ, Soon SJ (Eds), Quality Medical Publishing, St. Louis 1997. p.26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/48\">",
"      Shaw JH, Rumball EM. Complications and local recurrence following lymphadenectomy. Br J Surg 1990; 77:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/49\">",
"      Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989; 124:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26664/abstract/50\">",
"      Badgwell B, Xing Y, Gershenwald JE, et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol 2007; 14:2867.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7616 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26664=[""].join("\n");
var outline_f26_2_26664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261295543\">",
"      CLINICALLY NEGATIVE REGIONAL LYMPH NODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sentinel lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sensitivity and specificity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Multicenter selective lymphadenectomy trial-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Incidence of nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prognostic implications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Survival effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Minimal metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management of a positive SLNB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261295706\">",
"      Elective lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261296095\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261294206\">",
"      CLINICALLY APPARENT REGIONAL LYMPH NODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261294261\">",
"      Therapeutic lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H261294268\">",
"      Extent of dissection and morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7616\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7616|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/18/29999\" title=\"figure 1\">",
"      Sentinel node concept",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7616|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/55/23419\" title=\"table 2\">",
"      Morbidity LND melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15450?source=related_link\">",
"      Imaging studies in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_2_26665="Renal atheroembolus histology";
var content_f26_2_26665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56672%7ENEPH%2F68445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56672%7ENEPH%2F68445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal atheroembolus histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of an atheroembolus in a muscular renal artery showing cleft-like spaces (arrow) due to washout of the cholesterol crystals during histologic processing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal atheroembolus toluidine blue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thin section, toluidine blue stain shows the characteristic cholesterol clefts of an atheroembolus in the small renal artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26665=[""].join("\n");
var outline_f26_2_26665=null;
var title_f26_2_26666="Treatment of Duchenne and Becker muscular dystrophy";
var content_f26_2_26666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Duchenne and Becker muscular dystrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26666/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26666/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26666/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/2/26666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/2/26666/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/2/26666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/1\">",
"     1",
"    </a>",
"    ]. The Duchenne and Becker muscular dystrophies (as well as a third intermediate form) are caused by mutations of the dystrophin gene and are therefore named dystrophinopathies. Weakness is the principal symptom as muscle fiber degeneration is the primary pathologic process.",
"   </p>",
"   <p>",
"    The dystrophinopathies are inherited as X-linked recessive traits and have varying clinical characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duchenne muscular dystrophy (DMD) is associated with the most severe clinical symptoms",
"     </li>",
"     <li>",
"      Becker muscular dystrophy (BMD) has a similar presentation to DMD, but a relatively milder clinical course",
"     </li>",
"     <li>",
"      An intermediate group of patients, known as \"outliers,\" may be classified clinically as having either mild DMD or severe BMD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management and treatment of Duchenne and Becker muscular dystrophy will be discussed in this review. The genetics, pathogenesis, and clinical characteristics of the Duchenne and Becker muscular dystrophy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOID TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the mainstay of treatment for DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/2\">",
"     2",
"    </a>",
"    ], and are offered for boys five years of age and older who are no longer gaining motor skills, or whose motor skills are declining [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/3\">",
"     3",
"    </a>",
"    ]. The randomized trial evidence establishing the benefit of glucocorticoid therapy started at ages four to five years for boys with DMD is presented in the sections that follow. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Prednisone'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Deflazacort'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Earlier initiation of glucocorticoids may also be beneficial, though prospective data are limited to a single report of five boys with DMD who were started on glucocorticoids at ages 2 to 4 years and were followed for up to 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/4\">",
"     4",
"    </a>",
"    ]. One boy lost ambulation at age 10, while at last follow-up the remaining four boys (ages 16 to 18) were fully ambulant and three could still climb stairs. These outcomes surpass the typical course of DMD (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Prognosis'",
"    </a>",
"    below), in which ambulation is lost before age 13. The major side effects of glucocorticoid therapy in this report included short stature and delayed puberty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     Prednisone",
"    </a>",
"    is beneficial in the treatment of DMD and is associated with a significant increase in strength, muscle function, and pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/5\">",
"     5",
"    </a>",
"    ]. A practice parameter developed by the American Academy of Neurology (AAN) and the Child Neurology Society (CNS) in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ] identified six high quality randomized controlled trials of prednisone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/5,7-11\">",
"     5,7-11",
"    </a>",
"    ], and one of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/12\">",
"     12",
"    </a>",
"    ] for DMD. The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Average muscle strength increased by 11 percent with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) treatment compared with placebo. Strength increased significantly by 10 days, reached a maximum at 3 months, and was maintained at 6 and 18 months.",
"     </li>",
"     <li>",
"      Urinary creatinine excretion, a surrogate for muscle mass, increased with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      treatment after 6 months and 18 months by 30.5 and 36 percent compared with placebo. This finding supports an anabolic action of prednisone in DMD in contrast to its catabolic action on normal skeletal muscle in unaffected people.",
"     </li>",
"     <li>",
"      The results of standardized timed function testing (eg, time to climb stairs, walk nine meters, or arise from supine to standing) improved significantly with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      treatment compared with placebo. As an example, the average time to climb four stairs was approximately 43 percent faster with prednisone treatment compared with placebo (4 versus 7 seconds respectively).",
"     </li>",
"     <li>",
"      Forced vital capacity (FVC) improved significantly (10.5 percent higher) after six months of daily",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) treatment compared with placebo.",
"     </li>",
"     <li>",
"      Average muscle strength, improvements in timed function tests, and increases in FVC were significantly greater for",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day than for 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in studies that examined the prednisone dose-response.",
"     </li>",
"     <li>",
"      Alternate day therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (1.25 and 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day) was",
"      <strong>",
"       not",
"      </strong>",
"      sufficient to achieve the sustained benefit associated with daily prednisone ranging from 0.3 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. One small trial of 14 boys found that",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      5.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day was effective in preventing loss of ambulation after 36 months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insufficient data exist regarding the optimal age to begin treatment with glucocorticoids, or the optimal duration of such treatment.",
"     </li>",
"     <li>",
"      The most common side effects after 6 to 18 months of treatment with daily",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      were weight gain and cushingoid facial appearance. There was no significant increase in hypertension, diabetes, gastrointestinal bleeding, psychosis, compression fractures, or cataracts. However, retrospective data suggest that long-term use of glucocorticoids does increase the risk of vertebral compression fractures and long bone fractures. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Orthopedic outcomes of glucocorticoid therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      After 18 months, significantly more patients treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      developed weight gain (&gt;20 percent of baseline weight) compared with placebo (75 to 80 versus 20 to 24 percent respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later randomized controlled trial of 64 boys with DMD (ages 4 to 10 years) compared weekend dosing of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week given over two days) with daily dosing (0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    a day) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/13\">",
"     13",
"    </a>",
"    ]. After 12 months, there was similar benefit for leg and arm muscle strength and similar body mass index for both treatment groups, although some secondary outcome measures did not meet equivalence. In addition, there was a statistically significant increase in linear growth in the weekend dosing group. However, this particular finding requires confirmation in additional randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight gain in patients with DMD is not solely an undesirable side effect because it is associated with an increase in muscle mass as noted above. In addition, one study found that ambulatory patients treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    did not have significantly greater weight gain than placebo treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, nonambulatory patients treated with prednisone did have a significantly greater weight gain.",
"   </p>",
"   <p>",
"    The duration of six of the seven studies assessed by the practice parameter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ] ranged from 6 to 18 months, which is insufficient to evaluate clinically important endpoints such as loss of ambulation or decline in FVC. However, one longer term study found that the benefits of daily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy (improvements in arm and leg function, timed function tests, and FVC) were sustained for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar conclusions regarding benefit and side effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    treatment for DMD were reached in a systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/16\">",
"     16",
"    </a>",
"    ]. The mechanism of the beneficial effect of glucocorticoids in patients with DMD is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known of the effect of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    in patients with BMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Deflazacort",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deflazacort appears to be effective for the treatment of DMD, with efficacy and side effect profiles similar to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. Deflazacort is an oxazoline derivative of prednisone, and has an estimated dosage equivalency of 1:1.3 compared with prednisone. Thus, 1.3 mg of deflazacort is approximately equivalent to 1.0 mg of prednisone.",
"   </p>",
"   <p>",
"    Deflazacort is not approved by the US Food and Drug Administration (FDA) and is not available in the United States. It is available in Canada via the Special Access Programme (SAP), which provides access to nonmarketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. Deflazacort is available as a licensed pharmaceutical in some European, Asian, and South American countries.",
"   </p>",
"   <p>",
"    The 2005 practice parameter from the AAN and CNS examined two high quality studies of deflazacort for the treatment of DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and made the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily deflazacort (1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) treatment for nine months was associated with increased muscle strength and function compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , alternate day treatment with deflazacort (2.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day) for two years was beneficial in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/19\">",
"       19",
"      </a>",
"      ]. The mean prolongation of ambulation was 13 months.",
"     </li>",
"     <li>",
"      Side effects of deflazacort were similar to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      in the two high quality randomized controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. In two longer term studies of open treatment with daily deflazacort, asymptomatic cataracts were noted in 10 of 30 patients treated for a mean of 3.2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/20\">",
"       20",
"      </a>",
"      ] and in 6 of 13 patients treated for a mean of 5.4 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts outside the US routinely use deflazacort for DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/22\">",
"     22",
"    </a>",
"    ], and believe it offers a more favorable side effect profile than daily treatment with prednisone, particularly with regard to weight gain. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Prednisone versus deflazacort'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The available clinical data regarding the impact of deflazacort on cardiac function in patients with DMD are limited. In a retrospective cohort study of 33 patients with DMD, those receiving deflazacort for &ge;3 years were significantly more likely to have preserved cardiac function",
"    <span class=\"nowrap\">",
"     (20/21",
"    </span>",
"    patients), defined as ejection fraction &gt;45 percent, than those who had not received the medication",
"    <span class=\"nowrap\">",
"     (5/12)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/23\">",
"     23",
"    </a>",
"    ]. Larger long term prospective studies are needed to determine the effect of deflazacort on cardiac function in patients with DMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prednisone versus deflazacort",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    and daily deflazacort produced similar benefit in boys with DMD when compared in three open label trials that were included in the 2005 AAN and CNS practice parameter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ]. These trials ranged in duration from 12 to 24 months, and reported comparable improvements in muscle strength and function for prednisone and deflazacort treatment.",
"   </p>",
"   <p>",
"    Side effect profiles of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    and deflazacort were also similar in these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ], although one trial of 18 patients found that deflazacort treatment was associated with a lesser increase in body weight than prednisone treatment at 12 months (2 kg versus 5 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/24\">",
"     24",
"    </a>",
"    ]. The practice parameter concluded that the data are insufficient to determine whether deflazacort has fewer side effects than prednisone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ]. Nonetheless, deflazacort is used in preference to prednisone in some centers (eg, in Canada) for patients with DMD who may be predisposed to obesity based on body habitus or family history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480059\">",
"    <span class=\"h2\">",
"     Cardiovascular outcomes of glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from several small nonrandomized studies suggest that treatment with glucocorticoids for DMD reduces new-onset and progressive cardiomyopathy and lowers mortality via a reduction in deaths related to heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. While these findings require confirmation in larger prospective trials, we recommend glucocorticoid therapy for boys with DMD five years of age and older because of its beneficial effects for strength and muscle function as discussed in the previous sections and summarized below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Recommendations for glucocorticoid therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The symptomatic management of cardiac disease in DMD is discussed below. (See",
"    <a class=\"local\" href=\"#H258480474\">",
"     'Cardiac disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Orthopedic outcomes of glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective data suggest that long-term therapy with glucocorticoids for DMD reduces the risk of scoliosis and prolongs independent ambulation but increases the risk of osteoporosis and long bone and vertebral compression fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/28\">",
"     28",
"    </a>",
"    ]. There are also a number of other side effects of long-term glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures for assessing and maintaining bone health are described below (See",
"    <a class=\"local\" href=\"#H258480619\">",
"     'Bone health'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    Preventive measures for adults are discussed in detail separately and include dietary calcium and vitamin D supplementation, bisphosphonates, and DXA scanning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other immunosuppressive therapies have been studied for the treatment of DMD. In a randomized trial of 95 boys with DMD cited above,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    was added after six months to the patients who had been randomly assigned at enrollment to placebo or low dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/9\">",
"     9",
"    </a>",
"    ]. However, no improvement was observed with azathioprine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     Oxandrolone",
"    </a>",
"    , an anabolic (androgenic) steroid, was found in a pilot study to have effects similar to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , with fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, a randomized prospective trial reported that, although oxandrolone did not produce a significant change in the average manual muscle strength score as compared with placebo, there was a marked improvement in quantitative muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/30\">",
"     30",
"    </a>",
"    ]. The investigators felt that oxandrolone may be useful before initiating therapy with glucocorticoids because it is safe and accelerates linear growth. However, its beneficial effect in slowing the progression of weakness is not of sufficient magnitude to justify its routine use.",
"   </p>",
"   <p>",
"    In a preliminary study, the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for eight weeks was reported to improve clinical function in 15 children with DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/31\">",
"     31",
"    </a>",
"    ]. However, in a randomized placebo-controlled trial of 130 patients with DMD who completed treatment, cyclosporine did not improve muscle strength or functional abilities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recommendations for glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations for glucocorticoid therapy are in accordance with the 2005 practice parameter from the AAN and CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"     6",
"    </a>",
"    ] and subsequent data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      (0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week given over two weekend days) should be offered as treatment for boys with DMD who are five years of age or older. A balanced discussion of the potential benefits and risks of glucocorticoid treatment should be given to every patient prior to initiating therapy.",
"     </li>",
"     <li>",
"      Benefits and side effects of glucocorticoid therapy must be monitored. Timed muscle function tests, pulmonary function tests, and age at loss of independent ambulation are useful parameters to assess benefits. Cognizance of potential glucocorticoid therapy side effects (eg, weight gain, cushingoid appearance, short stature, decrease in linear growth, delayed puberty, long bone and vertebral fractures, acne, excessive hair growth, gastrointestinal symptoms, and behavioral changes) is important to assess risks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H14\">",
"       'Orthopedic outcomes of glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintaining the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      dose at 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day is optimal. This dose should be continued if the side effects are not severe. A gradual tapering of prednisone to as low as 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day will give significant but less robust improvement.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      dose should be decreased to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day if excessive weight gain occurs (&gt;20 percent over estimated normal weight for height over a 12 month period). The dose should be further decreased to 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day after three to four months if excessive weight gain continues.",
"     </li>",
"     <li>",
"      Deflazacort (0.9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) where available can also be used to treat DMD. Patients should be monitored for asymptomatic cataracts and weight gain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"       \"Cataract in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these recommendations, we suggest preventive measures to minimize bone loss for patients with DMD who are receiving prolonged glucocorticoid therapy. Such measures include dietary calcium and vitamin D supplementation, and yearly DXA scanning and a 25-hydroxyvitamin D level. (See",
"    <a class=\"local\" href=\"#H258480619\">",
"     'Bone health'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480440\">",
"    <span class=\"h1\">",
"     SYMPTOM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to muscle weakness, cardiac, pulmonary, and orthopedic complications are frequently associated with Duchenne (DMD) muscular dystrophy and Becker muscular dystrophy (BMD). The anticipation and early detection of organ involvement is important for optimal therapy. Furthermore, patients should be evaluated by pulmonary, anesthesia, and cardiac specialists prior to any surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480467\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines recommend universal immunization of infants and children with pneumococcal vaccine. Pneumococcal vaccination for healthy and high-risk children and adults is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, current guidelines recommend an annual influenza vaccination for all individuals six months of age and older. Detailed recommendations for influenza vaccination in children and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H7#H7\">",
"     \"Seasonal influenza vaccination in children\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480474\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slowing progression of the cardiomyopathy associated with dystrophinopathies such as DMD and BMD is an area of active research. Initial clinical studies have evaluated the effect of angiotensin converting enzyme (ACE) inhibitors and beta blockers, both of which are used to treat asymptomatic left ventricular dysfunction and overt heart failure. A further rationale for such therapy is the suggestion that the magnitude of force generation is an important determinant of cell injury in the dystrophinopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible preventive efficacy of ACE inhibitors, which are beneficial in asymptomatic left ventricular dysfunction in adults, was evaluated in a randomized trial of 57 children with BMD (mean age 10.7 years) who had a mean left ventricular ejection fraction (LVEF) of 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/35\">",
"     35",
"    </a>",
"    ]. The children were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    (2 to 4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo. There was no difference in LVEF at three years. All of the children were then treated with perindopril for two more years. Although the mean LVEF was still not different (58.6 versus 56.0 percent with placebo), an LVEF less than 45 percent was noted in only one of the 27 patients originally treated with perindopril compared to 8 of the 29 treated with placebo. After an additional year, there were three deaths in the placebo group, all among the eight patients with an LVEF &lt;45 percent.",
"   </p>",
"   <p>",
"    More data are needed to prove that ACE inhibitors slow progression of heart disease in children with DMD who have a normal LVEF.",
"   </p>",
"   <p>",
"    Results from a retrospective observational study suggest that early diagnosis and treatment of dilated cardiomyopathy in patients with DMD and BMD may lead to ventricular remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/36\">",
"     36",
"    </a>",
"    ]. Among 69 affected boys, an ACE inhibitor was started in 27 with DMD and four with BMD after the first abnormal echocardiogram indicative of dilated cardiomyopathy (eg, LVEF &lt;55 percent or left ventricular dilation); the mean age was 15 years. A beta blocker (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=see_link\">",
"     carvedilol",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/11/15544?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) was added after three months if echocardiography showed no improvement.",
"   </p>",
"   <p>",
"    At a mean follow-up of 3.3 years among 29 of the 31 patients who had repeat echocardiography, left ventricular size and function showed normalization, improvement, or stabilization in 19, 8, and 2 patients, respectively (66, 26, and 8 percent). In addition, the mean LVEF increased from 36 to 53 percent and there was evidence of improved ventricular geometry as measured by reduced sphericity.",
"   </p>",
"   <p>",
"    Given these data, we suggest treatment with an ACE inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a beta blocker for children with DMD or BMD who have evidence of ventricular dysfunction on cardiac imaging (ie, left ventricular ejection fraction &lt;55 percent or left ventricular dilation). Overt heart failure is treated with other therapies such as diuretics and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    as in children without muscular dystrophy. Cardiac transplantation is an option in patients with BMD who have severe dilated cardiomyopathy and limited or no clinical evidence of skeletal muscle disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480504\">",
"    <span class=\"h3\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography or cardiac MRI should be obtained around age 10 years or at the onset of symptoms and signs in boys with BMD and then repeated annually or biannually [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/37\">",
"     37",
"    </a>",
"    ]. Cardiac evaluation of female carriers should begin after teenage years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consensus guidelines published in 2010 recommend a baseline assessment of cardiac function at the time of diagnosis of DMD or by the age of six years, especially if this can be done without sedation; clinical judgment should be used to decide upon evaluation for patients who require sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ]. At minimum, the assessment should include an electrocardiogram and a noninvasive imaging study such as echocardiography or cardiac MRI. The cardiac evaluation should be repeated at least once every two years until the age of 10 or the onset of cardiac symptoms if they occur earlier, and then repeated annually thereafter. For patients with DMD who have abnormalities of ventricular function, the guidelines recommend surveillance at least every six months and initiation of pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480511\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overnight mouth intermittent positive pressure can be used to treat symptomatic nocturnal hypoventilation, and respiratory assistance may be used during periods of respiratory infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=see_link\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients with neuromuscular weakness and atelectasis may benefit from mechanical insufflation-exsufflation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=see_link&amp;anchor=H15#H15\">",
"     \"Atelectasis in children\", section on 'Mechanical insufflation-exsufflation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Baseline pulmonary function tests should be obtained prior to wheelchair confinement, usually around 9 or 10 years of age. Pediatric pulmonology evaluations should be obtained two times a year after any one of the following occurs: wheelchair confinement, vital capacity &lt;80 percent predicted, or age 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consensus guidelines published in 2010 recommend the following sequence of respiratory interventions for patients with DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. (The specified threshold values of peak cough flow and maximum expiratory pressure apply to older teenage and adult patients.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First step: Volume",
"      <span class=\"nowrap\">",
"       recruitment/deep",
"      </span>",
"      lung inflation using a self-inflating manual ventilation bag or mechanical insufflation&ndash;exsufflation when vital capacity is &lt;40 percent of predicted",
"     </li>",
"     <li>",
"      Second step: Manual and mechanically assisted cough techniques when:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Respiratory infection is present and baseline peak cough flow is &lt;270",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"     </li>",
"     <li>",
"      Baseline peak cough flow is &lt;160",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      or maximum expiratory pressure is &lt;40 cm water",
"     </li>",
"     <li>",
"      Baseline vital capacity is &lt;40 percent predicted or &lt;1.25 L in an older teenager or adult",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Third step: Nocturnal ventilation when:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Signs or symptoms of hypoventilation (patients with a vital capacity &lt;30 percent of predicted are at especially high risk)",
"     </li>",
"     <li>",
"      The baseline pulse oximetry is &lt;95 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood or end-tidal CO2 is &gt;45 mmHg while awake",
"     </li>",
"     <li>",
"      The apnea-hypopnea index is &gt;10 per hour on polysomnography, or there are four or more episodes of pulse oximetry &lt;92 percent, or there are drops in pulse oximetry of at least 4 percent per hour of sleep",
"      <br/>",
"      <br/>",
"      Optimally, the use of lung volume recruitment and assisted cough techniques should always precede initiation of noninvasive ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fourth step: Daytime ventilation, indicated for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Self extension of nocturnal ventilation into waking hours",
"     </li>",
"     <li>",
"      Abnormal deglutition due to dyspnea that is relieved by ventilatory assistance",
"     </li>",
"     <li>",
"      Inability to speak a full sentence without breathlessness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of hypoventilation with a baseline pulse oximetry &lt;95 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood or an end-tidal CO2 &gt;45 mmHg while awake",
"      <br/>",
"      <br/>",
"      Continuous noninvasive assisted ventilation with mechanically assisted cough can facilitate endotracheal extubation for patients who were intubated during acute illness or during anesthesia, followed by weaning to nocturnal noninvasive assisted ventilation, if applicable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifth step: Tracheostomy with indications including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient and clinician preference; the guidelines recommend the long-term use of noninvasive ventilation up to and including 24 hours daily in eligible patients",
"     </li>",
"     <li>",
"      Inability of patient to use noninvasive ventilation successfully",
"     </li>",
"     <li>",
"      Inability of the local medical infrastructure to support noninvasive ventilation",
"     </li>",
"     <li>",
"      Three failures to achieve extubation during critical illness despite optimum use of noninvasive ventilation and mechanically assisted cough",
"     </li>",
"     <li>",
"      The failure of noninvasive methods of cough assistance to prevent aspiration of secretions into the lung and drops in oxygen saturation below 95 percent or baseline, necessitating frequent direct tracheal suctioning via tracheostomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480538\">",
"    <span class=\"h2\">",
"     Complications related to anesthesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DMD have a high risk of complications when they undergo procedures requiring anesthesia or sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/33,42\">",
"     33,42",
"    </a>",
"    ]. These potentially life-threatening risks include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reactions to inhaled anesthetics and certain muscle relaxants",
"     </li>",
"     <li>",
"      Upper airway obstruction",
"     </li>",
"     <li>",
"      Hypoventilation",
"     </li>",
"     <li>",
"      Atelectasis",
"     </li>",
"     <li>",
"      Respiratory failure",
"     </li>",
"     <li>",
"      Difficulty weaning from mechanical ventilation",
"     </li>",
"     <li>",
"      Cardiac arrhythmias",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, DMD is associated with susceptibility to malignant hyperthermia or episodes that mimic malignant hyperthermia, with clinical manifestations that include rhabdomyolysis, hyperkalemia, and sudden cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/33,42-48\">",
"     33,42-48",
"    </a>",
"    ]. Avoidance of potential triggering agents, particularly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    and inhalational anesthetics such as halothane,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    , may reduce the risk of these events in patients with DMD or BMD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link&amp;anchor=H2139843#H2139843\">",
"     \"Severe hyperthermia (heat stroke) in adults\", section on 'Malignant hyperthermia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Chest Physicians (ACCP) published a consensus statement in 2007 regarding the management of patients with DMD undergoing anesthesia or sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/33\">",
"     33",
"    </a>",
"    ]. Key points of the ACCP recommendations regarding suggested management before (",
"    <a class=\"graphic graphic_table graphicRef74854 \" href=\"UTD.htm?9/20/9548\">",
"     table 1",
"    </a>",
"    ), during (",
"    <a class=\"graphic graphic_table graphicRef55467 \" href=\"UTD.htm?24/7/24700\">",
"     table 2",
"    </a>",
"    ), and after (",
"    <a class=\"graphic graphic_table graphicRef67162 \" href=\"UTD.htm?23/41/24220\">",
"     table 3",
"    </a>",
"    ) anesthesia or sedation are shown in the Tables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480565\">",
"    <span class=\"h2\">",
"     Orthopedic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic interventions in",
"    <span class=\"nowrap\">",
"     DMD/BMD",
"    </span>",
"    are specifically aimed at maintaining function, preventing contractures, and providing psychologic support. Patients should receive physical therapy to encourage mobility and to prevent or reduce the risk of contractures. The mainstays of physical therapy are passive stretching exercises to prevent contractures of the iliotibial band, the Achilles tendons, and flexors of the hip.",
"   </p>",
"   <p>",
"    Multiple additional interventions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    modalities may be used based upon the patient's requirements and severity of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lightweight plastic ankle-foot orthoses should be applied if the foot remains in plantar flexion during sleep.",
"     </li>",
"     <li>",
"      Standing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      walking may be maintained by using long-leg braces.",
"     </li>",
"     <li>",
"      Surgery may be performed to release contractures of the hip flexors, iliotibial bands, and Achilles tendons.",
"     </li>",
"     <li>",
"      Standing and ambulation may prevent scoliosis.",
"     </li>",
"     <li>",
"      Spine surgery to stabilize or correct scoliosis may improve patient comfort, particularly for those confined to a wheelchair, and may benefit pulmonary function [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39,49\">",
"       39,49",
"      </a>",
"      ]. However, surgery for scoliosis in DMD has not been evaluated in randomized controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Orthopedic evaluations should monitor for scoliosis and other complications and surgical interventions should be utilized as needed. Chest and spine radiography should be ordered on an as-needed basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480592\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on circumstances and treatment (eg, glucocorticoids), patients with DMD can be at risk of malnutrition or weight abnormalities, including being underweight or overweight for age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ]. Weight should be monitored and controlled to avoid obesity.",
"   </p>",
"   <p>",
"    Consensus guidelines published in 2010 recommend the following interventions to improve underweight and overweight status for patients with DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitor regularly for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Weight",
"     </li>",
"     <li>",
"      Linear height in ambulatory patients (measured every six months)",
"     </li>",
"     <li>",
"      Arm",
"      <span class=\"nowrap\">",
"       span/segmental",
"      </span>",
"      length in nonambulatory patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refer for a",
"      <span class=\"nowrap\">",
"       nutritional/dietetic",
"      </span>",
"      assessment:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At diagnosis",
"     </li>",
"     <li>",
"      At initiation of glucocorticoids",
"     </li>",
"     <li>",
"      If the patient is underweight (&lt;10th age percentile)",
"     </li>",
"     <li>",
"      If the patient is at risk of becoming overweight (85 to 95th age percentile)",
"     </li>",
"     <li>",
"      If the patient is overweight (&gt;95th age percentile)",
"     </li>",
"     <li>",
"      If there has been unintentional weight loss or gain",
"     </li>",
"     <li>",
"      If there has been poor weight gain",
"     </li>",
"     <li>",
"      If major surgery is planned",
"     </li>",
"     <li>",
"      If the patient is chronically constipated",
"     </li>",
"     <li>",
"      If dysphagia is present",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480619\">",
"    <span class=\"h2\">",
"     Bone health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DMD often have risk factors for poor bone health that may include decreased mobility, muscle weakness, and glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ]. Possible complications include long bone and vertebral fractures, osteopenia, osteoporosis, kyphoscoliosis, bone pain, and reduced quality of life.",
"   </p>",
"   <p>",
"    There are no clinical studies in children to guide preventive measures for glucocorticoid-induced osteoporosis. However, expert consensus guidelines published in 2010 recommend the following bone health assessments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Calcium",
"     </li>",
"     <li>",
"      Phosphate",
"     </li>",
"     <li>",
"      Alkaline phosphatase",
"     </li>",
"     <li>",
"      25-hydroxyvitamin D (25OHD) level in springtime or bi-annually",
"     </li>",
"     <li>",
"      Consider magnesium and parathyroid hormone levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Calcium (for calciuria)",
"     </li>",
"     <li>",
"      Sodium",
"     </li>",
"     <li>",
"      Creatinine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dual energy x-ray absorptiometry (DXA) scanning to measure bone mineral density",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Obtain baseline at age 3 plus years or start of glucocorticoid therapy",
"     </li>",
"     <li>",
"      Repeat annually for those at risk, including patients with a history of fractures, those on chronic glucocorticoid therapy, and those with a DXA Z score &lt;-2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spine radiograph, if kyphoscoliosis is present on examination, or if back pain is present, to assess for vertebral compression fracture",
"     </li>",
"     <li>",
"      Bone age (left wrist) radiography in patients with growth failure (height for age &lt;5",
"      <sup>",
"       th",
"      </sup>",
"      percentile or if linear growth is faltering) on or off glucocorticoid therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2010 consensus guidelines recommend the following interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin D supplementation is recommended for proven deficiency and should be considered in all children if levels cannot be maintained",
"     </li>",
"     <li>",
"      Calcium intake and possible supplementation should be carried out in consultation with a dietician",
"     </li>",
"     <li>",
"      Bisphosphonates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous bisphosphonates are indicated for vertebral fracture",
"     </li>",
"     <li>",
"      Oral bisphosphonates remain controversial as treatment or prophylactic measure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In accord with current guidelines, we suggest dietary calcium and vitamin D intake in the form of dairy products, other foods rich in calcium and vitamin D, and sunshine exposure. Calcium supplementation (500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is suggested for children with diminished intake of calcium-containing foods (eg, for children who do not like milk and dairy products). We recommend vitamin D supplementation if the serum concentration of vitamin D is &lt;30",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Others recommend supplementation for vitamin D levels &le;20",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the consensus guidelines regarding exercise published in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ] and detailed in the following section, we also suggest standing and weight-bearing exercise, ideally for at least 30 minutes each day, when possible.",
"   </p>",
"   <p>",
"    We refer patients to a dietitian for weight control and discussion of calcium and vitamin D intake. We also refer patients to a pediatric endocrinologist or bone specialist if the vitamin D level is &lt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (others use 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    as the limit) or if DXA scan shows marked deviation from age-normal or baseline values. In addition, we refer children who develop vertebral or long bone fractures to a pediatric endocrinologist or bone specialist for possible bisphosphonate treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258480680\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus guidelines published in 2010 recommend that all boys with DMD who are ambulatory or in the early non-ambulatory stage participate in regular submaximum (ie, gentle) exercise to avoid disuse muscle atrophy and other complications of inactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"     39",
"    </a>",
"    ]. The guidelines suggest a combination of swimming-pool and recreation-based exercises, noting that swimming may be beneficial for aerobic conditioning and respiratory exercise, and could be continued in the non-ambulatory phase if medically safe. Low-resistance strength training and optimization of upper body function may provide additional benefits. However, activity should be reduced if patients develop significant muscle pain or myoglobinuria within the 24 hour period after a specific activity, as these may indicate overexertion and contraction-induced muscle injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NOVEL THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of the gene responsible for the dystrophinopathies led to initial excitement that transfer of a functioning dystrophin protein (whether by transplanted myoblast or direct genetic manipulation) may provide substantial benefit to or even \"cure\" affected patients. Although myoblast transfer has been attempted in humans, the results have thus far not been encouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/54\">",
"     54",
"    </a>",
"    ]. However, in one patient who received a bone marrow transplant for severe combined immunodeficiency, donor nuclei persisted in a small number (&gt;1 percent) of myocytes for more than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, cells derived from bone marrow may serve as vector for genetic therapies.",
"   </p>",
"   <p>",
"    Preliminary clinical studies are evaluating systemic gene transfer by intravascular administration of recombinant adeno-associated viral (rAAV) vectors that carry microdystrophin or minidystrophin genes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. One such study found evidence of dystrophin-specific T-cells in four of six treated patients with DMD; the activity was unexpectedly present in two patients before vector treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/59\">",
"     59",
"    </a>",
"    ]. At 90 days after treatment, there was no evidence of transgene expression. The results suggest that cellular immunity may be an obstacle to successful dystrophin transgene therapy. The discovery of pre-existing T-cell immunity to dystrophin may be caused by priming of the cellular immune system to revertant dystrophin myofibers that express truncated dystrophin protein and are present at low levels in most patients with DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12402433\">",
"    <span class=\"h3\">",
"     Exon skipping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another investigational approach involves injection of antisense oligonucleotides that induce specific exon skipping during messenger RNA splicing, thereby correcting the open reading frame of the DMD gene and restoring dystrophin expression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/58,63-69\">",
"     58,63-69",
"    </a>",
"    ]. This type of molecular therapy has been validated in canine and mouse models of DMD with various oligonucleotides that can restore dystrophin expression by inducing exon skipping during messenger RNA splicing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Results from small clinical studies in humans suggest the promise of this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In small studies, intramuscular injection of oligonucleotides that induce skipping of exon 51 proved to be safe and induced dystrophin synthesis locally within the treated muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/63,69\">",
"       63,69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In preliminary results from a placebo-controlled trial with 12 patients, those assigned to the higher dose of the exon 51 skipping drug eteplirsen (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily intravenously) showed a statistically significant improvement in the six-minute walk test [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small open-label study found that weekly intravenous administration of an antisense oligonucleotide induced a dose-related increase in dystrophin production without drug-related adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/68\">",
"       68",
"      </a>",
"      ], while another open-label study reported that systemic weekly subcutaneous administration of an antisense oligonucleotide was associated with new dystrophin expression in 10 of 12 patients with DMD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/67\">",
"       67",
"      </a>",
"      ]. After a 12-week extension phase, improvement in the six-minute walk test was observed in 8 of 12 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional clinical trials are in progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ataluren",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataluren (PTC124) is an investigational orally administered drug being developed for the treatment of genetic defects caused by nonsense (stop) mutations. Ataluren promotes ribosomal read-through of nonsense (stop) mutations, allowing bypass of the nonsense mutation and continuation of the translation process to production of a functioning protein. This approach could benefit the estimated 10 to 15 percent of patients with",
"    <span class=\"nowrap\">",
"     DMD/BMD",
"    </span>",
"    who harbor nonsense (stop) mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/71\">",
"     71",
"    </a>",
"    ]. Encouraging results were reported in preclinical efficacy studies, where ataluren treatment of primary muscle cells from humans and mdx mice was associated with the production of dystrophin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/72\">",
"     72",
"    </a>",
"    ]. However, the clinical benefit of ataluren is not yet established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In January 2005, the US Food and Drug Administration (FDA) approved an indication for ataluren in the treatment of DMD. The approval was based upon the results of phase 1 studies in healthy adult volunteers showing that the drug is orally bioavailable and well tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a phase 2 study of 26 boys with nonsense-mutation-mediated DMD, increased full-length dystrophin expression was observed in vitro and in vivo with PTC124, and serum muscle enzyme levels decreased within 28 days of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/74\">",
"       74",
"      </a>",
"      ]. However, there were only minimal changes in muscle strength and timed functions with PTC124 treatment.",
"     </li>",
"     <li>",
"      A multicenter double-blind trial randomly assigned 174 ambulatory males (median age 8 years, range 5 to 20) with",
"      <span class=\"nowrap\">",
"       DMD/BMD",
"      </span>",
"      to high-dose ataluren, low-dose ataluren, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/75\">",
"       75",
"      </a>",
"      ]. At 48 weeks, patients treated with low dose ataluren had a mean change in the six-minute walk distance that was approximately 29 meters higher than that for placebo group, a distance close to the 30 meter change considered clinically significant. However, the mean change in the six-minute walk distance for the high-dose ataluren group was similar to that for placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are needed to determine whether ataluren is effective for the treatment of muscle weakness in DMD and BMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Creatine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatine monohydrate has been studied for its potential to increase muscle strength in neuromuscular disorders and muscular dystrophies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. In a randomized, controlled, crossover trial of 30 boys with DMD, each participant received treatment with creatine (about 0.1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) for four months and placebo for four months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/79\">",
"     79",
"    </a>",
"    ]. Creatine treatment was associated with improved grip strength of the dominant hand and increased fat free mass compared with placebo. The beneficial effects of creatine were independent of steroid use. However, creatine treatment was not associated with significant improvement on functional measures or activities of daily living. Creatine was well tolerated with no evidence of renal or liver dysfunction.",
"   </p>",
"   <p>",
"    Another small controlled trial randomly assigned 50 boys with DMD to either creatine 5",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    glutamine 0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/80\">",
"     80",
"    </a>",
"    ]. There was no statistically significant benefit for either treatment group compared with placebo as assessed by change in the modified manual muscle testing score, the primary outcome measure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In light of the limited data and apparently modest benefit attributed to creatine in these studies, demonstration of clinically important improvement in larger trials is needed before recommending this treatment for patients with DMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Deacetylase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several structurally unrelated deacetylase inhibitors (trichostatin A, valproic acid, and phenylbutyrate) can enhance muscle differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/81\">",
"     81",
"    </a>",
"    ] and increase muscle size by inducing the expression of follistatin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, trichostatin A treatment restored muscle function and morphology in dystrophin-deficient mdx mice and in alpha-sarcoglycan-deficient mice [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/83\">",
"     83",
"    </a>",
"    ]. Human trials are needed to determine if deacetylase inhibitors are beneficial for patients with Duchenne, Becker, or limb-girdle muscular dystrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"     \"Limb-girdle muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Myostatin inactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myostatin is a protein that has an inhibitory effect on muscle growth. Mice that would otherwise express the DMD phenotype but lack myostatin have an increased muscle mass compared to those with a wild-type myostatin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/84\">",
"     84",
"    </a>",
"    ]. Antibodies to myostatin also have a beneficial effect; treated animals have increased muscle mass, strength, lower serum creatine kinase, and less histologic evidence of muscle damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A myostatin mutation in a child with gross muscle hypertrophy has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/86\">",
"     86",
"    </a>",
"    ], suggesting that myostatin inactivation could be a therapeutic target to increase muscle bulk and strength in muscle wasting diseases such as DMD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/87\">",
"     87",
"    </a>",
"    ]. Clinical trials of myostatin inhibitors are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cell therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of skeletal muscle progenitors in the treatment of DMD and BMD is under investigation but remains experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/54,55,89,90\">",
"     54,55,89,90",
"    </a>",
"    ]. A technique that appears particularly promising in mice involves isolating and transplanting muscle satellite cells, a natural source of cells for muscle regeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among those with DMD, there may be some improvement between three and six years of age. However, this is followed by gradual but relentless deterioration.",
"   </p>",
"   <p>",
"    In the earlier literature, progression to wheelchair confinement occurred by the age of approximately 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of patients with DMD died in their late teens or twenties from respiratory insufficiency (most commonly) or arrhythmia secondary to cardiomyopathy. In some cases, the immediate cause of death was not apparent.",
"   </p>",
"   <p>",
"    Survival, neuromuscular function, and quality of life in DMD may be improving due to longer term treatment with glucocorticoids, advances in respiratory care, and increased utilization of assisted ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. One study prospectively followed 43 patients (ages 5 to 35 years) with DMD during the period from 1996 to 2006 with yearly assessments [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/96\">",
"     96",
"    </a>",
"    ]. The following observations were made regarding the ages at which patients reached milestones of disease progression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lost ambulation, mean 9.4 years (range 6-15 years)",
"     </li>",
"     <li>",
"      Became electric wheelchair dependent, 14.6 years (11-28)",
"     </li>",
"     <li>",
"      Needed assistance for eating and drinking, 18.2 years (12-23)",
"     </li>",
"     <li>",
"      Began assisted ventilation, 19.8 years (14-31)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The estimated median survival was 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, patients with BMD typically remain ambulatory beyond the age of 16 years and into adult life; they usually survive beyond the age of 30 years and have a mean age of death in the mid 40s [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/1,97,98\">",
"     1,97,98",
"    </a>",
"    ]. The most common cause of death is heart failure from dilated cardiomyopathy, which also causes considerable morbidity in these patients despite their milder skeletal muscle involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/2/26666/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=see_link\">",
"       \"Patient information: Muscular dystrophy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=see_link\">",
"       \"Patient information: Overview of muscular dystrophies (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151153968\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For boys five years of age and older with DMD who are no longer gaining motor skills, or whose motor skills are declining, we recommend glucocorticoid treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      or deflazacort (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Our preferred regimen is prednisone 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, although prednisone 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      a week given over two weekend days is an alternative dosing regimen. An alternative agent is deflazacort (0.9",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) where available. A balanced discussion of the potential benefits and risks of glucocorticoid treatment should be given to every patient prior to initiating therapy. The most common side effects of treatment with daily prednisone are weight gain and cushingoid facial appearance. Although data are limited and conflicting, some experts believe deflazacort offers a more favorable side effect profile than prednisone. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoid treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to muscle weakness, cardiac, pulmonary, and orthopedic complications are frequently associated with Duchenne (DMD) muscular dystrophy and Becker (BMD). The anticipation and early detection of organ involvement is important for optimal therapy. (See",
"      <a class=\"local\" href=\"#H258480440\">",
"       'Symptom management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with DMD, a baseline assessment of cardiac function is recommended at the time of diagnosis or by the age of six years, especially if this can be done without sedation. For children with DMD or BMD who have evidence of ventricular dysfunction on cardiac imaging (ie, left ventricular ejection fraction &lt;55 percent or left ventricular dilation) we suggest treatment with an angiotensin converting enzyme inhibitor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a beta blocker (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H258480474\">",
"       'Cardiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A step-wise sequence of respiratory interventions for patients with DMD is recommended by current guidelines, beginning with volume",
"      <span class=\"nowrap\">",
"       recruitment/deep",
"      </span>",
"      lung inflation methods, and progressing through manual and mechanically assisted cough techniques, nocturnal ventilation, daytime ventilation, and tracheostomy if that is compatible with patient and clinician preference. The guidelines recommend the long-term use of noninvasive ventilation up to and including 24 hours daily in eligible patients. (See",
"      <a class=\"local\" href=\"#H258480511\">",
"       'Pulmonary complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DMD have a high risk of complications when they undergo procedures requiring anesthesia or sedation. (See",
"      <a class=\"local\" href=\"#H258480538\">",
"       'Complications related to anesthesia and sedation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Orthopedic interventions in patients with DMD and BMD are specifically aimed at maintaining function, preventing contractures. (See",
"      <a class=\"local\" href=\"#H258480565\">",
"       'Orthopedic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depending on individual circumstances and treatments (eg, glucocorticoids), patients with DMD can be at risk of nutritional problems, including being underweight or overweight for age. Weight and growth should be monitored, and evaluation by a nutritionist is indicated for all patients at diagnosis and for indications discussed above. (See",
"      <a class=\"local\" href=\"#H258480592\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DMD often have risk factors for poor bone health that may include decreased mobility, muscle weakness, and glucocorticoid therapy. For all patients with DMD, we suggest dietary calcium and vitamin D supplementation in the form of dairy products, other foods rich in calcium and vitamin D, and sunshine exposure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For children with diminished intake of calcium-containing foods, we suggest calcium supplementation (500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Children with a serum concentration of vitamin D &lt;30",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      should receive vitamin D supplementation. (See",
"      <a class=\"local\" href=\"#H258480619\">",
"       'Bone health'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For boys with DMD who are ambulatory or in the early nonambulatory stage of the disorder, we suggest regular submaximum (ie, gentle) exercise to avoid disuse muscle atrophy and other complications of inactivity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H258480680\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Investigative treatments for DMD include gene therapy, exon skipping, ataluren, creatine, deacetylase inhibitors, myostatin inactivation, and cell therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Novel therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children with DMD, there may be some improvement between three and six years of age. However, this is followed by gradual but relentless deterioration. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/1\">",
"      Emery AE. The muscular dystrophies. Lancet 2002; 359:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/2\">",
"      Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007; 36:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/3\">",
"      Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/4\">",
"      Merlini L, Gennari M, Malaspina E, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012; 45:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/5\">",
"      Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/6\">",
"      Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/7\">",
"      Griggs RC, Moxley RT 3rd, Mendell JR, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991; 48:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/8\">",
"      Fenichel GM, Mendell JR, Moxley RT 3rd, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991; 48:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/9\">",
"      Griggs RC, Moxley RT 3rd, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/10\">",
"      B&auml;ckman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1995; 5:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/11\">",
"      Rahman MM, Hannan MA, Mondol BA, et al. Prednisolone in Duchenne muscular dystrophy. Bangladesh Med Res Counc Bull 2001; 27:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/12\">",
"      Siegel IM, Miller JE, Ray RD. Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study. IMJ Ill Med J 1974; 145:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/13\">",
"      Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/14\">",
"      Moxley RT 3rd, Pandya S. Weekend high-dosage prednisone: a new option for treatment of Duchenne muscular dystrophy. Neurology 2011; 77:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/15\">",
"      Fenichel GM, Florence JM, Pestronk A, et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991; 41:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/16\">",
"      Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; :CD003725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/17\">",
"      Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol 2003; 3:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/18\">",
"      Mesa LE, Dubrovsky AL, Corderi J, et al. Steroids in Duchenne muscular dystrophy--deflazacort trial. Neuromuscul Disord 1991; 1:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/19\">",
"      Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994; 17:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/20\">",
"      Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/21\">",
"      Schara U, Mortier W. Long-Term Steroid Therapy in Duchenne Muscular Dystrophy-Positive Results versus Side Effects. J Clin Neuromuscul Dis 2001; 2:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/22\">",
"      Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004; 14:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/23\">",
"      Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003; 91:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/24\">",
"      Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/25\">",
"      Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in duchenne muscular dystrophy. J Am Coll Cardiol 2013; 61:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/26\">",
"      Markham LW, Kinnett K, Wong BL, et al. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/27\">",
"      Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008; 38:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/28\">",
"      King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/29\">",
"      Fenichel G, Pestronk A, Florence J, et al. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997; 48:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/30\">",
"      Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001; 56:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/31\">",
"      Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993; 43:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/32\">",
"      Kirschner J, Schessl J, Schara U, et al. Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 2010; 9:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/33\">",
"      Birnkrant DJ, Panitch HB, Benditt JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007; 132:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/34\">",
"      Colan SD. Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs. Circulation 2005; 112:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/35\">",
"      Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 2005; 45:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/36\">",
"      Jefferies JL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005; 112:2799.",
"     </a>",
"    </li>",
"    <li>",
"     Darras BT, Miller DT, Urion DK. Dystrophinopathies. In: GeneReviews. file://www.ncbi.nlm.nih.gov/books/NBK1119/ (Accessed on September 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/38\">",
"      Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord 2003; 13:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/39\">",
"      Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/40\">",
"      Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004; 170:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/41\">",
"      Birnkrant DJ, Bushby KM, Amin RS, et al. The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 2010; 45:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/42\">",
"      Takagi A, Nakase H. Malignant hyperthermia-like reactions in Duchenne or Becker muscular dystrophy: review and hypothesis. Rinsho Shinkeigaku 2008; 48:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/43\">",
"      Oka S, Igarashi Y, Takagi A, et al. Malignant hyperpyrexia and Duchenne muscular dystrophy: A case report. Can Anaesth Soc J 1982; 29:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/44\">",
"      Wang JM, Stanley TH. Duchenne muscular dystrophy and malignant hyperthermia--two case reports. Can Anaesth Soc J 1986; 33:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/45\">",
"      Heiman-Patterson TD, Natter HM, Rosenberg HR, et al. Malignant hyperthermia susceptibility in X-linked muscle dystrophies. Pediatr Neurol 1986; 2:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/46\">",
"      Wedel DJ. Malignant hyperthermia and neuromuscular disease. Neuromuscul Disord 1992; 2:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/47\">",
"      Breucking E, Reimnitz P, Schara U, Mortier W. [Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types]. Anaesthesist 2000; 49:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/48\">",
"      Yemen TA, McClain C. Muscular dystrophy, anesthesia and the safety of inhalational agents revisited; again. Paediatr Anaesth 2006; 16:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/49\">",
"      Do T. Orthopedic management of the muscular dystrophies. Curr Opin Pediatr 2002; 14:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/50\">",
"      Cheuk DK, Wong V, Wraige E, et al. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev 2013; 2:CD005375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/51\">",
"      Bachrach LK. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscul Disord 2005; 15:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/52\">",
"      Biggar WD, Bachrach LK, Henderson RC, et al. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005; 15:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/53\">",
"      Quinlivan R, Roper H, Davie M, et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscul Disord 2005; 15:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/54\">",
"      Gussoni E, Blau HM, Kunkel LM. The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 1997; 3:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/55\">",
"      Gussoni E, Bennett RR, Muskiewicz KR, et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest 2002; 110:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/56\">",
"      Gregorevic P, Allen JM, Minami E, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/57\">",
"      Rodino-Klapac LR, Chicoine LG, Kaspar BK, Mendell JR. Gene therapy for duchenne muscular dystrophy: expectations and challenges. Arch Neurol 2007; 64:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/58\">",
"      Mendell JR, Rodino-Klapac LR, Malik V. Molecular therapeutic strategies targeting Duchenne muscular dystrophy. J Child Neurol 2010; 25:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/59\">",
"      Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/60\">",
"      Klein CJ, Coovert DD, Bulman DE, et al. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992; 50:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/61\">",
"      Arechavala-Gomeza V, Kinali M, Feng L, et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 2010; 20:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/62\">",
"      Moore MJ, Flotte TR. Autoimmunity in a genetic disease&mdash;a cautionary tale. N Engl J Med 2010; 363:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/63\">",
"      Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/64\">",
"      Wood MJ, Gait MJ, Yin H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain 2010; 133:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/65\">",
"      Lu QL, Yokota T, Takeda S, et al. The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol Ther 2011; 19:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/66\">",
"      Partridge T. The potential of exon skipping for treatment for Duchenne muscular dystrophy. J Child Neurol 2010; 25:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/67\">",
"      Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/68\">",
"      Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/69\">",
"      van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357:2677.",
"     </a>",
"    </li>",
"    <li>",
"     Sarepta Therapeutics news release. file://investorrelations.sareptatherapeutics.com/phoenix.zhtml?c=64231&amp;p=irol-newsArticle&amp;ID=1741044&amp;highlight= (Accessed on October 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/71\">",
"      Finkel RS. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010; 25:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/72\">",
"      Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/73\">",
"      Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/74\">",
"      Wong B, Bonnemann C, Finkel R, et al. Phase 2 study of PTC124 for nonsense mutation suppression therapy of duchenne muscular dystrophy (DMD) [abstract]. Ann Neurol 2007; 62 Suppl 11:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/75\">",
"      Finkel R, Wong B, Bushby K, et al. Results of a Phase 2b, dose-ranging study of ataluren (PTC124&reg;) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD). Neuromuscul Disord 2010; 20:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/76\">",
"      Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/77\">",
"      Walter MC, Lochm&uuml;ller H, Reilich P, et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology 2000; 54:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/78\">",
"      Louis M, Lebacq J, Poortmans JR, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003; 27:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/79\">",
"      Tarnopolsky MA, Mahoney DJ, Vajsar J, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004; 62:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/80\">",
"      Escolar DM, Buyse G, Henricson E, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005; 58:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/81\">",
"      Iezzi S, Cossu G, Nervi C, et al. Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad Sci U S A 2002; 99:7757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/82\">",
"      Iezzi S, Di Padova M, Serra C, et al. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 2004; 6:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/83\">",
"      Minetti GC, Colussi C, Adami R, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006; 12:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/84\">",
"      Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002; 52:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/85\">",
"      Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/86\">",
"      Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/87\">",
"      McNally EM. Powerful genes--myostatin regulation of human muscle mass. N Engl J Med 2004; 350:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/88\">",
"      Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/89\">",
"      Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/90\">",
"      Skuk D, Roy B, Goulet M, et al. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 2004; 9:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/91\">",
"      Cerletti M, Jurga S, Witczak CA, et al. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 2008; 134:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/92\">",
"      Blau HM. Cell therapies for muscular dystrophy. N Engl J Med 2008; 359:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/93\">",
"      Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 1998; 53:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/94\">",
"      Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002; 12:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/95\">",
"      Moxley RT 3rd, Pandya S, Ciafaloni E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010; 25:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/96\">",
"      Kohler M, Clarenbach CF, Bahler C, et al. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2009; 80:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/97\">",
"      Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993; 240:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/98\">",
"      Bushby KM. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. Hum Mol Genet 1999; 8:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/2/26666/abstract/99\">",
"      Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol 1997; 12:329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6181 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-77C9F1D2D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26666=[""].join("\n");
var outline_f26_2_26666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H151153968\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GLUCOCORTICOID TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prednisone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Deflazacort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prednisone versus deflazacort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480059\">",
"      Cardiovascular outcomes of glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Orthopedic outcomes of glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recommendations for glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258480440\">",
"      SYMPTOM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480467\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480474\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H258480504\">",
"      - Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480511\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480538\">",
"      Complications related to anesthesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480565\">",
"      Orthopedic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480592\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480619\">",
"      Bone health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258480680\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NOVEL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12402433\">",
"      - Exon skipping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ataluren",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Creatine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Deacetylase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Myostatin inactivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cell therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H151153968\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6181|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/20/9548\" title=\"table 1\">",
"      DMD pre anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/7/24700\" title=\"table 2\">",
"      DMD during anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/41/24220\" title=\"table 3\">",
"      DMD post anesthesia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34903?source=related_link\">",
"      Atelectasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=related_link\">",
"      Patient information: Muscular dystrophy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=related_link\">",
"      Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=related_link\">",
"      Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=related_link\">",
"      Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_2_26667="Evaluation pulmonic stenosis";
var content_f26_2_26667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Evaluation and monitoring of pulmonic stenosis (PS) in adolescents and young adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following tests should be performed in adolescents and young adults with PS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Electrocardiogram for initial evaluation and repeated every 5 to 10 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Transthoracic echocardiography for initial evaluation and repeated every 5 to 10 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Cardiac catheterization for evaluation of the transvalvular gradient if the Doppler peak jet velocity is greater than 3 m/sec (estimated peak gradient greater than 36 mmHg). Balloon dilation can be performed if indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following test is NOT indicated in adolescents and young adults with PS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Cardiac catheterization for initial diagnostic evaluation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26667=[""].join("\n");
var outline_f26_2_26667=null;
var title_f26_2_26668="Alterations of periph blood lymphocyte populations in SCID";
var content_f26_2_26668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alterations of peripheral blood lymphocyte populations in some severe combined immunodeficiency (SCID) syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gene",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD4",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD8",
"       </td>",
"       <td class=\"subtitle1\">",
"        B",
"       </td>",
"       <td class=\"subtitle1\">",
"        NK",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL2RG",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JAK3",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL2RA",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL7RA",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD3D",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RAG1, RAG2",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DCCRE1C",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MHCIID*",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ZAP70",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ADA",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PTPRC",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * MHC class II deficiency.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26668=[""].join("\n");
var outline_f26_2_26668=null;
var title_f26_2_26669="Gemcitabine for nonmetastatic pancreatic and biliary cancer";
var content_f26_2_26669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gemcitabine for nonmetastatic pancreatic and biliary cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length:&nbsp;4 weeks.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration schedule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Gemcitabine",
"        </strong>",
"       </td>",
"       <td>",
"        1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 100 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 minutes.",
"       </td>",
"       <td>",
"        Weekly for three weeks followed by one week of rest.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors not indicated (risk of neutropenic fever &lt;1 percent). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose may be needed for patients with liver impairment. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (including serum creatinine) and liver function prior to each cycle and otherwise as indicated during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        This regimen should not be initiated unless the white blood cell count is &gt;3500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets are &ge;100,000 cells/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        . During therapy, the dose of gemcitabine should be decreased by 25 percent if the absolute neutrophil count decreases to &lt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        but &ge;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or the platelets decrease to &lt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and &ge;50,000/mm",
"        <sup>",
"         3[2]",
"        </sup>",
"        . The US FDA approved product information recommends holding gemcitabine for an&nbsp;absolute neutrophil count&nbsp;&lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &lt;50,000/mm",
"        <sup>",
"         3[2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hemolytic-uremic syndrome (HUS):",
"        </strong>",
"        In clinical trials, HUS was reported in 0.25 percent of patients receiving gemcitabine. Consider diagnosis if the patient develops hemolysis and severe thrombocytopenia, with or without renal failure or central nervous system findings. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.&nbsp;Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Oettle H, et al. JAMA 2007; 297:267.",
"       </li>",
"       <li>",
"        Gemzar (gemcitabine hydrochloride). US FDA approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26669=[""].join("\n");
var outline_f26_2_26669=null;
var title_f26_2_26670="Gram stain lesion 1A answer";
var content_f26_2_26670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clostridium perfringens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of exudate from a bulla at the site of injection of intravenous drugs (x1000) shows large, Gram positive bacilli and the absence of leukocytes. Clostridium perfringens grew anaerobically from this specimen on blood agar. Clostridial infection may produce cellulitis or involve deeper tissues, as in gas gangrene.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26670=[""].join("\n");
var outline_f26_2_26670=null;
var title_f26_2_26671="Prepatellar bursa PI";
var content_f26_2_26671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Knee bursa (prepatellar bursa)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_2_26671=[""].join("\n");
var outline_f26_2_26671=null;
